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ABSTRACT

ABSTRACT
Background –
Diabetes is a chronic, metabolic disorder that is characterized by resulting from defects in insulin
secretion, insulin action or both which will affect the patient Quality of life. Pharmaceutical Care
is the responsible provision of drug therapy for of achieving definite therapeutic outcomes that
improve the patient‘s quality of life. It contributes to the resolution of medical conditions and can
help avoid undesirable outcomes about patient‘s drug therapy problems, resulting in benefits to
patients.
Objectives –
To study the impact of Pharmaceutical care in type 2 diabetic patients in a tertiary care hospital.
Methodology –
A prospective interventional study was conducted for a period of 8 months, after taking ethical
committee approval. Total of 104 patients were selected, 52 patients in the Intervention group
and 52 patients in the usual medical care group as per the inclusion criteria from medicine ward
2 and 4 of tertiary care hospital. Demographic characteristics were documented in the data
collection form and the patients were administered with Modified Diabetes Quality of life
questionnaire (MDQoL) and Knowledge, Attitude and practice questionnaire (KAP)
questionnaire in the different languages which is suitable for the patients after admission to
hospital, before discharge, during first and second follow-up. Out of 52 patients in the
intervention group 24 patients completed both 1rst and 2nd follow up and in the control group
among 52 patients, 12 patients completed the both the follow-up. Data was analyzed using IBM
SPSS 20 version.
Results –
Out of 104 DM patients from both the group majority of the study population were male, overall
number of male patient in both the group is 78( 75.01%). The average age of study population
was 61.38±12.2 years and majority of the patient had a diabetes history of more than 5 years and
HbA1c value of intervention group was 6.65±0.83% and for control group 7.42±0.80%.FBS

level was120.87±23.86 mg/dL in the intervention group and 123±33.07 mg/dL in the control
group.
Majority of patients in the intervention group had MDQoL score >70 and control group patients
had MDQoL score between 50 -70. There is improvement in the knowledge; attitude and
practice (KAP) score in the intervention group than that of control group. We observed there was
statistically significant increase in MDQoL score and KAP score of intervention group from day
of admission to 2nd follow up.(P<0.00)
Conclusion –
The study concludes that the providing Pharmaceutical care to the DM patients will improve the
quality of life, knowledge and also control glucose level in diabetic patients.

INTRODUCTION

INTRODUCTION
Diabetes is a chronic, metabolic disorder that is described by coming about because of
deformities in insulin release, insulin activity or both. Diabetes Mellitus (DM) joined by
unsettling influences in the starch, fat and protein digestion. (1)
It is principally grouped into numerous types, be that as it may, the most well-known types are
type 1 and type 2 DM. Type 1 DM is normally connected with dissatisfaction in insulin creation
coming about because of the devastation of pancreatic β-cells by T-cell intervened
autoimmunity. The type 2 DM (T2DM) is portrayed by insulin obstruction and a decrease in
insulin generation. (1 ), (4)
Pharmaceutical Care is the responsible arrangement of drug treatment to accomplish clear
restorative results that improve the quality of life for the patient.(3) The American Diabetes
Association perceives enlisted pharmacist as essential individuals from the multidisciplinary
groups in charge of conveying diabetes care and education. (10)
Pharmaceutical care is an expert practice that is embraced by other national and universal
elements, for example, WHO. It adds to comprehend the goals of ailments and can help stay
away from the unfortunate result with respect to patient‘s drug treatment issues and bringing
about the patients and to the societal advantages. (2)
According to the report of the International Diabetes Federation demonstrates that 246 million
grown-ups have the Diabetes mellitus in around the world. There was around 6.4% commonness
of Diabetes influencing 285 million grown-ups in 2010 and anticipated to be expanded to 7.7%
and influencing to 439 million grown-ups by 2030. (2)
Pharmaceutical care gives more patient-focused care as opposed to item arranged care in
ongoing time. Pharmaceutical care can be given by the means which incorporates building up an
expert/helpful relationship: the drug specialist should greet and feel for the patient. This will
empower the patient to open up to the pharmacist. (6)
Pharmaceutical care for patients with respect to therapeutic issues can be built up by the great
and uniform evaluation on resolving, result checking and side effects. The pharmacist can play
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out an assortment of patient-explicit administrations, including glucometer preparing adherence
at home systems, played out a physical evaluation of patients' feet, eye, skin, pulse, and weight.
(5)

Diabetes is related with high morbidity on account of long haul complications and prompts
staggering expense also decline in personal satisfaction. The general yearly mortality among
patients with diabetes is 2.9%, with the most well-known reason for death being identified with
cardiovascular disorders, particularly in type 2 diabetes. (17)
Many people with diabetes think that it‘s hard to accomplish HbA1c levels <7.0%, with <40% of
people with diabetes in a USA national survey accomplishing this objective. (18)
Additionally, in developing countries, including Eastern Europe, Asia, Latin America, and
Africa, it has been appeared 22% and 36% of people with type 1 diabetes and type 2 diabetes
have never had their HbA1c estimated and just 25% of people with type 1 diabetes and 36% of
people with type 2 diabetes have HbA1c levels <7.0%. (19)
Primary explanations behind the trouble in accomplishing target HbA1c levels may incorporate
issues clinging to complex oral and injectable treatments, doubts about insulin tolerability,
insulin resistance, fears about the danger of hypoglycemia and weight increase after insulin
initiation. (20)
Type 2 diabetes patients have a more prominent occurrence of cardiovascular disorder,
cerebrovascular disease, and renal illness than the all-inclusive community. Hypertension is
increasingly regular in people with type 2 diabetes than in the general population. (21)
The national and international study showed that patients with diabetes can benefit from
pharmaceutical care programs and significantly reduce levels of hemoglobin A1C.

(5,14,15 ,16)

Thus, studies on the impact of pharmaceutical care programs in primary care are appropriate to
assess the effect of the intervention on type 2 diabetes. Numerous investigations have been
embraced to recognize factors that impact pharmacists‘ behaviors to aid pharmaceutical care
implementation. (22)
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NEED FOR THE STUDY:
For the treatment of patients with diabetes mellitus, different types of therapeutic regimens may
exist, glycemic control is still fundamental in diabetes management. The control in the glycemic
level will reduce the acute and chronic diabetic complications, and optimizes quality of life. (7)

Patient's quality of life is influenced by a person's physical wellbeing, mental state, and
dimension of independence. Social dealings, patients wellbeing status, sickness state and
association with the related features of their environment, this is different elements that influence
patients quality of life. (6)
Various studies have shown benefit from the pharmaceutical care provided by the clinical
pharmacists such asSriram S et al (2016) conducted a study which showed the pharmacist intervened individualized
pharmaceutical care administrations positively affect QOL, Glycemic control, and drug
adherence which improves the restorative result of the patients. The intervention group got
medicine directing, guidelines on way of life alterations, dietary guidelines in regards to their
prescribed medications. (2)
E Jorge et al (2011) directed an investigation on deciding the efficiency of pharmaceutical care
to improve control of type-2 diabetes mellitus. The study discovered that Increased effectiveness
of

the

anti-diabetic

therapy

was

not

demonstrated

in

patients

intervened

with

pharmacotherapeutic monitoring, however, the investigation demonstrated a decrease in
healthcare costs. (14)

Mahwi To et al (2011)done a study to estimate the efficiency of pharmaceutical care on the
control of clinical parameters, such as fasting glycaemia and HbA1c also to evaluate drug
therapy problems in patients with type 2 DM. The investigation demonstrated quantifiable
enhancements in the glycemic control, goals of medication treatment issues and upgrades in the
consistency toward hostile to diabetic medicine. (15)
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Kasturba Hospital is a super specialty tertiary care hospital with nine medicine units. More than
2000 diabetic patients get admitted to the Department of Medicine at Kasturba Hospital Manipal
per year. So we wanted to conduct to study the impact of pharmaceutical care in type 2 DM
patients.
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AIM AND OBJECTIVES

OBJECTIVES
Primary objective –


To study the impact of Pharmaceutical care in type 2 diabetic patients in a tertiary care
hospital.

Secondary objective

To study the demographic characteristics of diabetes patients



To assess the knowledge, attitude, and practice (KAP) and QOL in DM patients before
and after the Pharmaceutical care in different time intervals.



To assess the impact of pharmaceutical care in diabetic patients.
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REVIEW OF
LITERATURE

REVIEW OF LITERATURE
Introduction
Type 2 Diabetes is a chronic and progressive metabolic disorder characterized by changes in the
production and secretion of insulin or a defect in the hormone sensitivity of tissue. One of the
most common chronic diseases is diabetes mellitus. (12)

The origin and etiology of diabetes mellitus may vary significantly, but always involve insulin
secretions or response defects or both at some stage of the disease. Diabetes mellitus origin and
etiology may vary widely but always include deficiencies in either insulin secretion or response
or both at some point during disease. (40)

A disease characterized by' excessive urine emptying' finds its place in ancient times through
manuscripts from Egypt dating back to 1500 B.C. Banting, Best, and Collip ligated the
pancreatic duct in 1921, working in Macleod's laboratory, causing the exocrine pancreas to be
destroyed while leaving the islets intact. In their elegant animal experiments, using canine insulin
extracts to reverse induced diabetes, they concluded that insulin deficiency was the cause of
diabetes. (41)

Diabetes development involves several pathogenic processes. These range from autoimmune
destruction of pancreatic cells resulting in insulin deficiency to abnormalities resulting in insulin
action resistance. Symptoms of marked hyperglycemia include polyuria, polydipsia, loss of
weight, sometimes polyphagia, and blurred vision. Impairment of growth and sensitivity to
certain infections can also accompany chronic hyperglycemia. Hyperglycemia with ketoacidosis
or non-ketotic hyperosmolar syndrome is an acute, life-threatening effect of uncontrolled
diabetes. (43)

Any characteristic can define new diabetes mellitus classification intentions; the intention is to
consolidate etiological views on Diabetes. Classification of diabetes mellitus includes
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Type 1 diabetes mellitus –
It is characterized by the destruction of beta cells caused by an autoimmune process, usually
resulting in an absolute insulin deficiency. In addition to the loss of insulin secretion, the
function of pancreatic α-cells is also abnormal and excessive glucagon secretion occurs in
patients with type 1 diabetes mellitus.

(40)

Individuals with an increased risk of developing such diabetes often find themselves in an
autoimmune -pathological process on pancreatic islets and genetic markers with serologic
evidence. In this form of diabetes, the rate of oscillation is very variable, with some persons
(mainly children) quickly and others slowly (principally adults). Some patients, especially
children and teenagers, can be the first to develop ketoacidosis. (43)
Type 2 diabetes mellitus –
The relative importance of defects in insulin secretion or in the peripheral action of the hormone
has been and will continue to be a cause for discussion in the occurrence of type 2 DM. These
mechanisms break down in type 2 diabetes, with the result that the two main pathological defects
in type 2 diabetes are impaired insulin secretion through pancreatic β-cell dysfunction and
impaired insulin action through insulin resistance. (40)

There may be a sufficient degree of hyperglycemia in the latter category to cause pathological
and functional changes in various target tissues, but without clinical symptoms, long before
diabetes is detected. Most patients with diabetes are obese, and obesity itself causes some level
of insulin resistance. Most body fat distributed in the abdominal region can be enhanced by
traditional weight criteria in patients not obese.

(43)

This type of diabetes rarely involves spontaneous ketoacidosis; when seen, it usually occurs as a
result of the stress of a new disease, such as infection. For many years, DGDM has been defined
as any degree of glucose intolerance with initial or initial detection of pregnancy. Whereas in
most cases the delivery resolves, the definition is whether the condition persists or not following
pregnancy and does not rule out the possibility for anteriorated or simultaneous beginning of
unrecognized glucose intolerance. It is often linked to the strong genetic predisposition of type 1
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diabetes as well as to the autoimmune form. Genetics of this diabetes form, however, are
complex and unclear. (43)

Over the past three decades, T2DM and its complications have reached epidemic levels,
particularly in developing countries. T2DM is a global crisis that threatens the health and
economy of the world. About 1 in 11 adults worldwide have T2DM and about 75 percent of
diabetes mellitus patients live in developing countries.

(29)

Gestational Diabetes Mellitus –
Women with type 1 diabetes mellitus are classified as Gestational Diabetes Mellitus (GDM)
during pregnancy and women with undiagnosed asymptomatic type 2 diabetes mellitus found
during pregnancy. Gestational diabetes mellitus (GDM) is defined as any degree of glucose
intolerance with initiation or initial recognition during pregnancy.

(44)

For many years, DGDM has been defined as any degree of glucose intolerance with initial or
initial detection of pregnancy. While delivery resolves in most cases, the definition is whether or
not the condition persists after pregnancy and does not rule out the possibility of an unrecognized
glucose intolerance starting anteriorly or simultaneously.

(43)

Following discussions from 2008 to 2009, the International Association of Diabetes and
Pregnancy Groups (IADPSG) recommended that high-risk women with diabetes during their
initial prenatal visit, including the American Diplomatic Diabetes Association (ADA), use
standard criteria to participate in the initial pre-borne visit. (43)

Women with GDM have an increased risk of developing type 2 diabetes after pregnancy.
Obesity and other factors that promote insulin resistance appear to increase the risk of type 2
diabetes following GDM, while islet cell markers — directed autoimmunity is associated with an
increase in the risk of type 1 diabetes. In late adolescence and young adulthood, the risk of
obesity, glucose intolerance and diabetes increases for offspring of women with GDM (44)
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Other specific type (Monogenic diabetes) Genetic defects MODY (youth's maturity onset diabetes) is characterized by impaired insulin
secretion in response to a minimum or no insulin resistance glucose stimulus. Patients typically
have mild hyperglycemia at an early age, but diagnosis may be delayed depending on
presentation severity.

(1)

Several forms of diabetes in some beta cell function are associated with monogenetic defects.
Early hyperglycemia often characterizes these forms of diabetes (usually before age 25).(43)
They are hereditary in an autosomal dominant pattern. Anomalies have been identified on
various chromosomes in six genetic loci to date.

The most common form is associated with mutations on chromosome 12 in a hepatic
transcription factor called the nuclear hepatocyte factor (HNF)-1 alpha. Anti-insulin receptor
antibodies can cause diabetes by binding to the receptor of insulin, blocking insulin binding to its
receptor in target tissues. However, in some cases, these antibodies may act as an insulin agonist
after binding to the receptor and therefore cause hypoglycemia.
Anti-insulin receptor antibodies are sometimes found in patients with systemic lupus
erythematosus and other autoimmune diseases. (43)

Epidemiology of Diabetes
There is an expanding number of people with Type 2 diabetes mellitus around the world. There
are right now in excess of 194 million individuals living with diabetes around the world.
Glycaemia control, great lipid the board, and circulatory strain control appear to be absolutely
critical so as to avoid vascular confusions, full scale and miniaturized scale vascular illnesses are
the most significant reasons for unpleasantness and mortality in the patient. (25)
In developing countries, the major burden of diabetes mellitus is now taking place rather than in
developed countries.80% of cases of diabetes mellitus in less developed countries and regions
worldwide. Asia has emerged as the' Diabetes Epicenter' of the world over a relatively short
period of time as a result of rapid economic development, urbanization and nutritional transition.
(26)
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Diabetes prevalence is rising rapidly, particularly in the urban population of India. Between 1971
and 2000 a 10-fold increase was observed. The National Urban Diabetes Survey (NUDS), a
population-based study was conducted in six Indian metropolitan cities, recruiting 11,216
subjects aged 20 years and above representing all socio-economic strata. (27)In India,
preliminary data from a national youth diabetes registry revealed that 25% of patients with
diabetes mellitus who were below 25 years of age had T2DM. (29)
An oral tolerance test for glucose was conducted using capillary glucose and diabetes was
defined using the WHO criteria. The study reported age-standardized prevalence of type 2
diabetes of 12.1 %. This study also found that the prevalence in southern India was above 13.5%
in Chennai, 12.4% in Bangalore and 16.6% in Hyderabad; 11.7% in eastern India (Kolkata),
11.6% in northern India (New Delhi), 11.6% in northern India and 9.3% in western India.
The study also suggested a large pool of subjects with impaired glucose tolerance (IGT), 14%
with a high risk of conversion to diabetes. (30)
Diabetes prevalence in adults aged 18–99 years was estimated at 8.4% in 2017 and forecast to
increase to 9.9% in 2045. The high prevalence of diabetes, particularly in low and middleincome countries, has significant social, financial and developmental implications. (31)

Complications of Diabetes
With plasma glucose concentration and duration of diabetes, the risk of vascular complications
increases. It also depends on age, gender, genes, and lifestyle once diabetes is diagnosed,
lifestyle adaptation is mandatory, and treatment with hypoglycemic agents cannot be avoided, as
it is known that more than 50% do not fully adhere to recommendations for diet and exercise.

(25)

Symptoms such as polyuria, Polydipsia, weight loss, sometimes polyphagia, and blurred vision
include marked hyperglycemia. Chronic hyperglycemia may also be accompanied by impaired
growth and susceptibility to certain infections. Acute and life-threatening consequences are
ketoacidose or non ketotic hyperosmolar syndrome uncontrolled diabetes. (43)

Significant hyperglycemia includes symptoms like polyuria, polydipsia, weight loss, polyphagia
sometimes and blurring of the vision. Chronic hyperglycemia also may lead to impaired growth
Department of Pharmacy Practice
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and sensitivity to some infections. Ketoacidosis or non-ketotic hyperosmolar diabetes are acute
and life threatening consequences.

(26)

Acute diabetes complications include hypoglycemia, hyperglycemic crises, ketoacidosis diabetes
(DKA) and other diseases. The level of hyperglycemia (if any) could change over time,
depending on the extent of the underlying disease process. The severity of the metabolism may
advance, return, or stay the same. The extent of hyperglycemia thus reflects the seriousness of
the underlying metabolic process more than the nature of the process itself.(43)
Chronic complications such as
Diabetic retinopathy
Diabetic maculopathy and proliferative retinopathy (PDR) complications, such as vitreous
haemorrhage, retinal detachment and neovascular glaucosis, are responsible for vision loss.
Diabetic retinopathy has the potential to blind mellitus diabetes complication..

During laser photocoagulation, advanced stages of diabetic retinopathy must be treated in a
timely fashion with vitreo-retinal procedure and limited visual forecasting. Recent studies have
shown that the entire retinal neurovascular system has been impaired by mellitosis, resulting in
the loss, even before the damage occurs, for neurovascular coupling, neuro degeneration and
neuro inflammation.(45)
Diabetic nephropathy
The presence of 0.5 g/24 h proteinuria has classically defined diabetic nephropathy. Overt
nephropathy, clinical nephropathy, proteinuria, or macro albuminuria has been referred to this
stage.
In most 40% of diabetes patients, diabetic nephropathy takes place even if high glucose levels
are maintained over a long time. This observation increased the susceptibility of a subset of
patients to diabetic nephropathy. Differential diagnoses are usually historical, physical,
laboratory and kidney imaging. Only under special circumstances is renal biopsy recommended.
In long-term patients with type 1 diabetes (around 10 years of diabetes), diabetes diagnosis is
easily established, particularly where retinopathy is also present. (46)
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Diabetic neuropathy
In fact, neuropathy in patients with diabetes is around 30 percent, with up to 50% developing
neuropathy in the event of their condition. Diabetes can cause various harm to the peripheral
nervous system, but distal symmetric polyneuropathy (DSP) is the most common presentation.
(47)

Diabetic neuropathy is one of the most basic complexities of both type1 and type 2 diabetes.
Peripheral neuropathy (or diabetic polyneuropathy) can present as lost vibe that can prompt
neuropathic ulcers, and it is a main source of removal. It is the most widely recognized kind of
neuropathy in individuals with diabetes, in part as a result of different sampling methods and
differing diagnostic criteria. (55)

Management and Treatment of Diabetes
Treatment for diabetes mainly involves a change in lifestyle, if these changes do not affect
patients will be treated with oral anti-diabetic drugs or insulin or both. Diabetes care mainly
includes patient education and primary health care, according to the American Diabetes
Association, which means that an interdisciplinary health strategy can play an important role in
the patient self-service process and promote control of diabetes.

(13)

Adequate glycemic control with weight loss, exercise, and/or oral glucose loss may be achieved
in some people with diabetes. Other persons who are secreted with residual insulin but need
exogenous insulin to have sufficient Without it, glycemic control may survive. Persons with
extensive beta cell destruction and therefore no residual insulin secretion need insulin survival.
(43)

Diabetes is a perpetual dynamic problem with various biological defects, requiring the use of
different kinds of medicines in order to improve disease power over the life span of patients. To
date, there have been classes of oral medication, such as biguanides, sulphonylureas, and
injectable insulin alternatives, such as human and analog insulin, moving towards becoming
household names in diabetes treatment. At a HbA1c level at least 6.5–7.0 percent, diabetes is
therapeutically targeted. In order to achieve these goals, quick and postprandial controls on
glucose must be dealt with.(52)
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In people with diabetes, the mortality rates for people with diabetes can be 11 times higher and
90 per cent who have diabetes have type-2 diabetes (formerly non-insulin based diabetes) and
require glucose control by oral agents or insulin. (51)
Various type of anti-diabetic drugs includes


Biguanides



Sulphonylureas



Meglitinides



Thiazolidinediones



Alpha-glucosidase inhibitors



Dipeptidyl peptidase IV (DPP-IV) inhibitors



Glucagon-like peptide-1 (GLP-1) analogues

Biguanides
A few greatuanides, the main ones metformin and phenformin, are available on the commercial
market for a number of years now mainly because of their potential to cause a serious lifestyle
threats to lactic acidosis. Metformin has been available over the last four decades. It has several
mechanisms that are postulated to reduce plasma glucose. Since metformin does not directly
stimulate the ß cell, there is no hypoglycemia or weight gain.(52)
Side effects can be a metformin issue. Although gastrointestinal complaints can be mild and
temporary, up to 30% of patients develop, especially if dosages are slowly increased. The major
complaints are bloating, flatulence, diarrhea, abdominal discomfort and pain. Metformin's
biggest concern is the possible for a build-up of lactic acid. (51)
Sulphonylureas
For the past 50 years there has been a drug group called sulphonylurea (SU). They all have a
similar action mechanism (glibenclamide, glipizid and gliclazide) mediated by the closeding of
ATP-sensitive potassium channels (K+). (52)
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Examples of first generation SUs are Acetohexamide, tolbutamide and chlorpropamide.
Glibenclamide (Daonil) and glipizide (Mingidiab) and gliclazide (Diamicron) are examples of a
second generation SUs. (52)
Edema and weight gain are associated with the major side effect, TZDs. Changes in fat
distribution resulting in an increase in adiposes and visceral fat in the subcutaneous fat can lead
to a weight increase. It may also be caused by an increase in plasma volume. It is thought that the
edema is due to a reduction of sodium rejection and an increase in sodium and water retention.
(51)

Meglitinides
Their far shorter half life and lack of sulphonic acident movement distinguish them from SUs,
allowing them to be used in patients that are allergic to sulphates. Glinides include repagline
(NovoNorm), a benzoic acid derivative, and phenylalanine (Starlix) derivative. (52)
Thiazolidinediones
Gamma agonists activated through the selective butxisome proliferator (PPAR) are
Thiazolidinediones (TZD). PPARs are associated with human gene transcript. The activation of
these receptors controls the transcription of the glucose-producing, transporting, and using
insulin-responsive genes. Rosiglitazone has been shown to improve insulin sensitivity
significantly and to reduce ß-cell loss rate. (52)
Alpha-glucosidase inhibitors
These medicines do not target a specific physiological defect in diabetes but rather delay the
breakdown and absorption of complex carbon hydrates in the small intestines by inhibiting αglucosidazed enzymes found on the brush border of the intestinal wall. It slows carbohydrate
absorption. The HbA1c level can be cut by 0.5–1 %, while the level of postprandial glucose with
such inhibitors can be reduced by about 2.2–2.8 mmol / L. (52)
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Dipeptidyl peptidase IV (DPP-IV) inhibitors
DPP-IV inhibitors lower HbA1c as monotherapy by 0.79-0.94 percent and affect both the control
of fasting and postprandial glucose. Compared to sulphonylureas and TZD, they are considered
weight neutral. (52)
In October 2006, in people with type 2 diabetes the FDA approved Januvia (Sitagliptin). It can
be used with metformin or thiazolidenediones alone and well tolerated. The first type of new
type of medicine is type 2 diabetes treatment. It helps the body to respond to meal glucose by
improving insulin levels and adjusting other hormones.

(51)

Glucagon-like peptide-1 (GLP-1) analogues
Glucagon-like-peptide-1 (GLP-1) is a small intestine insulinotropic hormone secreted by the L
cells. GLP-1 has numerous important biological actions with glucose-dependent stimulus of
insulin release. GLP-1 agents have still not had their long-term effect on glycaemic control and
their impact on the function of ß cels in human beings remains an active area of investigation but
GLP-1 stimulates ß-celles and neogenesis in animal modeling. (52)
Insulins
There are different types of insulin that act fast or very slowly, making it easier for those who
need insulin to control their sugars at rest or at mealtime, including Humalog, Novolog, and
Apidra, the fast-acting insulin products, and the long-acting products Lantus and Levemir.
Insulin Lispro Introduced in 1996, lispro differs from human insulin through a switch at lysine
B28 and proline B29. The lispro is a hexameric formulation in the vial, but when injected, it
dissociates into a monomeric formulation, leading to faster absorption and shorter duration of
action.
Insulin Aspart is the newest rapid-acting insulin analog; it differs from human insulin by
substituting B28 aspartic acid. The maximum regular insulin concentration time is 52 minutes
versus 145 minutes. Aspart showed better control of PPG and less nocturnal hypoglycemia
compared with regular insulin. Insulin Glargine differs from human insulin by replacing
asparagine with glycine at A21 and adding 2 arginines to the Cterminus B-chain. Glargine was
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designed to imitate normal basal insulin with a slow absorption and long half-life. Glargine is
stable at a pH of 4 and precipitates at physiological pH.. (51)

Pharmaceutical Care
According to the definition of Hepler & Strand pharmaceutical care is ‗the responsible provision
of drug therapy for the purpose of achieving definite outcomes that improve a patient‘s quality of
life‖. (3)
Pharmaceutical care is a cooperative, patient based system for achieving unique positive results
from the responsible supply of medicinal products. Pharmaceutical care is a idea and practice
where the patient is the most important beneficiary of the efforts of the pharmacist. The
pharmacist focuses on drug therapy attitude, behavior, commitment, ideas, knowledge,
responsibilities and capabilities on the provision of drug therapy. (32)
Improving a pharmaceutical care program in community and health care pharmacies probably
requires considerable effort from the pharmacist, who needs to devote time and resources to
personalized patient counseling. This skill in dedicating a personal counseling area and also
becoming extra concerned with computer applications to expand what is conceivable for
consultation through networks providing drug information and discovering drug interactions. In
addition, computer systems facilitate drug remedy monitoring and database handling to make
certain confidentiality and thus enhance the quality of health care for pharmacists. (28)
The principles of pharmaceutical care derive from the idea of good pharmacy practice and take
patient care as well as financial aspects into consideration. The goal is to acquire
pharmacotherapy based on rational evidence that benefits every patient and society. Over the
past few years, many research showed improved patient outcomes as pharmacists expanded their
involvement in the management of cooperative drug therapy.

(28)

In 1990, the American Association of Pharmacy Colleges (AACP) also presented the idea of
pharmaceutical care as "the pharmacy mission for the 1990s," providing the basis for
overcoming resistance, financial and logistical challenges for healthcare and drug manufacturers,
as well as ignorance and inertia among pharmacists themselves. (28)
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As pharmaceutical care has been introduced slowly but steadily, many studies have begun to be
carried out on drug use, prescription habit analysis, prescription prevalence, therapeutic profiles,
compliance with prescriptions, incidence reports and medication errors, and major ongoing
projects are now being carried out in different countries. (28)
The substantial amount of work that has been done over the past few years provides the best
evidence as to whether pharmaceutical care improves patient health and has positive effects on
the entire health system. Sometimes, however, the results do not reflect successful interventions.
Because the variables analyzing the clinical, humanistic and economic aspects are difficult to
assess. (28)

Basic element of Pharmaceutical Care
Basic Elements of Pharmaceutical Care includes


Patient-oriented



Both acute and chronic complications addressed



Stress on avoidance of drug related problems



Documented system on patients record necessity and care.



Offering constant care in systematic way.



Taking support of other health care providers in integrating the care provided.



Highly answerable and responsible



Emphasis on uplifting patients health quality of life.

First, patients need timely and accurate response from the initiator physician, nurse practitioner,
etc. to their basic medical problems. Patients need timely and accurate responses to signs and
symptoms that would most often refer pharmacists and other co-therapists to detect and resolve
drug therapy problems.
Obvious therapeutic goals should direct the use of medicinal products. They are essential for
monitoring and patient involvement in care. They provide the standard for assessing therapy
progress. These comparisons and judgments are made much more precise by explicit goals.
Estimating probability of severity would partly depend on how readily a potential DTP would be
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detected and controlled if it were to develop. In addition, they should be made in the context of
the severity of the medical problem and specific therapeutic alternatives for these judgments to
be realistic.

(24)

The patient actively cooperates in pharmaceutical care in his own care and the results are more
carefully monitored by the pharmacist. Where appropriate, this step should include some
discussion of what the patient and pharmacist should expect each other to do. The pharmacist
may advise the patient to take the medicine safer or more effective ways. This may need to be
discussed with the prescriber beforehand or, depending on the circumstances; the pharmacist
may simply notify the prescriber of the recommendation.
Documentation also enhances efficiency by enabling each individual to see and add to what has
already been accomplished, rather than repeating work already done. If the process is consistent
among the providers, efficient documentation will be much easier. (24)

Benefits of Pharmaceutical Care
The need for PC is particularly invaluable in the management of chronic diseases, where
compromise in management results in resource loss, complications, disabilities and death.
Pharmaceutical care is a central process in which patients use pharmacists ' expertise in a
multidisciplinary and collaborative patient care process to improve patients ' clinical, economic
and humanistic outcomes. Due to the holistic and individualistic treatment of each patient,
patient-centeredness in PC is a generalist approach. (32)
The PC plan is aimed at eliminating or preventing all forms of problems with drug therapy
(DTP). It involves patient and clinician collaboration. There are three types of PC-related health
outcomes: economic (drug linked and non-drug-related), clinical (medical, physiological and
metabolic) and humanistic. (Fulfillment of patients) (32)
The goal of pharmaceutical care is to ‗improve the quality of life‘ of an individual patient by
accomplishing definite (specified) therapeutic outcomes related to medication. The desired
outcomes are (33)
 Curing the disease of a patient.
 Eliminating or reducing the symptomatology of a patient.
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 Arrest or slow down a process of disease.
 A disease or symptomatology prevention.

It would presumably be necessary for the pharmacist who should devote time and resources to
personalized patient counseling to improve a program of pharmaceutical care in community and
hospital pharmacies. This effort involves dedicating private counseling to computer applications
and expanding the possibility of consultation by networks that provide information about drugs
and detect drug interactions. Computer systems also enable drug treatment and databases to be
monitored to ensure confidentiality and improve the quality of medical attention to pharmacists.
(28)

Studies Related Pharmaceutical care
The substantial work done in recent years has demonstrated the greatest possible impact on the
healthcare system as a whole by ensuring that the pharmaceutical treatments improve patients '
health. But the results sometimes fail to reflect successful interventions because the variables that
analyze the clinical, humanistic and economic factors are difficult to evaluate.

Bukhsh A et al (2018) done a study to evaluate the efficacy of pharmacist-based diabetes
educational interventions on clinical outcomes of adults with type 2 diabetes mellitus. From the
date of database initiation, a systematic search was conducted across five databases. The network
meta-analysis (NMA) was covered by all randomized clinical studies evaluating the efficacy of
drug based interventions in patients with type 2 diabetes. A total of 43 studies were included
with 6259 patients with type 2 diabetes.
The findings of this review show that all interventions had a significantly positive effect on
HbA1c, but there was no statistical evidence from this study that one intervention to achieve
glycemic control was significantly better than the other. Education based on pharmacist diabetes
plus pharmaceutical care showed maximum effectiveness on HbA1c and other clinical outcomes.
(37)

Shareef J et al (2016) done a study in the Department of Pharmacy Practice, NGSM Institute of
Pharmaceutical Sciences, Paneer, Mangalore, Karnataka, NGSM Institute of Pharmaceutical
Sciences, Paneer, Mangalore, Department of General Medicine, KS Hegde Medical Academy &
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Hospital, Deralakatte, Mangalore, Karnataka, India. Study conducted in a hospital teaching
hospital on the impact of clinical pharmacist interventions in drug therapy in patients with
diabetes mellitus. A prospective interventional study was conducted over a 10-month period in
the medicine wards of a hospital teaching tertiary care. In the medicine ward, a total of 174 cases
were followed up and reviewed over a period of ten months. Of the total of 174 cases reviewed,
out of 151 patients, 189 drug related issues were identified. During ward rounds in hospitalized
patients with diabetes mellitus, the study showed the involvement of a clinical pharmacist as a
member of the healthcare team to help identify and prevent drug-related problems that will help
rationalize drug therapy, achieve better therapeutic results and improve patient care. (35)
Alhabib S et al (2016) conducted a diabetes narrative review of the evidence from the literature
in order to answer the present question of what is the evidence of the role of clinical pharmacists
in managing diabetic patients. This study was conducted in the Department of Family and
Community Medicine, Saudi Arabia, National Guard Health Affairs. Five databases, including
the Cochrane library, MEDLINE, EMBASE, TRIP, and Science Direct, search for data. This
review also attempted to search for other potentially eligible trials or ancillary publications by
searching for the reference lists of included trials, (systematic) reviews, meta-analysis and
evaluation reports on health technology. In most studies, the result showed that the role of
pharmacists was primarily to specify and communicate all drug-related issues including poor
compliance with drugs and side effects to the physician. They found a statistically significant
decrease in coronary heart disease, blood pressure, HA1c, quality of life, and lipid profile for
those receiving pharmacist care. (34)
Upadhyay D et al (2015) conducted self-funded research work in the Discipline of Social and
Administrative Pharmacy, School of Pharmaceutical Sciences, University Sains Malaysia,
Penang, Malaysia. Department of Pharmacology, Manipal College of Medical Sciences and
Manipal Teaching Hospital, Pokhara, Nepal. American University of the Caribbean School of
Medicine,

Cupecoy, St. Maarten .Department of Medicine, Manipal College of Medical

Sciences and Manipal Teaching Hospital, Pokhara, Nepal. Determine the baseline level of
satisfaction of newly diagnosed diabetes patients and explore the impact of pharmaceutical care
intervention on the satisfaction of patients during their follow-up at a Nepal hospital for tertiary
care. An interventional, pre-post non-clinical randomized controlled trial was designed for 162
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patients[ control group (n=54), test group 1 (n=54) and test group 2 (n=54)] who were randomly
distributed. Pharmaceutical care was provided to patients in test groups, while patients in control
groups received their usual care only from physicians / nurses. The test groups on the Friedman
test showed a significant improvement in the satisfaction scores of patients. The study showed
that, through a pharmaceutical care program, pharmacist could act as a counselor and help
patients manage diabetes. (16)
Wishah R et al (2014) conducted a study to assess the impact on glycemic control and other
health-related clinical outcomes of pharmaceutical care interventions in patients with type 2
diabetes in Al-Hussein Hospital (Al-Salt-Jordan), Ministry of Health, Jordan , Faculty of
Nursing, Mutah University, Al-Karak, Jordan ,Department of Biopharmaceutics and Clinical
Pharmacy, Faculty of Pharmacy, The University of Jordan, Jordan. Following the six-month
follow-up, a randomized controlled clinical trial was conducted on 106 patients with
uncontrolled type 2 diabetes, significantly decreasing the mean of patients in the HbA1c and
FBS intervention group compared to control group patients. This study showed an improvement
in HbA1c, FBS, and lipid profile in addition to self-reported adherence to medication, diabetes
knowledge, and self-care activities in patients with type 2 diabetes who received pharmaceutical
care interventions. The results suggest the advantages of integrating clinical pharmacology. (38)
Al-Taweel D et al (2013) conducted a study to identify pharmacists‘ potential contributions to
the delivery of pharmaceutical care to patients with type 2. This research work was done This
research work was done by Kawa A. Obeid Department of Internal Medicine, School of
Medicine,

Department of Clinical Pharmacy, School of Pharmacy, Sulaimani University,

Kurdistan-Iraq. A prospective and randomized control trial study was conducted with 130
patients with type 2 diabetes with HbA1c of more than 7.0% divided into two groups of
intervention and control group. The results showed that the involvement of pharmacists in direct
patient care in our specialty outpatient care clinic as members of the inter-professional team is
associated with a positive impact on glycemic control in diabetes patients. In addition, a
pharmacist's follow-up of the intervention group contributed to the resolution of 108 identified
drug therapy issues.(22)
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N. Al Mazroui et al (2009) conducted research work in the Departments of Pharmacy,
Nephrology, Cardiology and Endocrinology, Sheikh Zayed Military Hospital, Abu Dhabi, UAE
and Clinical and Practice Research Group, School of Pharmacy, Queen‘ University Belfast, UK.
In total, a controlled prospective clinical trial for 240 patients with type 2 diabetes with a 12month follow-up were recruited into an intervention group. The study showed a significant
decrease in HbA1c levels in intervention group patients and a reduction in cardiovascular risk
scores among type 2 dimmed patients was achieved through the pharmaceutical care program.
Compared to control group patients in the 12-month evaluation in intervention patients, overall
medication expertise, adherence to medicine and lifestyle adherence was significantly higher. (5)
Roozendaal B et al (2009) conducted a study in patients with type 2 diabetes to develop an
evidence-based checklist to identify potential drug-related problems (PDRP) applied to records
of ambulatory type 2 diabetes patients in New South Wales, Australia. The relevant group of
medicines and the potential drug related issues in type 2 diabetes have been identified following
a thorough review of the literature. A PDRP checklist with six key sections has been successfully
developed. A checklist was used to indicate 682 potential DRPs, an average per patient of 4.6
(SD= 1.7). The PDRP check list has been successfully developed and the checklist can assist
pharmacists and other medical professionals in the systemic identification of problems in their
treatment and management of type 2 diabetes patients and enhance their metabolic control earlier
interventions. (36)
Coast Senior E et al (1998) conducted a study on the impact on the glycemic control of patients
with type 2 diabetes mellitus by clinical pharmacists involved direct patient care in the Veterans
Affairs Medical Center (VAMC) in Pittsburgh, PA. This study shows that pharmacists working
in interdisciplinary primary care teams can have a positive effect on glycemic monitoring in
patients with insulin-requiring type 2 diabetes. Pharmacists alone provided all aspects relating to
diabetes management. The study showed significant reductions in FBG and HbA1C levels in
comparison to the group of medical practitioners within the group assigned to pharmacistmanaged care. (39)
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METHODOLOGY

METHODOLOGY
Study site
Department of Medicine Kasturba Hospital, Manipal. Medicine unit 2 and 4
Study design
Prospective Interventional study
Study duration
The duration of study was 8 months, from August 2018 to March 2019.
Ethical Approval
The ethical committee approval was obtained from the Kasturba Medical College and Kasturba
Hospital Institutional Ethics Committee, Manipal (IEC:464/2018). (Appendix 1)
Study Criteria
Patients with type 2 diabetes admitted in medicine wards/OPDs (Unit 2&4) during the study
period were included with following inclusion and exclusion criteriaInclusion Criteria:


Type 2 Diabetic patients above 18 years of age admitted in the in Department of
Medicine at Kasturba Hospital, Manipal



DM patients glycosylated Hemoglobin should be more than 7%

Exclusion Criteria:


Type 1 Diabetic patients



Gestational diabetes patients



Bedridden patients



Patients who are not willing to participate in the study.
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Study Sample size
104 Type 2 DM patients (Intervention group = 52, Usual medical care group = 52)

Sources of data


Patient data collection form, included following information

 Patient Demographics
 Patient history notes
 Drug treatment charts
 Laboratory reports (Different time intervals)
 Discharge summary


Interviewing the both group by using KAP and MDQoL-17 questionnaire after
admission, before discharge, during first and second followup.



Providing patient information leaflets to Intervention group patients.

Study Material
1) Patient Profile form
2) Patient information leaflets
3) KAP questionnaire
4) MDQoL-17 Quality of life questionnaire
5) Informed consent form
6) Patient information sheet
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Patient Profile form
Includes Demographic details, History of Present Illness, Social History, Family History, Past
Medical History, Lab values- Body Mass Index (BMI), Blood Pressure (BP), total cholesterol,
triglyceride, Low- Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), Fasting blood
glucose, Postprandial sugar, HbA1c, Serum creatinine, List of medicines. (Appendix 2)

Patient information leaflets
This is the validated PIL for Diabetes (Vooradi et al)(8) includes information on diabetes such as
definition, risk factors, normal values of blood sugar levels, complications, dietary requirements,
exercise, life style modifications and information of commonly prescribed medications. It is
prepared in 2 different languages which are suitable for the patients. That provided information
to patient enrolled in Intervention group. (Appendix 3)

KAP questionnaire (Knowledge, Attitude, Practice questions)
S. Palaian et al developed and validated KAP questionnaire in the year 2003.(9) It consisted of 25
questions: seven attitude/practice questions (numbers 8, 11, 13, 16, 17, 23, and 24) and 18
knowledge-related questions. For the knowledge questions, each question was scored as one (1)
for a correct answer and as zero (0) for an incorrect answer. (Appendix 4)

Table 1: KAP Domains and Item numbers
Domains

No. of Items

Item Numbers

Attitude/Practice questions

7

8, 11,13,16, 17, 23, 24

Knowledge

18

1,2,3,4,5,6,7,9,10,12,14,15,18,19,20,21,22,25
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Quality of life questionnaire MDQoL-17
The MDQoL-17 questionnaire was developed and validated by Acharya LD et al in the year
2010.(11)It consists of 17 questions that comprise seven domains, which include physical
functioning, role limitations due to physical health problems, role limitations due to personal or
emotional problems, emotional well-being, social functioning, energy/ fatigue, and general
health perceptions. The scores are 0-100, 0 being the minimum and 100 being the maximum
score Scores represent the percentage of total possible score. This can be applied to evaluate QoL
of more number of diabetes patients thus enhancing and strengthening the MDQoL tool.
(Appendix 5)
Table 2: MDQoL-17 Domains and Item numbers
Domains

No. of Items

Item Numbers

Physical functioning

3

4, 5, 6

Role limitations due to
physical health

1

7

Role limitations due to
emotional

2

11, 12

Energy fatigues

1

17

Emotional well being

3

8, 9, 10

Social functioning

4

13, 14, 15, 16

General health

3

1, 2, 3

Table 3: Response category and scores of MDQoL-17
Item Number

Response category and Scores

1, 2, 7, 13

1 100, 2 75, 3 50, 4 25, 50

3
4, 5, 6
8, 9, 10, 11, 12, 14, 15, 16
17

10, 225, 350, 475, 5100
10, 250, 3100
10, 220, 340, 460, 580, 6100
1100, 280, 360, 440, 520, 60
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Table 4: Assessment of MDQoL Score for different QOL Score range
MDQoL score

QOL Score range

Less than 50
50-70
More than 70

Poor
Moderate
better

Informed consent form
A suitably prepared informed consent by Kasturba Medical College and Kasturba Hospital
Institutional Ethics Committee, Manipal in 2 different languages which was taken as consent by
patients which is used for the purpose of the study. (Appendix 6)

Patient information sheet
Patient information sheet is prepared in 2 different languages as per Ethics Committee format
which includes details about the study. It is given to patient to inform regarding the study.
(Appendix 7)

Operational modality
Patients diagnosed with type 2 diabetes in the department of medicine unit 2 and 4 of the hospital
between the period August 2018 to March 2019 was identified, and enrolled in the study as per
inclusion criteria. Informed consent obtained from the patients, once the patient is ready to
participate in this study. There are two arms for the study Intervention group and the Usual
medical care group.
As per the sample size calculation (Sample size and power was calculated using the two sample,
continuous outcome, two-tailed t-test approach, with type 1 and type 2 errors fixed at 5% and
10% respectively) total of 104 type 2 DM patients is included in the study, 52 patients in the
Intervention group and 52 patients in the Usual medical care group.
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The intervention group was provided with Pharmaceutical care in addition to standard medical
care given by the physician. Pharmaceutical care includes medication order review , Patient
counseling which done by using validated PIL in 2 different languages which are suitable for the
patients, related to lifestyle changes and information regarding medicine. Relevant data collected
from the patient medical record by using Data collection form. These data collected from Day of
Admission, Before Discharge, 1st Follow-up, 2nd Follow-up.
The Usual medical care group was not provided with the Pharmaceutical care such as
Counseling, Medication order review, Patient information leaflets. Patient data is collected using
Data collection form similar to the intervention group. Follow up of patients was identified with
the help of Physician on further visits. Usual medical care group will be provided with routine
care as followed by the hospital by physician and nurses.
Both Intervention group and Usual medical care group administered with the Knowledge,
Attitude, and Practice KAP questionnaire and MDQoL-17 quality of life questionnaire to the all
the patients with any one language (Kannada/English) which are suitable for the patients. The
Interview was be conducted approximately for 20 minutes for each questionnaire. These data
collected on Day of Admission, Before Discharge, 1st Follow-up, 2nd Follow-up. Follow-up of
patients was identified with the help of Physician on further visits.
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Patients recruited after Ethical
Committee approval N=104

Patients allocated to
intervention group( From
medicine unit 2) (N=52)

First follow-up
completed
(N=41)

Second follow-up
completed
(N=24)

Patients allocated to Control
group( From medicine unit 4)
(N=52)

First follow-up
completed
(N=28)

Second follow-up
completed
(N=12)

Patient who completed both the follow-up their result is
analyzed using SPSS version 20, which includes
Demographic characteristics, Blood glucose level(FBS),
HbA1c, Quality of life (MDQoL) questionnaire and KAP
questionnaire.
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Data Analysis and Statistics
Data collected was documented and evaluated using SPSS version 20 for various parameters like
demographic characteristics of the patients which includes gender, age group, duration of
diabetic history, duration of hospitalization, number of diabetic drugs prescribed and the lab
values Blood glucose levels, glycosylated Hb, creatinine, urea level was analyzed. Demographic
data was expressed using descriptive statistics. Lab values analysis of both the group analysed
comparing the mean values. KAP and MDQoL -17 result pairwise comparison for different time
interval analyzed by two way repeated measure ANOVA. Independent paired test is used to
analysis between the group mean±SD both for KAP and MDQoL questionnaires. P value <0.05,
was considered as significant.
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RESULTS

RESULTS
A Prospective Interventional study was conducted in the Department of Medicine at
Kasturba Hospital Manipal. Patients diagnosed with type 2 diabetes in the department
of medicine unit 2 and 4 of the hospital between the period August 2018 to March
2019 was identified, and enrolled in the study as per inclusion criteria. A total of 104
type 2 DM patients is included in the study, 52 patients in the Intervention group and
52 patients in the Usual medical care group.

1. Demography of the patients
a) Gender wise distribution in Intervention Group:
Out of 104 Type 2 Diabetes patients, 52 patients included in the intervention group. Out of which
26 (46.4%) were male patients and 26 (46.4%) were female patients, which is showed in
Figure.1.
Fig.1: Gender wise distribution in Intervention Group
26(46.4%)
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b) Gender wise distribution in Control Group:
Out of 104 Type 2 Diabetes patients,52 patients included in the control group. Out of which
all 52 (100%) were male patients which is showed in Figure.2.
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Fig.2: Gender wise distribution in Control Group
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c) Age group wise distribution in Intervention Group:
Out of 52 type 2 Diabetes patients, 14 (25%) were between 41 and 50 years of
age, 14 (25%) were between 51 and 60 years, 14 (25%) were between 61 and 70
years, 9(16.1%) were between 71 and 80 years of age, 1(1.8%) were between 81
and 90 years of age group as represented in Figure 3.
Fig.3: Age group wise distribution in Intervention Group
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d) Age group wise distribution in Control Group:

Out of 52 type 2 Diabetes patients, 2(3.8%) were between 31 and 40 years of age,
10 (19.2%) were between 41 and 50 years, 14 (26.9%) were between 51 and 60
years of age, 20 (38.5%) were between 61 and 70 years, 5(9.6%) were between 71
and 80 years of age, 1(1.2%) were between 81 and 90 years of age group as
represented in Figure 4.
Fig 4: Age group wise distribution in Control Group
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e) Distribution of Body mass index (BMI) of Intervention and Usual medical
care (Control) group
In the Intervention group out of 52 patients 3(5.4%) patients BMI was 18.4 and below, 1(1.8%)
patients was between 18.5-22.9, 55.4(59.6%) patients was between 23-24.9, 17(30.4%) was 25
and above Body mass index. (Kg/m2)
In the Control group out of 52 patients 3(5.8%) patients was 18.4 and below, 15(28.8%) patients
was between 18.5-22.9, 18(43.8%) patients was between 23-24.9, 16(30.8%) patients was 25 and
above Body mass index.(Kg/m2) showed in the Table 5.

Department of Pharmacy Practice

Page 33

Table 5: Distribution of Body mass index (BMI) (Kg/m2)
BMI (Kg/m

2

)

Intervention group
N=52
No. of patients n(%)

18.4 and below
18.5-22.9
23-24.9
25 and Above

3(5.4)
1(1.8)
55(59.6)
17(30.4)

Usual medical care(Control)
group
N=52
No. of patients n(%)
3(5.8)
15(28.8)
18(34.8)
16(30.8)

f ) Diabetic History of patients
Out of 52 patients in the intervention group 6(11.53%) patients were having diabetic history Less
than 1 year, 12(23.07%) patients had history of diabetes for 1 to 5 years, 19(36.53%) patients had
history of diabetes for 6 to 10 years, 15(28.84%) patients had history of diabetes more than 10
years.
Among 52 patients in the control group 8(15.38%) patients were having diabetic history Less
than 1 year, 19(36.53%) patients had history of diabetes for 1 to 5 years, 14(26.92%) patients had
diabetic history for 6 to 10 years,11(21.15%) patients had history of diabetes more than 10 years.
Showed in the table 6.
Table 6: Diabetic History of patients
History of DM
(years)
Less than 1
1 to 5
6 to 10
More than 10

Intervention group
N=52
No. of patients n(%)
6(11.53)
12(23.07)
19(36.53)
15(28.84)

Usual medical care(Control) group
N=52
No. of patients n(%)
8(15.38)
19(36.53)
14(26.92)
11(21.15)

g) Duration of Hospitalization
In the intervention group 10(17.9%) were hospitalized less than 5 days, 13(23.2%) patients were
hospitalized between 6-10 days, 23(41.1%) patients were hospitalized between 11-15 days,
6(10.7%) were hospitalized more than 15 days.
In the control group 11(21.2%) were hospitalized less than 5 days, 28(53.8%) patients were
hospitalized between 6-10 days, 11(21.2%) patients were hospitalized between 11-15 days,
2(3.8%) were hospitalized more than 15 days.
Department of Pharmacy Practice

Page 34

Table 7: Duration of Hospitalization
Duration of Hospitalization Intervention group
(Days)
N=52

0-5
6-10
11-15
Above 15

No. of patients n(%)
10(17.9)
13(23.2)
23(41.1)
6(10.7)

Usual medical care(Control)
group
N=52
No. of patients n(%)
11(21.2)
28(53.8)
11(21.2)
2(3.8)

h) Prescription patterns of Diabetic drug
In the intervention group there were 17(30.4%) patients being treated with oral hypoglycemic
agents, 22(39.3%) patients were taking Insulin monotherapy and 13(23.2%) patients were taking
combination of insulin and oral hypoglycemic agents(OHA).

In the control group there were 22(39.3%) patients being treated with oral hypoglycemic agents,
18(32.1%) patients were taking Insulin monotherapy and 12(21.4%) patients were taking
combination of insulin and oral hypoglycemic agents as shown in the fig.5 and fig.6
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Fig.5: Prescription patterns of Diabetic drug in the Intervention Group

N=52
12(21.4%)
22(39.3%)
OHA
Insulin
18(32.1%)

Both

Fig.6: Prescription patterns of Diabetic drug in the Usual medical care (Control)
Group
N=52
22(23.2%)

17(30.4%)
OHA
Insulin

13(39.3%)
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2. Lab values analysis of Intervention and Usual medical care group
Among 52 patients in the intervention group 24 patients completed both 1rst and 2nd follow-up,
where as in control group 12 patients completed their both the follow-up. Various test were
conducted to determine the glycemic control, glycosylated hemoglobin (HbA1c), Fasting blood
sugar (FBS), post prandial blood sugar (PBBS), serum creatinine and serum urea at the day of
admission, before discharge, first follow up and second follow up. Patients in the both the group
who completed 1rst and 2nd follow–up their lab values are analyzed. There is improvement in the
FBS, PPBS, HbA1c values of intervention group. Details showed in the Table 8.

Table 8: Lab values analysis of Intervention and Usual medical care group(Control)
Parameter
target
(mean±S
D)
Study
group

Day of
(DOA)
(%)

admission Day of
(DOD)
(%)

discharge First follow up
(%)

Second follow up
(%)

Interventio
n
N=24

Control
N=12

Intervention
N=24

Control
N=12

Interventio
n
N=24

Control
N=12

Intervention Control
N=24
N=12

8.7±2.19

8.5±2.0
8

NA

NA

7.10±1.09

7.47±1.
3

6.65±0.83

7.42±0.80

174±82.75

180.16±
99.40

150.45±39.6 151.83
5
±43.18

138.74±38.
36

155±68.
92

120.87±23.
86

123±33.07

Post
prandial
Blood
Sugar
(mg/dl)
Creatinine
(mg/dl)

201.41±66.
21

227.58±
61.96

180.70±54.1 196.08
4
±33.62

197.70±53.
59

208.91±
75.07

181.16±48.
04

195.25±65.
76

1.34±0.95

1.05±0.
61

1.16±0.57

1.19±0.80

0.98±0.
55

0.88±0.61

0.99±0.63

Urea
(mg/dl)

36.52±27.3
8

32.25±2
4.34

32.20±15.72 26.66±
16.10

25.62±11.8
5

22.58±1
0.97

26.33±17.0
9

17.66±6.91

HBA1c
(%)
Fasting
Blood
Sugar
(mg/dl)
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3. Assessment of MDQoL Score for Intervention Group
Out of 52 patients in the intervention group, 41 patients came for first follow up and 24 patients
completed the second follow up. The patients who completed both first and second follow up
their MDQOL score is showed in table 9.
Table 9: Assessment of MDQoL Score for Intervention Group
Patient No.
N=24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Day of admission Day of discharge First Follow Up
DOA
DOD
56.53
50.00
55.00
59.61
56.92
59.61
59.61
63.46
62.69
65.76
58.46
67.69
66.15
70.00
48.84
56.92
61.15
56.15
65.38
62.69
56.15
44.61
62.30
55.02
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58.07
51.92
60.02
60.38
53.46
61.11
58.88
63.84
65.00
65.38
71.92
74.23
74.23
76.15
57.69
63.46
69.61
68.07
70.76
73.07
57.69
61.92
80.76
71.92

58.84
55.00
87.69
80.00
81.92
83.30
73.86
80.38
75.76
76.53
67.30
82.30
87.69
76.53
82.30
69.61
84.23
83.07
85.76
74.12
70.76
68.16
82.02
73.02

Second
up

Follow

60.00
61.53
89.23
81.00
82.32
83.84
80.38
81.34
78.92
80.76
78.46
83.02
89.28
80.76
87.30
71.28
84.48
85.38
86.36
74.82
72.32
82.12
82.18
75.82
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i)

Assessment of MDQoL Score for different QOL Score range in intervention Group

In the intervention group patients who had completed their second follow up their MDQoL score
range during day of admission (DOA) 1(4.0%) patients had poor QoL score, 23(92%) had
Moderate QoL score. During day of discharge 15(60%) patients had Moderate QoL score,
9(36%) had Better QoL score. During First follow up 5(20%) had Moderate, 19(76%) had Better
QoL score. In the second follow up 2(8.0%) had Moderate QoL score, 22(88%) had Better QoL
score. These score range was measured using compare mean analysis. It is showed in table 10.

Table 10: Assessment of MDQoL Score for different QOL Score range in intervention
Group
MDQoL
Range
N= 24

Scores DOA

Poor
Moderate

DOD

1rst follow up

2nd Follow up

1(4.0%)

-

-

-

23(92%)

15(60%)

5(20%)

2(8.0%)

-

9 (36%)

19(76%)

22(88%)

Better
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4. Assessment of MDQoL Score for Usual medical care (Control ) Group
Out of 52 patients in the Usual medical care (Control) group,28 patients came for first follow up
and 12 patients completed the second follow up. The patients who completed both first and
second follow up their MDQOL score of Usual medical care (Control) group showed in table 11.
Table 11: Assessment of MDQoL Score for Usual medical care (Control) Group
Patient No.
N=12

Day of admission Day of discharge First Follow Up
DOA
DOD

1
2
3
4
5
6
7
8
9
10
11
12

65.0
58.07
49.23
60.32
55.38
58.46
45.38
53.84
64.23
65.05
70.76
68.84

58.07
58.87
53.07
66.53
57.69
68.84
48.46
59.23
68.02
70.38
71.92
70.38

59.23
69.61
55.0
77.69
63.07
69.23
67.69
58.46
66.82
71.32
70.82
68.18

Second
up

Follow

66.15
71.15
54.02
78.12
62.38
66.15
66.18
62.32
62.18
70.82
70.12
67.13

j) Assessment of MDQoL Score for Different QOL Score range in Usual medical care
(Control) Group
In the Usual medical care (Control) group patients who had completed their second follow up
their MDQoL score range during day of admission (DOA) 2(16.7%)patients had poor QoL score,
9(75.0%)had Moderate, 1(8.3%) had Better QoL score. During day of discharge 1(8.3%) patients
had poor QoL score, 8(66.7%) patients had Moderate QoL score, 3(25.0%) had Better QoL
score. During First follow up 9(75.0%) had Moderate QoL score, 3(25.0%) had Better QoL
score. In the second follow up had 7(58.3%) Moderate QoL score, 4(33.3%) had Better QoL
score. These score range was measured using compare mean analysis, showed in table 12.
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Table 12: Assessment of MDQoL Score for Different QOL Score range in Usual medical
care (Control) Group

MDQoL
Range
N= 12

Scores

Poor
Moderate

DOA

DOD

1rst follow up

2nd Follow up

2(16.7%)

1(8.3%)

-

-

9(75.0%)

8(66.7%)

9(75.0%)

7(58.3%)

1(8.3%)

3(25.0%)

3(25.0%)

4(33.3%)

Better

Table 13: Assessment of MDQoL Score mean±SD for Intervention and Usual medical care
(Control) Group
Group
(mean±SD)
Intervention
N=24
Control
N=12

Day of admission Day of discharge
DOA
DOD
59.19±6.08
65.39±7.61
59.19±7.71

63.62±7.70

First Follow Up
76.67±8.52

Second Follow
up
79.70±7.45

66.42±6.36

66.39±6.014

The MDQoL score mean value in the day of admission for Intervention group is 59.19±6.08 and
for control group 59.19±7.71.During Day of discharge 65.39±7.61 for Intervention group,
63.62±7.70 for control group. In the First Follow up 76.67±8.52 for intervention group and
66.42±6.36 for control group. For the Second Follow up Intervention group had 79.70±7.45
mean±SD and the control group had 66.39±6.014. Independent paired test is used to analysis
between the group mean±SD.
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k) Comparison of MDQoL Score for Intervention and Usual medical care (Control )
Group
The Assessment of MDQoL Score between the group was calculated by Two Way Repeated
Measure Anova. The p<0.00 considered as significant, There is a significant difference between
the MDQoL scores in each follow up as indicated by the P value (0.00) in the both the group.
Score is change at different time intervals or follow up, it is called as Interaction of time with
that of score. The greenhouse geisser source p value found to be significant (p<0.00) for different
time intervals. There is significant improvement in the quality of life score in the intervention
group more than that of control group.
Table 14: Assessment of MDQoL Score Pair-wise comparison for Intervention and Usual
medical care (Control) Group
No.
of Group
Times

Time intervals

1

DOD
First Follow-up
Second Follow-up

2

Intervention DOA
N=24
First Follow-up
Second Follow-up

3

DOA
DOD
Second Follow-up

4

Control
N=12

DOA
DOD
First Follow-up

Mean
difference

Std. error

Significance

-4.638
-12.179
-13.677*

0.979
1.417
1.425

0.000
0.000
0.000

4.638
-7.540
-9.039

.979
1.491
1.455

0.000
0.000
0.000

12.179
7.540
-1.499

1.417
1.491
0.595

13.677
9.039
1.499

1.425
1.455
0.595

0.000
0.000
0.100
0.000
0.000
0.100

The pairwise analysis shows statistical significant (p<0.00) improvement in MDQoL score of
DM patients in both the group between day of admission, day of discharge, first follow up and
second follow up.
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5. Assessment of KAP Score for Intervention Group
Out of 52 patients in the intervention group, 41 patients came for first follow up and 24 patients
completed the second follow up. The patients who completed both first and second follow up
their KAP score showed in table 15 and figure 7.
Tab 15: Assessment of KAP Score for Intervention Group
Patient No.
N=24

Day of admission Day of discharge First Follow Up
DOA
DOD

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

19.00
11.00
18.00
16.00
19.00
15.00
18.00
18.00
15.00
18.00
17.00
18.00
18.00
19.00
11.00
14.00
17.00
15.00
12.00
11.00
13.00
16.00
14.00
18.00

20.00
14.00
21.00
19.00
21.00
17.00
21.00
18.00
19.00
20.00
15.00
19.00
20.00
21.00
16.00
18.00
17.00
18.00
19.00
18.00
17.00
19.00
20.00
21.00

22.00
18.00
22.00
21.00
21.00
21.00
18.00
20.00
21.00
21.00
21.00
20.00
19.00
21.00
20.00
19.00
19.00
19.00
19.00
20.00
21.00
21.00
21.00
22.00

Second
up

Follow

23.00
21.00
23.00
22.00
20.00
22.00
22.00
23.00
22.00
21.00
19.00
20.00
21.00
22.00
21.00
21.00
22.00
19.00
21.00
21.00
21.00
22.00
21.00
22.00

Considering the scores from day of admission till the second follow up there is improvement in
the knowledge, attitude and practice score in the intervention group. There was statically
significant improvement (p<0.00) in the KAP score which is analyzed using the two way
repeated measure Anova.
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Fig.7: Assessment of KAP Scores of Intervention Group
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6) Assessment of KAP Score for Control Group
Out of 52 patients in the Usual medical care (Control) group,28 patients came for first follow up
and 12 patients completed the second follow up. The patients who completed both first and
second follow up their KAP score of Usual medical care (Control) group showed in table 16 and
fig 8.
Tab 16: Assessment of KAP Score for Control Group
Patient No.
N=12

1
2
3
4
5
6
7
8
9
10
11
12

Day of admission Day of discharge First Follow Up
DOA
DOD
18.00
19.00
12.00
17.00
14.00
11.00
12.00
13.00
17.00
11.00
20.00
20.00

16.00
20.00
16.00
15.00
15.00
13.00
17.00
14.00
16.00
16.00
18.00
21.00

19.00
18.00
17.00
17.00
19.00
18.00
21.00
20.00
15.00
17.00
18.00
20.00

Second
up

Follow

19.00
19.00
18.00
15.00
20.00
21.00
19.00
18.00
17.00
15.00
17.00
19.00

Considering the scores from day of admission till the second follow up there is not much
improvement in the knowledge, attitude and practice score in the control group. There was
statically significant (p<0.00) in the KAP score which is analyzed using the two way repeated
measure Anova.
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Fig.8: Assessment of KAP Scores of Control Group
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Table 17: Assessment of KAP Score mean±SD for Intervention and Usual medical care
(Control) Group

Group
(mean±SD)
Intervention
N=24
Control
N=12

Day of admission Day of discharge First Follow Up
DOA
DOD
15.83±2.69
18.66±1.94
20.29±1.19
15.33±3.52

16.41±2.31

18.25±1.65

Second Follow
up
21.33±1.09
18.08±1.83

The KAP score mean value in the day of admission for Intervention group is15.83±2.69 and for
control group15.33±3.52.During Day of discharge 18.66±1.94 for Intervention group,
16.41±2.31 for control group. In the First Follow up 20.29±1.19 for intervention group and
18.25±1.65 for control group. For the Second Follow up Intervention group had 21.33±1.09
mean±SD and the control group had 18.08±1.83. Independent paired test is used to analysis
between the group mean±SD. This result shows there is improvement in KAP score of
Intervention group from date of admission till the 2nd follow-up compare to that of Control
group.
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l) Assessment of KAP Score for Intervention and Usual medical care
(Control) Group
The Assessment of KAP Score between the group was calculated by Two Way Repeated
Measure Anova. The p<0.00 value is considered as significant, There is a significant difference
between the KAP scores in each follow up as indicated by the P value (0.00) in the both the
group.
Score is change at different time intervals or follow up, it is called as Interaction of time with
that of score.The greenhouse geisser source p value found to be significant (p<0.00) for different
time intervals in the intervention group. In the control group there is no much improvement the
scores. There is significant improvement in the KAP score in the intervention group more than
that of control group.
Table 18: Assessment of KAP Score Pair-wise comparison for Intervention and Usual
medical care (Control) Group
No. of Group
Times
1

2
Intervention

Time intervals

Std. error

Significance

DOD
First Follow-up
Second Follow-up
DOA
First Follow-up
Second Follow-up

Mean
difference
-1.708
-3.604
-4.125
1.708
-1.896
-2.417

0.396
0.491
0.564
0.396
0.364
0.440

0.001
0.000
0.000
0.001
0.000
0.000

DOA
DOD
Second Follow-up

3.604
1.896
-0.521

0.491
0.364
0.223

0.000
0.000
0.152

DOA
DOD
First Follow-up

4.125
2.417
0.521

0.564
0 .440
0.223

0.000
0.000
0.152

3

Control
4

The pairwise analysis KAP score between day of admission (DOA) to first follow up and second
follow up showed significance (P<0.00) as well day of admission (DOA) to day of discharge
(DOD) showed significance in the intervention group. In

the control group there is no

significance in KAP score from day of admission (DOA) to first follow up and second follow
up.(P>0.00).
Department of Pharmacy Practice

Page 47

DISCUSSIONS

DISCUSSION
This study is conducted in order to evaluate the impact of pharmaceutical care in type 2 DM
patients in the Indian set-up. A prospective interventional study was planned out in tertiary care
hospital in South India. A total of 104 patients were recruited, out of which 52 patients in the
intervention group and 52 patients in the control group. Out of which 41 patients in the
intervention group completed their 1rst follow up, 24 patients completed their both 1rst and 2nd
follow up. As well in the usual medical care (control) group 24 patients completed 1rst follow up
and 12 patients completed both the follow up.
In this study majority of the study population were male ,overall number of male patient in both
the group is 78( 75.01% ). This was similar to the observation from the study carried out by
Sriram S et al in which majority of the patients were male 63(52.5%).

(2)

Al Mazroui N et al

included 234 type 2 DM patients in their study, out of which in Intervention group 84 (70%)
and in control group 82 (68.3%) were male patients, It shows most of DM patients are male in
both groups. It may be due to more admission of male patients in the hospital. (5)

In our study mean age for type 2 DM was found to be 61.38±12.2 years, most of patients are of
age between 40 to 70 years. Which is similar to study conducted by Gholami A et al in which
they reported the mean age of type 2 DM patients was 59.65±12.3 years for type 2 diabetes
patients.

(54)

In most of developing countries majority of patients with type 2 DM are in the age

group 45- 65 years.

(55)

Sarah W et al observed in a study that most of the patients between age

40 to 65 have high prevalence of type 2 Diabetes. (56)
The patients who completed both 1rst and 2nd follow up their mean HbA1c value in intervention
group found to be 6.65±0.83 % and in control group found to be 7.42±0.80%.Similarly fasting
blood glucose levels mean value of the intervention group is 120.87±23.86 mg/dL and in control
group 123±33.07 mg/dL. In this study we observed there was statistically significant decrease in
HbA1c levels and Fasting Blood Glucose level from day of

admission to second follow

up.(p<0.00)
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A similar study conducted by Sriram S et al where the average HbA1c values for the control
group was 8.95 ± 2.47 % and that for the intervention group was 8.63 ±2.27%.The pooled mean
difference in the change of HbA1c was 0.76% and FBG 19.13% between the intervention and
control group. The interventions of pharmacists include diabetes education and counseling on
drugs, disease, diet, exercise, lifestyle modification that achieves the goal of treatment,
improving quality of life, all of these interventions aimed at improving glycemic control. (2)

A study by Rafsanjani Z et al where patients in the intervention group achieved HbA1C level of
5.8 ± 0.8 % while HbA1C increased in the control group up to 6.7 ± 1.4 %and the difference
between groups was significant (P = .02).These observations lead to the program being
successful for patients requiring intensive diabetes management with target A1C level below 6
%. In the intervention group, adherence to medicines and self - care practices significantly
improved. (57)
The MDQoL score for intervention group showed statistically significant improvement (p<0.00)
from day of admission to 2nd follow up. Where as in control group there was statistically
significant decrease in the MDQoL score from day of admission to second follow up (p>0.00).It
shows there is a impact on quality of life of DM patients who received Pharmaceutical care
provided by the clinical pharmacist.

A Study conducted by Al Mazroui N et al, Health-related quality of life (SF36 Questionnaire)
questionnaire was administered from baseline, 4rth, 6th, 12th month of follow up in both
intervention and control group. Intervention group patients‘ quality of life scores improved over
time (P < 0.001), whereas those of control group patients remained relatively constant. Overall
the 12-month assessment in the intervention patients when compared with control group patients
(P < 0.05). (5)

Similarly the study by Clifford R et al, where Diabetes Quality of Life (DQOL) questionnaire
was administered in the pharmaceutical care group and control group. Patients in the
pharmaceutical care group attended six-month appointments at six-week intervals with an
experienced clinical pharmacist. Whereas control group received usual outpatient care. The
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Pharmaceutical care program affect the patient‘s QOL and it significantly improved patient
satisfaction by the care provided by the clinical pharmacist in Pharmaceutical care group. (60)

Improvement in quality of life may be partly attributed to increased contact by diabetic patients
with the clinical pharmacist, but is also likely to be associated with improved adherence to
lifestyle counseling. The results of this study show that PC interventions can have a positive
impact on how patients with diabetes can cope with day-to-day activities and quality of life.

There was statistically significant improvement (p<0.00) in the KAP score of the intervention
group from day of admission to 2nd follow up and in control group there was statistically
significant decrease in the KAP score from day of admission to second follow up (p>0.00).It
was proved that patient counseling with PIL will improve the knowledge related to disease and
drugs.
A study conducted by S. Palaian et al where both test and control group admistred with KAP
qustionarie at different intervals of time.There was significant improvement in the KAP score
from day of admission to first follow up in the test group (P = .013).where as in control group no
such improvement was observed. The test group's median knowledge score on the day of
discharge is increased; this was substantially higher on the day of admission (P=.003). Similarly,
in the first and second follow-up assessments, the median knowledge scores were significantly
higher (P <.001) than on the day of admission (P <.001). The enhanced scores of knowledge
clearly indicate the advantages of counseling provided by pharmacists, although they did not
translate into improved attitudes or results of practice. (9)
A Prospective Comparative study conducted by Sriram S et al where patients of Intervention
group were subjected to The Problem Areas in Diabetes Scale (PAID) questionnaire. The PAID
scores during the first interview had a value of 49.78 ± 22.34 and after the counseling session
with a lower score of 31.39 ± 17.12 showed significant improvement of PAID scores (p<
0.00).The PAID scores were significantly higher in patients newly diagnosed with diabetes
followed by 1-5yrs and female patients, but there was no difference based on age according to
study. (2)
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LIMITATIONS AND
FUTURE DIRECTIONS

LIMITATIONS & FUTURE DIRECTIONS
Limitations


Time constrain – could not follow up all the patients

Future directions


Study can be conducted on large sample size for longer duration of time.



Similar study can be conducted on other chronic disease such as hypertension, asthma,
hyperlipidemia etc.
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CONCLUSION

CONCLUSION
Present study was carried out in order to Study the impact of Pharmaceutical care on the type 2
Diabetic patients in a tertiary care hospital in South India. Results from this study suggests that
pharmacist involvement in an inter professional team has resulted in an improved glycemic
control as shown in significant change in lab values, patient quality of life and knowledge related
to disease and medications.
The improved scores of KAP and MDQoL clearly indicate the benefits of counseling provided
by pharmacists in the Intervention group. Majority of intervention patients had Better QoL score
(>70) during second follow up. There was a significant improvement in the knowledge, attitude
and practice of the intervention group patients than that of control group. As well significant
improvement in the patient quality of life seen after the counseling and education by using
patient in formation leaflet. Study conclude that there is a overall positive impact on quality of
life, control of blood glucose level and knowledge related to disease and medication by
providing Pharmaceutical care to the type 2 DM patients.
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APPENDICES

PATIENT DATA COLLECTION FORM
DEPARTMENT OF PHARMACY PRACTICE, MCOPS, MANIPAL
Patient Hosp. NO. :
Age:
Weight:
Complaints On Admission:

Date of Admission:
Sex:
BMI:

Date of Discharge:

History of Diabetes:
Social History:
Family History:
Provisional Diagnosis Lab values
HbA1c (%)
FBS
PPBS
HDL (mmol/L)
LDL (mmol/L)
TG (mmol/L
TC(mmol/L)
TC:HDL
Creatinine
(µmol/L)
Urea
Blood pressure
(mmHg)
BMI
Weight
Comment

Final Diagnosis -

Date of admission Date of Discharge

1rst follow up

2nd follow up

DRUG WITH DOSE & ROUTE
Generic Name

Brand Name

PROGRESS CHART
Date

Follow up

Investigations

Drug Related Problem

Drug /Dosing
Problem/Medication Error

Adverse Drug Reaction(ADR)

Drug – Drug /Food Interaction

Date of admission
Problem
Intervention
Date of Discharge
Problem
Intervention
1rst follow up
Problem
Intervention
2nd follow up
Problem
Intervention

DISCHARGE MEDICATION
DRUG

STRENGTH

FREQUENCY

NO. OF DAYS

Counseling Diabetic Patients
Appendix A: Knowledge, Attitude, and Practice (KAP) Questionnaire
1. Diabetes is a condition in which the body contains:

 a higher level of sugar in the blood than normal.
 a lower level of sugar in the blood than normal.
 either a higher or a lower level of sugar in the blood than normal.
 I don’t know
2. The major cause of diabetes is:

 an increased availability of insulin in the body.
 a decreased availability of insulin in the body.
 I don’t know
3. The symptom(s) of diabetes is/are:

 increased frequency of urination.
 increased thirst and hunger.
 increased tiredness.
 slow healing of wounds
 all the above
 I don’t know
4. Diabetes, if not treated:

 can lead to eye problems.
 can lead to kidney problems.
 can lead to foot ulcers.
 can lead to heart problems.
 all the above
 I don’t know
5. The most accurate method of monitoring diabetes is:

 checking blood glucose levels.
 checking urine sugar.
 I don’t know
6. In a diabetic patient, high blood pressure can increase or worsen:








the risk of heart attack.
the risk of stroke.
the risk of eye problems.
the risk of kidney problems.
all the above
I don’t know

7. A diabetic patient should measure his or her blood pres-sure:








once a year.
once every six months.
once every two months.
once every month.
need not check at all
I don’t know

8. When was your blood pressure checked last?







one week ago
one month ago
two months ago
six months ago
one year ago

9. The lifestyle modification(s) required for diabetic patients is/are:

 weight reduction.
 stopping smoking.
 stopping alcohol intake.
 all the above
 I don’t know
10. A diabetic patient should have his or her eyes checked:

 once a year.
 once every six months.
 need not check at all
11. When did you have your last eye examination? o one month ago

 six months ago
 one year ago
 two years ago
 not done at all
12. Regular urine tests will help in knowing:

 the status of liver function.
 the status of kidney function.
 the control of diabetes.
 I don’t know

13. When was your last urine exam? o one month ago





six months ago
one year ago
not done at all

14. The important factors that help in controlling blood sugar are:







a controlled and planned diet
regular exercise
medication
all the above
none

15. A regular exercise regimen will help in:
 increasing blood circulation.




enhancing insulin action.
I don’t know

16. Do you exercise regularly?



Yes
o
If yes, how often?
 Every
o day

 Noo
Once
o weekly

Once
o monthly

17. Are you following a controlled and planned diet?
 Yes
o
 No
If yes, how often?
 Always
o



oSometimes



oRarely

18. The well-balanced diet includes:






green leafy vegetables.
fiber-rich food.
low sugar, oil, and fat.
I don’t know

19. For proper foot care, a diabetic patient:






should inspect and wash the feet daily.
should select the best possible footwear.
should walk barefoot inside and outside the house.
should not walk barefoot inside and outside the house.

20. Treatment of diabetes comprises:







antibiotic therapy.
blood transfusions.
substituting insulin.
taking more bitter vegetables.
I don’t know

21. Diabetes cannot be treated with:







insulin.
glibenclamide.
metformin.
antibiotics.
I don’t know

22 Upon control of diabetes, the medicines:






can be stopped immediately.
can be stopped after one month.
should be continued for life.
I don’t know

23. Do you miss taking the doses of your diabetic medication?



Yes



If yes, how often?
occasiona
 lly
o

No



oonce a week



oonce a month

24. Are you aware of blood sugar levels falling below normal when you are taking drugs?



Yes



No

If yes, did you at any time experience any of the following symptoms?






weakness
confusion
visual disturbances
I don’t know

25. How do you manage hypoglycemic symptoms?






by taking sugar
by taking medicines
by taking insulin
I don’t know

ªÀÄzsÀÄªÉÄÃºÀ gÉÆÃVAiÀÄ°è w¼ÀÄªÀ½PÉ, ¤®ÄªÀÅ ªÀÄvÀÄÛ C¨sÁå¸À PÀÄjvÀ ¥Àæ±ÁßªÀ½
1) ªÀÄzsÀÄªÉÄÃºÀ JA§ PÁ¬Ä¯ÉAiÀÄ°è



gÀPÀÛzÀ°è ¸ÀPÀÌgÉ CA±À ¸ÁªÀiÁ£ÀåªÁVgÀÄzÀQÌAvÀ eÁ¹Û EgÀÄªÀÅzÀÄ.



gÀPÀÛzÀ°è ¸ÀPÀÌgÉ CA±À ¸ÁªÀiÁ£ÀåªÁVgÀÄzÀQÌAvÀ PÀrªÉÄ EgÀÄªÀÅzÀÄ.



¸ÀPÀÌgÉ CA±À gÀPÀÛzÀ°è eÁ¹Û/PÀrªÉÄ EgÀÄªÀÅzÀÄ.



£À£ÀUÉ UÉÆwÛ®è.

2) ªÀÄzsÀÄªÉÄÃºÀ JA§ PÁ¬Ä¯ÉAiÀÄ ¥ÀæªÀÄÄR PÁgÀtªÉAzÀÀgÉ.



E£ÀÄì°£ï zÉÃºÀzÀ°è ºÉaÑ£À CA±ÀzÀ°è EgÀÄªÀÅzÀÄ.



E£ÀÄì°£ï zÉÃºÀzÀ°è PÀrªÉÄ CA±ÀzÀ°è EgÀÄªÀÅzÀÄ.



£À£ÀUÉ UÉÆwÛ®è.

3) ªÀÄzsÀÄªÉÄÃºÀ PÁ¬Ä¯ÉAiÀÄ aºÉß K£ÉAzÀgÉ



DUÁUÀ ªÀÄÆvÀæªÁUÀÄwÛgÀÄªÀÅzÀÄ.



¨ÁAiÀÄjPÉ ºÁUÀÆ ºÀ¹ªÉ eÁ¹Û EgÀÄªÀÅzÀÄ.



¨ÉÃUÀ£É ¸ÀÄ¸ÁÛUÀÄªÀÅzÀÄ.



UÁAiÀÄUÀ¼ÀÄ ¨ÉÃUÀ ªÁ¹AiÀiÁUÀ¢gÀÄªÀÅzÀÄ.



ªÉÄÃ¯É ºÉÃ½zÀ J¯Áè PÁgÀtUÀ¼ÀÄ



£À£ÀUÉ UÉÆwÛ®è.

4) ªÀÄzsÀÄªÉÄÃºÀPÉÌ aQvÉìAiÀÄ£ÀÄß ¤ÃqÀ¢zÀÝgÉÉ



PÀtÂÚUÉ vÉÆAzÀgÉ §gÀÄªÀÅzÀÄ.



ªÀÄÆvÀæPÉÆÃ±ÀzÀ vÉÆAzÀgÉ §gÀÄªÀÅzÀÄ.



¥ÁzÀzÀ ºÀÄtÂÚ£À vÉÆAzÀgÉ §gÀÄªÀÅzÀÄ.



ºÀÈzÀAiÀÄzÀ vÉÆAzÀgÉ §gÀÄªÀÅzÀÄ.



ªÉÄÃ¯É ºÉÃ½zÀ J¯Áè vÉÆAzÀgÉUÀ¼ÀÄ.



£À£ÀUÉ UÉÆwÛ®è.

5) ªÀÄzsÀÄªÉÄÃºÀ PÁ¬Ä¯ÉAiÀÄ ¤AiÀÄAvÀætzÀ°è EqÀ®Ä C£ÀÄ¸Àj¸À¨ÉÃPÁzÀ CwÃ ªÀÄÄRå PÀæªÀÄ JAzÀgÉ gÀPÀÛzÀ ¸ÀPÀÌgÀ CA±À



gÀPÀÛzÀ ¸ÀPÀÌgÀ CA±ÀªÀ£ÀÄß ¥ÀvÉÛ ºÀZÀÄÑªÀÅzÀÄ.



ªÀÄÆvÀæzÀ ¸ÀPÀÌgÉ CA±ÀªÀ£ÀÄß ¥ÀvÉÛ ºÀZÀÄÑªÀÅzÀÄ.



£À£ÀUÉ UÉÆwÛ®è.

6) ªÀÄzsÀÄªÉÄÃºÀ gÉÆÃVAiÀÄ°è C¢üPÀ gÀPÀÛzÉÆvÀÛqÀªÀÅ



ºÀÈzÀAiÀÄWÁvÀ §gÀÄªÀ ¸ÁzsÀåvÉ ºÉaÑ¸ÀÄvÀÛzÉ.



PÀtÂÚ£À vÉÆAzÀgÉ §gÀÄªÀ ¸ÁzsÀåvÉ ºÉaÑ¸ÀÄvÀÛzÉ.



ªÀÄÆvÀæPÉÆÃ±ÀzÀ vÉÆAzÀgÉ §gÀÄªÀ ¸ÁzsÀåvÉ ºÉaÑ¸ÀÄvÀÛzÉ.



ªÉÄÃ¯É ºÉÃ½zÀ J¯Áè vÉÆAzÀgÉUÀ¼ÀÄ.



£À£ÀUÉ UÉÆwÛ®è.

7) ªÀÄzsÀÄªÉÄÃºÀ gÉÆÃVAiÀÄÄ vÀ£Àß gÀPÀÛzÉÆvÀÛqÀªÀ£ÀÄß ¤AiÀÄ«ÄvÀªÁV vÀ¥Á¸ÀuÉ ªÀiÁqÀ¨ÉÃPÁzÀ ¸ÀªÀÄAiÀÄ



ªÀµÀðPÉÆÌAzÀÄ ¨Áj.



6 wAUÀ½UÉÆªÉÄä.



2 wAUÀ½UÉÆªÉÄä.



1 wAUÀ½UÉÆªÉÄä.



vÀ¥Á¸ÁuÉ ªÀiÁqÀ¨ÉÃPÁV®è.



£À£ÀUÉ UÉÆwÛ®è.

8) ¤ªÀÄä gÀPÀÛzÉÆvÀÛqÀªÀÅ PÀqÉAiÀÄ¨Áj ¥ÀjÃQë¹zÀÄÝ AiÀiÁªÁUÀ



MAzÀÄ ªÁgÀzÀ »AzÉ.



MAzÀÄ wAUÀ¼ÀÀ »AzÉ.



JgÀqÀÄ wAUÀ¼À »AzÉ.



DgÀÄ wAUÀ¼À »AzÉ.



MAzÀÄ ªÀµÀðzÀ »AzÉ.

9) ªÀÄzsÀÄªÉÄÃºÀ gÉÆÃVAiÀÄÄ ªÀiÁqÀ¨ÉÃPÁzÀ fÃªÀ£À ±ÉÊ°AiÀÄ§zÀ¯ÁªÀuÉAiÀÄÄ



vÀÆPÀªÀ£ÀÄß PÀrªÉÄ ªÀiÁqÀÄªÀÅzÀÄ.



©Ãr ¹UÀgÉÃmï ¸ÉÃzÀÄªÀÅzÀ£ÀÄß PÀrªÉÄ ªÀiÁqÀÄªÀÅzÀÄ.



ªÀÄzsÀå¥Á£À ¤°è¸ÀÄªÀÅzÀÄ.



ªÉÄÃ¯É ºÉÃ½zÀ J¯Áè PÁgÀtUÀ¼ÀÄ.



£À£ÀUÉ UÉÆwÛ®è.

10) M§â ªÀÄzsÀÄªÉÄÃºÀ gÉÆÃV vÀ£Àß PÀtÄÚUÀ¼À£ÀÄß AiÀiÁªÁUÀ ¥ÀjÃPÉë ªÀiÁr¸À¨ÉÃPÀÄ



ªÀµÀðPÉÆÌAzÀÄ ¨Áj.



6 wAUÀ½UÉÆªÉÄä.



¥ÀjÃPÉë ªÀiÁqÀ¨ÉÃPÁV®è.

11) ¤ªÀÄä PÀtÂÚ£À ¥ÀjÃPÉë PÀqÉAiÀÄ¨ÁjUÉ ªÀiÁrzÀÄÝ AiÀiÁªÁUÀ?



MAzÀÄ wAUÀ¼ÀÀ »AzÉ.



6 wAUÀ¼ÀÀ »AzÉ.



MAzÀÄ ªÀµÀðzÀ »AzÉ.



JgÀqÀÄ ªÀµÀðzÀ »AzÉ.



F »AzÉ ªÀiÁqÀ¯ÉÃ E®è.

12) ¤AiÀÄ«ÄvÀ ªÀÄÆvÀæ¥ÀjÃPÉë ªÀiÁqÀÄªÀÅzÀjAzÀ F PÉ¼ÀUÉ PÉÆnÖgÀÄªÀ §UÉÎ w½AiÀÄ®Ä ¸ÀºÁAiÀÄ ªÀiÁqÀÄvÀÛzÉ.



¦vÀÛPÉÆÃ±ÀzÀ PÁgÀå.



ªÀÄÆvÀæPÉÆÃ±ÀzÀ PÁgÀå.



ªÀÄzsÀÄªÉÄÃºÀzÀ ªÉÄÃ¯É ¤AiÀÄAvÀæt.



£À£ÀUÉ UÉÆwÛ®è.

13) ¤ªÀÄä ªÀÄÆvÀæ ¥ÀjÃPÉëAiÀÄ£ÀÄß PÀqÉAiÀÄ¨Áj ¥ÀjÃPÉë ªÀiÁrzÀÄÝ AiÀiÁªÁUÀ?



MAzÀÄ wAUÀ¼ÀÀ »AzÉ.



6 wAUÀ¼ÀÀ »AzÉ.



MAzÀÄ ªÀµÀðzÀ »AzÉ.



ªÉÄÃ¯É ºÉÃ½zÀÄÝ AiÀiÁªÀÅzÀÄ C®è.

14) gÀPÀÛzÀ°ègÀÄªÀ ¸ÀPÀÌgÉ CA±ÀªÀ£ÀÄß ºÀvÉÆÃnAiÀÄ°èqÀ®Ä ªÀiÁqÀÄªÀ ªÀÄÄRåªÁzÀ «zsÁ£ÀUÀ¼ÉÃ£ÉAzÀgÉ?



¤AiÀÄ«ÄvÀ ªÀÄvÀÄÛ PÀæªÀÄ§zÀÝªÁzÀ DºÁgÀ.



PÀæªÀÄªÁV ªÁåAiÀiÁªÀÄ ªÀiÁqÀÄªÀÅzÀÄ.



OµÀzsÀUÀ¼ÀÄ.



ªÉÄÃ¯É ºÉÃ½zÀ J¯Áè PÁgÀtUÀ¼ÀÄ.



AiÀiÁªÀÅzÀÄ C®è.

15) ¥Àæw ¢£À ªÁåAiÀiÁªÀÄ ªÀiÁqÀÄªÀÅzÀjAzÀ?



gÀPÀÛ ¥ÀjµÀ®£É CxÀªÁ gÀPÀÛ¸ÀAZÁgÀ ºÉaÑ¸ÀÄvÀÛzÉ.



E£ÀÄì°£ï ¥ÀæªÀiÁt ºÉZÀÄÑvÀÛzÉ.



£À£ÀUÉ UÉÆwÛ®è.

16) ¤ÃªÀÅ PÀæªÀÄªÁV ªÁåAiÀiÁªÀÄ ªÀiÁqÀÄwÛÃgÁ?



ºËzÀÄ



E®è.

ºËzÁzÀgÉ JµÀÄÖ ¨Áj



¥ÀæwÃ¢£À.



ªÁgÀPÉÆÌAzÀÄ ¨Áj



wAUÀ½UÉÆªÉÄä

17) ¤ÃªÀÅ PÀæªÀÄ§zÀÝªÁzÀ DºÁgÀ ¥ÀxÀåªÀ£ÀÄß ªÀiÁqÀÄwÛÃgÁ?




ºËzÀÄ
E®è.
ºËzÁzÀgÉ JµÀÄÖ ¨Áj



AiÀiÁªÁUÀ®Æ.



PÉ®ªÀÅ ¨Áj



C¥ÀgÀÆ¥À

18) ¸ÀªÀÄvÉÆÃ®£À DºÁgÀªÀÅ



¸ÉÆ¥ÀÄà vÀgÀPÁjUÀ¼ÀÄ.



£ÁgÀÄ ¥ÀzÁxÀðUÀ¼ÀÄ.



PÀrªÉÄ ¸ÀPÀÌgÉ, JuÉÚ fqÀÄØ ¥ÀzÁxÀðUÀ¼ÀÄ.



£À£ÀUÉ UÉÆwÛ®è.

19) ¥ÁzÀzÀ ¸ÀÄgÀPÀëvÉUÁV M§â ªÀÄzsÀÄªÉÄÃºÀ gÉÆÃVAiÀÄÄ



¢£Á®Æ ¥ÁzÀªÀ£ÀÄß ¥ÀjÃQë¸À¨ÉÃPÀÄ ºÁUÀÆ vÉÆ¼ÉAiÀÄ¨ÉÃPÀÄ.



PÁ°UÉ ¸ÀjºÉÆAzÀÄªÀ M¼ÉîAiÀÄ ¥ÁzÀgÀPÉëUÀ¼À£ÀÄß ºÁPÀ¨ÉÃPÀÄ.



§jUÁ®°è ªÀÄ£ÉAiÀÄ M¼ÀUÉ ºÁUÀÆ ºÉÆgÀUÉ £ÀqÉAiÀÄ¨ÉÃPÀÄ.



§jUÁ®°è ªÀÄ£ÉAiÀÄ M¼ÀUÉ ºÁUÀÆ ºÉÆgÀUÉ £ÀqÉAiÀÄ¨ÁgÀzÀÄ.

20) ªÀÄzsÀÄªÉÄÃºÀªÀ£ÀÄß F AiÀiÁªÀ «zsÁ£ÀUÀ½AzÀ UÀÄt¥Àr¸À§ºÀÄªÀÅzÀÄ?



CAn §AiÉÆÃnPïì.



gÀPÀÛ PÉÆqÀÄªÀÅzÀjAzÀ.



E£ÀÄì°£ï PÉÆqÀÄªÀÅzÀjAzÀ.



PÀ» ¥ÀzÁxÀðUÀ¼À£ÀÄß ¸ÉÃ«¸ÀÄªÀÅzÀjAzÀ.



UÉÆwÛ®è.

21) ªÀÄzsÀÄªÉÄÃºÀ gÉÆÃUÀPÉÌ F PÉ¼ÀV£À AiÀiÁªÀ aQvÉì ¤ÃqÀ§ºÀÄzÀÄ?



E£ÀÄì°£ï.



qÀAiÉÆÃ¤¯ï



UÉèöÊPÉÆÃªÉÄÃmï



DAn §AiÉÆÃnPïì.



£À£ÀUÉ UÉÆwÛ®è.

22) ªÀÄzsÀÄªÉÄÃºÀ gÉÆÃUÀªÀÅ ºÀvÉÆÃnUÉ §AzÀ£ÀAvÀgÀ, OµÀzsÀUÀ¼À£ÀÄß



PÀÆqÀ¯ÉÃ ¤°è¸À§ºÀÄzÀÄ.



MAzÀÄ wAUÀ¼À £ÀAvÀgÀ ¤°è¸À§ºÀÄzÀÄ.



fÃªÀ£À ¥ÀÆwð vÉUÉzÀÄPÉÆ¼Àî¨ÉÃPÀÄ.



£À£ÀUÉ UÉÆwÛ®è.

23) ¤ÃªÀÅ ¤ªÀÄä ªÀÄzsÀÄªÉÄÃºÀ gÉÆÃUÀzÀ ªÀÄzÀÄÝUÀ¼À£ÀÄß vÀ¦à¸ÀÄwÛÃgÁ?




ºËzÀÄ
E®è.
ºËzÁzÀgÉ JµÀÄÖ ¸Áj



C¥ÀgÀÆ¥À.



ªÁgÀPÉÆÌªÉÄä



wAUÀ½UÉÆªÉÄä.

24) ªÀÄzsÀÄªÉÄÃºÀ gÉÆÃUÀzÀ aQvÉìUÉ G¥ÀAiÉÆÃV¸ÀÄªÀ OµÀzsÀUÀ¼ÀÄ, ¤ªÀÄä gÀPÀÛzÀ ¸ÀPÀÌgÉ ¥ÀæªÀiÁtªÀ£ÀÄß ¸ÁªÀiÁ£ÀåQÌAvÀ
PÀrªÉÄ ªÀiÁqÀÄªÀ §UÉÎ ¤ªÀÄUÉ w½¢zÉAiÉÄÃ?




ºËzÀÄ
E®è.
ºËzÁzÀgÉ, F PÉ¼ÀUÉ PÉÆnÖgÀÄªÀ AiÀiÁªÀÅzÁzÀgÀÆ ®PÀëtUÀ¼ÀÄ ¤ªÀÄä°è PÁtÂ¹ªÉAiÉÄÃ?



§®»Ã£ÀvÉ



ªÀiÁ£À¹PÀ zË§ð®å



zÀÈ¶Ö ªÀiÁAzÀåvÉ



UÉÆwÛ®è.

25) gÀPÀÛzÀ°è ¸ÀPÀÌgÉ ¥ÀæªÀiÁt PÀrªÉÄAiÀiÁzÁUÀ ¤ÃªÀÅ AiÀiÁªÀ jÃwAiÀÄ°è ¤¨sÁ¬Ä¸ÀÄwÛÃj?



¸ÀPÀÌgÉ ¸ÉÃ«¸ÀÄªÀÅzÀjAzÀ.



OµÀzsÀUÀ¼À£ÀÄß ¸ÉÃ«¸ÀÄªÀÅzÀjAzÀ.



E£ÀÄì°£ï vÉUÉzÀÄPÉÆ¼ÀÄîªÀÅzÀjAzÀ.



UÉÆwÛ®è.

APPENDIX III
Development of Modified Diabetes quality of life questionnaire (MDQoL17)
1. How is your overall health after being diagnosed as diabetic?
o Excellent
o Very good
o Good
o Fair
o Poor
2. Diabetes has worsened your quality of life?
o Not at all
o Slightly
o Moderately
o Quite a bit
o Extremely
3. You get sick quite often compared to others?
o Definitely true
o Mostly true
o Don’t Know
o Mostly false
o Definitely false
4. Walking for Normal daily chores (like going to work or market)?
o Yes Limited a Lot
o Yes Limited a Little
o No Not limited at All
5. Climbing several flights of stairs?
o Yes limited a lot
o Yes limited a little
o No not limited at all
6. Climbing one flight of stairs?
o Yes limited a lot
o Yes limited a little
o No not limited at all
7. Diabetes is affecting your Work life?
o Not at all
o Slightly
o Moderately
o Quite a bit
o Extremely

8.

Do you feel downhearted or depressed?
o All of the time
o A good bit of time
o Some of time
o A little of time
o None of the time
9. Is Diabetes affecting your peace of mind?
o All of the time
o Most of the time
o A good bit of time
o Some of time
o A little of time
o None of the time
10.
Do you feel scared when you think about living with diabetes?
o All of time
o Most of the time
o A good bit of time
o Some time
o A little of time
o None of the time
11.
Whether diabetes made you feel lost since it restricts the food items you like?
o All of time
o Most of the time
o A good bit of time
o Some time
o A little of time
o None of the time
12.
Is diabetes making you lose your confidence in your abilities?
o All of the time
o Most of the time
o A good bit of time
o Some of time
o A little of time
o None of the time
13.
Is diabetes is affecting your Family life?
o Not at all
o Slightly
o Moderately
o Quite a bit
o Extremely

14.

Do you feel embarrassed managing your Diabetes in public (like taking
tablets/injecting the medicine)?
o All of the time
o Most of the time
o A good bit of time
o Some of the time
o A little of time
o None of the time

15. Whether Diabetes is a hindrance when you are planning for any travel ?
o All of the time
o Most of the time
o A good bit of time
o Some of the time
o A little of time
o None of the time
16. Is Diabetes bringing up economic burden to you?
o All of the time
o Most of the time
o A good bit of time
o Some of the time
o A little of time
o None of the time
17. Do you feel Energetic?
o
o
o
o
o
o

All of the time
Most of the time
A good bit of time
Some of time
A little of time
None of the time

ªÀÄzsÀÄªÉÄÃºÀ gÉÆÃVUÀ¼À°è fÃªÀ£À UÀÄtªÀÄlÖ C¼ÉAiÀÄÄªÀ ¥Àæ±ÁßªÀ½
1.

¤ÃªÀÅ ¸ÀPÀÌgÉ PÁ¬Ä¯ÉAiÀÄªÀgÀÄ JAzÀÄ w½zÀ £ÀAvÀgÀ ¤ªÀÄä DgÉÆÃUÀåzÀ ªÀÄlÖ ºÉÃVzÉ?
1) CvÀÄåvÀÛªÀÄ
2) GvÀÛªÀÄ
3) M¼ÉîAiÀÄ
4) ¸ÁzsÀgÀt
5) CzsÀªÀÄ
2. ¸ÀPÀÌgÉ PÁ¬Ä¯ÉAiÀÄÄ ¤ªÀÄä DgÉÆÃUÀåzÀ UÀÄtªÀÄlÖªÀ£ÀÄß PÀÄA¢¹zÉAiÉÄÃ?
1) K£ÀÆ E®è
2) vÀÄA¨Á PÀrªÉÄ
3) ¸ÁzsÀgÀt
4) wÃªÀæ
5) Cw wÃªÀæªÁV
3. ¨ÉÃgÉAiÀÄªÀjUÉ ºÉÆÃ°¹zÀ°è ¤ÃªÀÅ C£ÁgÉÆÃUÀå ¦ÃrvÀgÁVgÀÄ«gÁ?
1) RArvÀªÁVAiÀÄÆ ¸ÀvÀå
2) ºÉZÁÑV ¸ÀvÀå
3) £À£ÀUÉ UÉÆwÛ®è
4) ¸ÁªÀiÁ£ÀåªÁV vÀ¥ÀÄà
5) RArvÀªÁVAiÀÄÆ vÀ¥ÀÄà
4.
¢£À ¤vÀåzÀ PÉ®¸ÀUÀ½UÁV £ÀqÉAiÀÄÄªÀÅzÀÄ (¸ÁªÀiÁ£ÀÄ vÀgÀ®Ä ¸ÀAvÉUÉ ºÉÆÃUÀÄªÀÅzÀÄ EvÁå¢)
1) ºËzÀÄ vÀÄA¨Á PÀrªÉÄAiÀiÁVzÉ
2) ºËzÀÄ ¸Àé®à PÀrªÉÄAiÀiÁVzÉ
3) E®è K£ÀÄ ¥ÀjuÁªÀÄªÁV®è
5.
ºÀ®ªÀÅ ªÀÄºÀrUÀ¼À£ÀÄß ºÀvÀÄÛªÀÅzÀÄ
1) ºËzÀÄ vÀÄA¨Á PÀqÀÄªÉÄAiÀiÁVzÉ
2) ºËzÀÄ ¸Àé®à PÀqÀÄªÉÄAiÀiÁVzÉ
3) E®è K£ÀÆ ¥ÀjuÁªÀÄªÁV®è
6.
MAzÀÄ ªÀÄºÀrAiÀÄ£ÀÄß ºÀvÀÄÛªÀÅzÀÄ
1) ºËzÀÄ vÀÄA¨Á PÀrªÉÄAiÀiÁVzÉ
2) ºËzÀÄ ¸Àé®à PÀrªÉÄAiÀiÁVzÉ
3) E®è K£ÀÆ ¥ÀjuÁªÀÄªÁV®è
7.
¸ÀPÀÌgÉ PÁ¬Ä¯ÉAiÀÄÄ ¤ªÀÄä ¢£À¤vÀåzÀ ZÀlÄªÀnPÉAiÀÄ ªÉÄÃ¯É ¥ÀjuÁªÀÄ ©ÃjzÉAiÉÄÃ
1) K£ÀÆ E®è
2) vÀÄA¨Á PÀrªÉÄ
3) ¸ÁzsÀgÀt
4) wÃªÀæ
5) Cw wÃªÀæªÁV
8.
¤ÃªÀÅ AiÀiÁªÁUÀ®Æ zÀÄ:TUÀ¼ÁVgÀÄwÛÃgÁ?
1) J®è ¸ÀªÀÄAiÀÄ
2) ºÉaÑ£À ¸ÀªÀÄAiÀÄ
3) ¸Àé®à ¸ÀªÀÄAiÀÄ
4) PÉ®ªÀÅ ¸ÀªÀÄAiÀÄ
5) Cw PÀrªÉÄ ¸ÀªÀÄAiÀÄ
6) AiÀiÁªÁUÀ®Æ E®è

9.

10.

11.

12.

13.

14.

15.

¸ÀPÀÌgÉ PÁ¬Ä¯ÉAiÀÄÄ ¤ªÀÄä ªÀÄ£À¹ì£À ±ÁAwUÉ vÉÆAzÀgÉ GAlÄªÀiÁrzÉAiÉÄÃ?
1) J®è ¸ÀªÀÄAiÀÄ
2) ºÉaÑ£À ¸ÀªÀÄAiÀÄ
3) ¸Àé®à ¸ÀªÀÄAiÀÄ
4) PÉ®ªÀÅ ¸ÀªÀÄAiÀÄ
5) Cw PÀrªÉÄ ¸ÀªÀÄAiÀÄ
6) AiÀiÁªÁUÀ®Æ E®è
¸ÀPÀÌgÉ PÁ¬Ä¯ÉAiÉÆA¢UÉ §zÀÄPÀ®Ä ¤ªÀÄUÉ ¨sÀAiÀÄ GAmÁUÀÄªÀÅzÉÃ?
1) J®è ¸ÀªÀÄAiÀÄ
2) ºÉaÑ£À ¸ÀªÀÄAiÀÄ
3) ¸Àé®à ¸ÀªÀÄAiÀÄ
4) PÉ®ªÀÅ ¸ÀªÀÄAiÀÄ
5) Cw PÀrªÉÄ ¸ÀªÀÄAiÀÄ
6) AiÀiÁªÁUÀ®Æ E®è
¸ÀPÀÌgÉ PÁ¬Ä¯ÉAiÀÄÄ ¤ªÀÄUÉ EµÀÖªÁzÀ DºÁgÀzÀ ¸ÉÃªÀ£ÉAiÀÄ°è ¤§ðAzsÀ GAlÄªÀiÁrzÉAiÉÄÃ?
1) J®è ¸ÀªÀÄAiÀÄ
2) ºÉaÑ£À ¸ÀªÀÄAiÀÄ
3) ¸Àé®à ¸ÀªÀÄAiÀÄ
4) PÉ®ªÀÅ ¸ÀªÀÄAiÀÄ
5) Cw PÀrªÉÄ ¸ÀªÀÄAiÀÄ
6) AiÀiÁªÁUÀ®Æ E®è
¸ÀPÀÌgÉ PÁ¬Ä¯É¬ÄAzÀ ¤ªÀÄä DvÀä«±Áé¸ÀªÀÅ PÀrªÉÄAiÀiÁVzÉAiÉÄÃ?
1) J®è ¸ÀªÀÄAiÀÄ
2) ºÉaÑ£À ¸ÀªÀÄAiÀÄ
3) ¸Àé®à ¸ÀªÀÄAiÀÄ
4) PÉ®ªÀÅ ¸ÀªÀÄAiÀÄ
5) Cw PÀrªÉÄ ¸ÀªÀÄAiÀÄ
6) AiÀiÁªÁUÀ®Æ E®è
¸ÀPÀÌgÉ PÁ¬Ä¯ÉAiÀÄÄ ¤ªÀÄä PËlÄA©PÀ fÃªÀ£ÀzÀ ªÉÄÃ¯É ¥ÀjuÁªÀÄ GAlÄªÀiÁrzÉÃAiÉÄÃ?
1) K£ÀÆ E®è
2) vÀÄA¨Á PÀrªÉÄ
3) ¸ÁzsÀgÀt
4) wÃªÀæ
5) Cw wÃªÀæªÁV
¸ÁªÀðd¤PÀ ªÀ®AiÀÄzÀ°è ¸ÀPÀÌgÉ PÁ¬Ä¯ÉAiÀÄ G¥ÀZÀgÀuÉAiÀÄÄ vÉÆAzÀgÉ GAlÄªÀiÁqÀÄvÀÛzÉÃAiÉÄÃ?
1) J®è ¸ÀªÀÄAiÀÄ
2) ºÉaÑ£À ¸ÀªÀÄAiÀÄ
3) ¸Àé®à ¸ÀªÀÄAiÀÄ
4) PÉ®ªÀÅ ¸ÀªÀÄAiÀÄ
5) Cw PÀrªÉÄ ¸ÀªÀÄAiÀÄ
6) AiÀiÁªÁUÀ®Æ E®è
¥ÀæAiÀiÁt ªÀiÁqÀ®Ä wÃªÀiÁð¤¹zÁUÀ ªÀÄzsÀÄªÉÄÃºÀ PÁ¬Ä¯ÉAiÀÄÄ K£ÁzÀgÀÆ vÉÆAzÀgÉ PÉÆqÀÄvÀÛzÉAiÉÄÃ?
1) J®è ¸ÀªÀÄAiÀÄ
2) ºÉaÑ£À ¸ÀªÀÄAiÀÄ
3) ¸Àé®à ¸ÀªÀÄAiÀÄ
4) PÉ®ªÀÅ ¸ÀªÀÄAiÀÄ
5) Cw PÀrªÉÄ ¸ÀªÀÄAiÀÄ
6) AiÀiÁªÁUÀ®Æ E®è

16.

17.

ªÀÄzsÀÄªÉÄÃºÀ gÉÆÃUÀªÀÅ DyðPÀ ºÉÆgÉAiÀÄ£ÀÄß PÉÆqÀÄwÛzÉÃAiÉÄÃ?
1) J®è ¸ÀªÀÄAiÀÄ
2) ºÉaÑ£À ¸ÀªÀÄAiÀÄ
3) ¸Àé®à ¸ÀªÀÄAiÀÄ
4) PÉ®ªÀÅ ¸ÀªÀÄAiÀÄ
5) Cw PÀrªÉÄ ¸ÀªÀÄAiÀÄ
6) AiÀiÁªÁUÀ®Æ E®è
¤ÃªÀÅ AiÀiÁªÁUÀ®Æ ±ÀQÛ¨sÀjvÀgÁVgÀÄwÛÃgÁ?
1) J®è ¸ÀªÀÄAiÀÄ
2) ºÉaÑ£À ¸ÀªÀÄAiÀÄ
3) ¸Àé®à ¸ÀªÀÄAiÀÄ
4) PÉ®ªÀÅ ¸ÀªÀÄAiÀÄ
5) Cw PÀrªÉÄ ¸ÀªÀÄAiÀÄ
6) AiÀiÁªÁUÀ®Æ E®è

PATIENT INFORMATION LEAFLET ON DIABETES

What is Diabetes?

• Steroid medications use

Diabetes is a disease in which your blood sugar

• Diabetes during pregnancy

levels will be increased than the normal.

What are the complications of diabetes?

What is the role of insulin in the body?

If your blood sugar levels are very high, then it affects

Insulin is a hormone that helps your body to take

different parts of your body such as eyes, feet, skin,

sugar from blood. It is changed into energy which will

heart, kidney and nervous system.

be used for your daily activities. Whenever the insulin

What are the normal values of blood sugar levels?

levels are low, then the sugar level will be increased

Blood sugar levels

and causes diabetes.
What are the signs and symptoms of diabetes?

Normal values

On an empty stomach (fasting) Less than 100 mg/dl

The following are the signs and symptoms of
One or two hours after meals

hyperglycemia

Less than 140mg/dl

What is HbA1C?
It is the general test used to know the sugar level from
Frequent
urination

Sudden
weight
loss

Always
tired

past 120 days. The normal value should be in the

range of 6-7%.
What diet should I take?
The blood sugar levels will be controlled by eating
healthy diet, exercising regularly, taking medications
properly as prescribed by your doctor.

Numbness or
tingling
hands/feet

Always
thirsty

Wounds that
won’t heal

Skin
Infections
What are the risk factors for diabetes?
The following are the risk factors for diabetes

• Maintain normal body weight

• Eat healthy foods such as green leafy vegetables,
whole grains, fruits, and beans, low fat dairy foods
such as skimmed milk, yogurt, egg white, and

• Age 45 or older

skinless chicken , poultry and low fat fish

• Obese or overweight

• Foods containing high content of sugar should be

• Family history

avoided

• Emotional Stress

• Avoid banana, pineapple and watermelon

• Lack of physical activity

• Foods which have high starch such as bread, rice

• Smoking

and potatoes should be minimized as it raises the
blood sugar levels

• Avoid

eating foods which contain

high fats and oils such as cheese,

What

are

the

signs

and

symptoms

of

hypoglycemia and how it can be managed?

butter, burger, pizza, red meat and fried
items

Stop
smoking

Shaking

Sweating

Anxious

Dizziness

Hunger

Irritable

Headache

Blurred
vision

Limit alcohol
intake

Exercise

Weakness/Fati
gue
• Before you start an exercise program, contact your
doctor for your physical examination

• Hypoglycemia is a condition in which your sugar

• Do physical activity regularly such as aerobic

levels in the blood are very low. Hypoglycemia is

activity for at least 30 minutes a day.

caused by taking too much diabetic medication at a
time, change of insulin dose, missing a meal,

Foot care

delaying a meal, doing more exercise than normal
You must have regular feet checkup by

or drinking alcohol.

yourself. Whenever you go out, wear

• Always carry packets of table sugar, sugar candies

socks and shoes. Select the shoes

or glucose packets with you when you go out.

which are comfortable to your feet.

• Check your blood sugar levels regularly at your

Check your feet daily at night. If you find

local doctor or nearby hospital when you feel

any cracks on your feet, apply Vaseline

hypoglycemic symptoms.

to the feet. Check your
shoes everyday for any cracks, stones
or nails.
Eye care
Go for your eye checkup regularly at

your local doctor or near by hospital as
it may cause eye problems.

PATIENT INFORMATION LEAFLET ON INSULIN

What is insulin?

• Keep your insulin vial away from direct sunlight.

It is used to control your blood sugar levels.

• Protect your insulin (bottles, pens, and cartridges)

What are the types of injecting insulin available

from extremes of hot and cold.

in the medical store?
How many times should I take insulin in a day?
Depending on your blood sugar levels your doctor may
prescribe.
When should I take insulin?
Depending on the doctor’s prescription and the type of
Insulin pen

Insulin vial
with
syringe

insulin given by your doctor, you have to take insulin at

Insulin pump

the correct time as prescribed.
What are the target blood sugar levels in diabetic

Who should take the insulin?
Insulin is given for the Type 2 diabetic patients,
patients who do not respond to oral diabetic
medications, pregnant women, during infection
conditions, serious heart, kidney and liver problems
with diabetes and it is most needed for the Type 1
diabetic patients.

patients?
Depending on your doctor prescribed, you need to
check your blood sugar levels using your blood glucose
meter
The blood sugar level targets are:
• Upon waking or during fasting 70 to 130 mg/dl
• Less than 180 mg/dl 1 to 2 hours after the start of a

What are the insulin injection sites?

meal

Insulin is taken subcutaneously depend on your

What are the necessary precautions to be taken

doctor’s prescription.

while using the insulin?
• Before using the insulin, carefully read the instructions

Areas to inject

Upper

or explained by your health care professional or your

arms,

doctor

Abdomen,
Upper

• Inject this medication under the skin as directed by

thighs,

your doctor.

Buttocks

• Before injecting each dose, clean the injection site
with rubbing spirit.
Where should I store insulin vial?

• Change the injection site each time to minimize the

• It is recommended that insulin should be stored in

injury under the skin and to avoid developing problems

a refrigerator (2°C to 8°C), do not freeze the insulin

under the skin.

vial.

• Do not use insulin injection if it is colored, or has solid

• Unopened

particles or clumps in it.

vials

of

insulin,

cartridges

and

preloaded pens can be stored in the refrigerator until

• Use it at the same time each day as prescribed by

the expiry date.

your doctor.

• Store the insulin vials in a closed container or in a

• Always carry packets of table sugar, sugar candies or

cool place while you are travelling to any place.

glucose packets with you when you go out

• Check at your local doctor regularly when you feel

What are the common side effects with the

hypoglycemic symptoms like shaking, sweating,

insulin injection?

anxiety, dizziness, headache, weakness.

• Hypoglycemia: Taking too much insulin may cause

What are the special precautions while using the

low blood sugar level.

insulin injections?

• Deposition of the fatty tissues at the

• Do not rub the area after the injection

site of injection: This causes swelling

• Do not inject insulin into the skin which is red,

at the injecting area, itchy, redness.

swollen, or itchy, always change the area to be
• Weight gain

injected
• Check the expiration date before using, and don't
use any insulin beyond its expiration date

• Do not change brands or types of insulin without
directions of your doctor
• Check your urine/blood sugar level regularly as
directed by your doctor
• Dispose insulin syringe, when the needle is dull or
bent or has come into contact with anything other than
clean skin.
• If you forget to take your insulin, your blood sugar
may go too high (hyperglycemia), which can lead to
serious problems.
What

are

the

types

of

insulin

preparations

available?
• Rapid-acting insulin will work within a few minutes
after injection, but it shows effects only for a few hours
• Regular- or short-acting insulin takes about 30
minutes to show its effects and lasts for 3 to 6 hours
• Intermediate-acting insulin takes 2 to 4 hours to show
its effects, and its effects can last for 18 hours
• Long-acting insulin takes 6 to 10 hours to show its

effects
Use the insulin preparation as prescribed by your
doctor, depending on the diabetes type and your blood
sugar levels.

GLIMEPIRIDE

METFORMIN

What is Glimepiride?

What is Metformin?

It is given to control your blood sugar levels

It is given to control your blood sugar levels.

What are the available strengths?

What are the available strengths?

1mg, 2mg, 4mg

500mg, 850mg, 1 g

How much dose should I take?

How much dose should I take?

This medication is taken orally, and should be taken

The dose of medication varies from patient to

once daily depend on your doctor prescribed. The dose

patient depending on the present disease condition.

of medication varies from patient to patient depending on

How to take the medication?

the present disease condition.

Take this tablet by mouth with a glass of water

How to take the medication?

. Take the whole tablet at a time. Do not crush or

Take this tablet by mouth with a glass of water

. Take

chew the tablet.

the whole tablet at a time. Do not crush or chew the

When to take the medication?

tablet.

The tablet should be taken once or twice daily after

When to take the medication?

meals as prescribed your doctor. If it prescribed

Take this tablet by mouth after breakfast or with first

once daily, then take the medication at the particular

meal of the day as prescribed by your doctor.

time as your doctor prescribed.

What should I do if I miss the dose?

What should I do if I miss the dose?

If you forget to take the dose, take it soon as you

If you forget to take the dose, take it soon as you

remember. If you do not remember till the following day,

remember. If you do not remember till the following

skip the missed dose. Don’t take two tablets together.

day, skip the missed dose. Don’t take two tablets

What are the common side effects?

together.

Hypoglycemia, dizziness, headache and nausea, weight

What are the common side effects?

gain

Change in taste, nausea and vomiting, weight loss

What are the necessary precautions to be taken?

What are the necessary precautions to be

Take the tablet same time each day to avoid

taken?
The tablet should be taken at the same

hypoglycemic symptoms.

• Eat sufficient meal before taking this medication.

time each day to avoid hypoglycemic symptoms.

• This medication makes you feel dizzy. Do not drive or

• Drink plenty of fluids while taking this medication.

do any activity that makes you alert.

• Eat sufficient meal before taking this medication

• Keep the medication out of the reach of children.

• Before taking this medication, report your doctor if

• Never share your medication with anyone.

you are suffering from acute illness, infections, liver

What are the foods to be avoided during the course

disease or kidney disease.

of treatment?

• Keep the medication out of the reach of children.

Ask your doctor or pharmacist before using any other

• Never share your medication with anyone.
What are the foods to be avoided during the
course of treatment?

medicine, including over the counter medicines, vitamins

and herbal products.

Ask your doctor or pharmacist before using any

Where should the tablet be stored?

other

Store the tablet in a closed container at room

medicines, vitamins and herbal products.
Where should I store the tablet?

temperature, away from heat, moisture and direct light..

medicine,

including

over

the

counter

Store the tablet in a closed container at room

temperature, away from heat, moisture and direct
light.

GLIBENCLAMIDE

What is Glibenclamide?
It is given to control your high blood sugar levels.
What are the available strengths?
2.5mg, 5mg
How much dose should I take?

The dose of medication varies from patient to patient
depending on the present disease condition. This
medication should be taken once daily as prescribed
by your doctor.
How to take the medication?
Take this tablet by mouth with a glass of water

.

Take the whole tablet at a time. Do not crush or chew
the tablet.
When to take the medication?
Take this medication with breakfast or your first main
meal of the day unless your doctor tells you.
What should I do if I miss the dose?
If you forget to take the dose, take it soon as you
remember. If you do not remember till the following
day, skip the missed dose. Don’t take two tablets
together.
What are the common side effects?

Hypoglycemia, heartburn, weight gain
What are the necessary precautions to be taken?
Take the tablet same time each day to avoid
hypoglycemic symptoms.
• Tell your doctor if you have kidney, liver, heart
problems.
• Don’t drink alcohol while using this medication.
• Keep all the medications out of the reach of children.
• Never share your medication with anyone.

Where should the tablet be stored?
Store the tablet in a closed container at room
temperature, away from heat, moisture and direct
light.

ಭಧುಮೇಸ ಕುರಿತಹದ ರ ೇಗಿ ಮಹಹಿತಿ ತ್ರ

ಭಧುಮೇಸ ಎಂದರೇನು?

ಭಧುಮೇಸದ ತೆ ಡಕುಗಳು ಯಹಸಸ?

ಭಧುಮೇಸಸ, ನಿಭೆ ಯಕತದ ಷಕಕರಮ ಭಟ್ಟಸ ಸಹಮಹನಯಕ್ಕಂತ್

ಒಂದುಳೇಲ ನಿಭೆ ಷಕಕರಮ ಭಟ್ಟಗಳು ಅತಿ ಷಙಹಾದಲ್ಲಿ, ಅದು ನಿಭೆ

ಷಙಹಾಗಿಯುಸದರಿಂದ ಕಂಡುಫಯು ಒಂದು ಕಹಯಿಱ.

ದೇಸದ ವಿವಿಧ ಭಹಗಗಳು ಅಂದರ, ಕಣುು, ಕಹಲ್ಲನ ಪಹದ, ಚಭಜ, ಸೃದಮ,

ದೇಸದಲ್ಲಿ ಇನುಸಲ್ಲನ್ ನ ಕಹಮಜಳೇನು?

ಕ್ಡಿು ಭತ್ುತ ನಯಹಯಸದ ಮೇಱ ರಿಣಹಭನುುಂಟ್ುಮಹಡುತ್ತದ.

ಇನುಸಲ್ಲನ್, ಯಕತದಿಂದ ಷಕಕರ ಅಂವನುು ತೆಗೆದುಕ ಳಳಲು ನಿಭೆ ದೇಸಕಕ

ಯಕತ ಷಕಕರ ಭಟ್ಟಗಳ ಸಹಮಹನಯ ರಿಮಹಣಗಳು ಯಹಸಸ?

ಷಹಹಮ ಮಹಡು ಒಂದು ಹಹೇಜನ್ ಆಗಿದ. ಇದು ವಕ್ತಯಹಗಿ

gÀPÀÛzÀಲ್ಲಿ ¸ÀPÀÌgÉ0iÀÄ ¥ÀæªÀiÁt

ಮಹಪಹಜಡುಷ ಂದಿ, ನಿಭೆ ದೈನಂದಿನ ಚಟ್ುಟ್ಟಕಗಳನುು ಮಹಡಲು
ನೆಯಳಹಗುತ್ತದ. ಇನುಸಲ್ಲನ್ ಭಟ್ಟಸ ಕಡಿಮಯಹದಹಗಱಲಿ, ಷಕಕರ
ಭಟ್ಟಸ ಷಙಹಾಗುತ್ತದ ಭತ್ುತ ಭಧುಮೇಸನುು ಉಂಟ್ುಮಹಡುತ್ತದ.

¸ÁªÀiÁ£Àå ¥ÀæªÀiÁt

ಖಹಲ್ಲ ಷ ಟ್ಟಟಮಲ್ಲಿ

ಗಿಂತ ಕಡಿಮೆ 100mg/dl

ಊಟ್ಳಹದ ಎಯಡು ಗಂಟ್ಟಗಳ ನಂತ್ಯ ಗಿಂತ ಕಡಿಮೆ 140mg/dl

ಭಧುಮೇಸದ ಚಿಷುಗಳು ಭತ್ುತ ಲಕ್ಷಣಗಳು ಯಹಸಸ?
ಷೈರ್ ಗಿಿಶಮಿಯಹದ ಚಿಷುಗಳು ಭತ್ುತ ಲಕ್ಷಣಗಳು ಈ ಕಳಗಿನಂತಿಳ:

HbA1C ಎಂದರೇನು?
ಇದು ಕಲದ 120 ದಿನಗಳಲ್ಲಿ ಷಕಕರ ಭಟ್ಟನುು ತಿಳಿಮಲು ಫಳಷಱಹಗು
ಒಂದು ಸಹಮಹನಯ ರಿೇಕ್ಷೆ. ಇದಯ ರಿಮಹಣಸ 6-7% ರೇಣಿಮಲ್ಲಿಯಬೇಕು.
ಯಹ ರಿೇತಿಮ ಥಯನುು ನಹನು ತೆಗೆದುಕ ಳಳಬೇಕು?
ನಿಭೆ ಳೈದಯಯ ಷಲಷಮ ಮೇರಗೆ, ಆರ ೇಗಯಳಹದುದನುು ಶೇವಿಷುಸದರಿಂದ,

ದೇ ದೇ ಭ ತ್ರ
ವಿಷರ್ಜನೆ

ಸಟಹತ್ ತ್ ಕ
ನಶಟ

ಯಹಳಹಗಲ
ದಣಿದಿಯುಸದು

ನಿಮಮಿತ್ಳಹಗಿ

ಳಹಯಯಹಭ

ಮಹಡುಸದರಿಂದ,

ತೆಗೆದುಕ ಳುಳಸದರಿಂದ

ಔಶಧಿಮನುು

ಯಕತಷಕಕರ

ಭಟ್ಟನುು

ನಿಮಂತ್ರಣದಲ್ಲಿರಿಷಫಸುದು.
• ಷಸರ್ ದೇಸ ತ್ ಕನುು ಕಹಪಹಡಿಕ ಳಿಳ

ಕೈಗಳಲ್ಲಿ/ಪಹದದ
ಅಡಿಮಲ್ಲಿ
ಭಯಗಟ್ಟಟದಂತಿಯುಸ
ದು ಅಥಳಹ
ರ್ುಮೆನೆನಿಷುಸದು

ಯಹಳಹಗಲ
ಬಹಯಹರಿಕ

ಗಹಮಗಳು
ಳಹಸಿಯಹಗದಿಯುಸ
ದು
• ಆರ ೇಗಯಕಯ ಆಹಹಯಗಲಹದಂತ್ಸ ಸಸಿಯುಎಱಮ ತ್ಯಕಹರಿಗಳನುು, ಇಡಿೇ
ಧಹನಯಗಳನುು, ಸಣುುಗಳನುು, ಭತ್ುತ ಅರಕಹಳು, ಕಡಿಮ ಕ ಬಿಿಯು
ಹಹಲ್ಲನ ಆಹಹಯಗಲಹದ ಕನೆ ತೆಗೆದ ಹಹಲು, ಷಯು, ಟ್ಟಟಮ ಬಿಳಿಭಹಗ,
ಭತ್ುತ ಚಭಜಯಹಿತ್ ಮಹಂಷ, ವುದಧ ಭತ್ುತ ಕಡಿಮ ಕ ಬಿಿಯು ಮಿೇನನುು

ಚಭಜದ
ಶ ೇಂಕುಗಳು

ಶೇವಿಸಿ.
• ಅತಿ ಷಚುಾ ಷಕಕರಮ ಅಂವವಿಯು ಆಹಹಯನುು ತ್ಯಜಿಸಿ.

ಭಧುಮೇಸಸ ಯಹರಿಗೆ eÁ¹Û ಫಯಫಸುದು?

• ಬಹಲಸಣುು, ಅನಹನಸ್ ಭತ್ುತ ಕಲಿಂಗಡಿ ಸಣುನುು ತ್ಯಜಿಸಿ.

F PÉ¼ÀV£À CA±ÀUÀ½zÀÝgÉ ªÀÄzsÀÄªÉÄÃºÀ ಫgÀÄªÀ ¸ÁzsÀåvÉUÀ¼ÀÄ eÁ¹Û

• ಷಚಿಾನ

• 45 ಶಜದಯು ಅಥಳಹ ೃದಧಯು

ಆಲ ಗಡ್ಡಡಮನುು ಕಡಿಮ ಶೇವಿಸಿ, ಏಕದಂರ ಇಸಗಳು ಯಕತ ಷಕಕರ

• ಬ ರ್ುು ಅಥಳಹ ಅತಿಯಹದ ತ್ ಕ

ಭಟ್ಟನುು ಷಚುಾ ಮಹಡಫಸುದು.

• ಕೌಟ್ುಂಬಿಕ ಹಿನೆುಱ
• ªÀiÁ£À¹PÀ ಒತ್ತಡ
• ದೈಹಿಕ ಚಟ್ುಟ್ಟಕಮ ಕ ಯತೆ
• ಧ ಭಪಹನ
• ಗಭಹಜಶೆಮ ಷಭಮದಲ್ಲಿ ಭಧುಮೇಸ
• ಸಿಟೇರಹಯ್ಡಡ ಔಶಧಿಗಳ ಉೇಗ

ಪಿಶಟವಿಯು

• ಷಚುಾ
ಎಣ್ಣುಯಿಯು

ಕ ಬಿಿನ

ಆಹಹಯಗಲಹದ

ಅಂವವಿಯು

ಆಹಹಯಗಲಹದ

ಚಿೇಸ್,

ಬರಡ್,

ಭತ್ುತ
ಬಣ್ಣು,

ಫಗಜರ್, ಪಿಝಹ, ಕಂಸ ಮಹಂಷ ಭತ್ುತ ಕರಿದ
ದಹಥಜಗಳನುು ತ್ಯಜಿಸಿ.

ಅನು

ಭತ್ುತ

ಷೈಪಹಗಿಿಶಮಿಯಹದ ಚಿಷುಗಳು ಅಥಳಹ ಲಕ್ಷಣಗಳು ಯಹಸಸ ಭತ್ುತ
ಇದನುು ಷೇಗೆ ನಿಮಂತ್ರಣ ಮಹಡಫಸುದು?
ಆಱ ಕೇಹಹಲ್ ಶೇನೆ
ಮಿತಿಗೆ ಳಿಸಿ

ಧ ಭಪಹನ
ನಿಲ್ಲಿಸಿ
ಳಹಯಯಹಭ

ಕಂಪನ

ತ್ಱಷುತ್ುತಸದು

ಬಯುಸದು

ಆತ್ಂಕ

ಸಸಿಸ

ಕ್ರಿಕ್ರಿ

• ನಿೇಸ ಳಹಯಯಹಭನುು ಆಯಭಿಷು ದಲು, ನಿಭೆ ದೈಹಿಕ
ರಿೇಕ್ಷೆಗಹಗಿ ಳೈದಯಯನುು ಷಂಕ್ಜಸಿ.
• ಏರ ೇಬಿ

ಚಟ್ುಟ್ಟಕಮಂತ್ಸ

ದೈಹಿಕ

ಚಟ್ುಟ್ಟಕಮನುು

ನಿಮಮಿತ್ಳಹಗಿ, ದಿನಕಕ ಕನಿಶಟ 30 ನಿಮಿಶ ಮಹಡಿ.

ನಿವಯಕ್ತ / ಷುಷುತ

ತ್ಱನೆ ೇಸ

ದೃಷ್ಟಟ
ಭಬಹಿಗುಸದು

• ಷೈಪಹಗಿಿಶಮಿಯಹಸ, ಯಕತದಲ್ಲಿ ಷಕಕರಮ ಭಟ್ಟಸ ಅತಿೇ ಕಡಿಮ ಇಯು

ಕಹಲ್ಲನ ಆರೈಕ
ನಿಭೆ ಪಹದನುು ನಿೇಳೇ ನಿಮಮಿತ್ಳಹಗಿ ರಿೇಕ್ಷಿಸಿಕ ಳಿಳ.
ಯಹಳಹಗಱಹದಯ
ಭತ್ುತ

ನಿೇಸ ಷ ಯಗಡ್ಡ ಷ ೇಗುಳಹಗ ಸಹಸ

ಪಹದಯಕ್ಷೆಮನುು

ಧರಿಸಿ.

ನಿಭೆ

ಪಹದಕಕ

ಷರಿಷ ಂದು ಪಹದಯಕ್ಷೆಮನುು ಆಯಕ ಮಹಡಿ. ರತಿದಿನ
ರಹತಿರ ನಿಭೆ ಪಹದನುು ರಿೇಕ್ಷಿಸಿ. ಒಂದುಳೇಲ ನಿಭೆ
ಪಹದದಲ್ಲಿ ಬಿಯುಕುಗಳು ಕಂಡುಫಂದಲ್ಲಿ ಪಹದಕಕ ಳಹಯಸ್
ಲ್ಲೇನ್

ಅನುು ಱೇಪಿಸಿ. ನಿಭೆ ಪಹದಯಕ್ಷೆಮಲ್ಲಿ

ಯಹಸದೇ ಬಿಯುಕು, ಕಲುಿ ಅಥಳಹ ಲಗಳಿಳಯೇ ಎಂದು
ರತಿದಿನ ರಿೇಕ್ಷಿಸಿ.

ಒಂದು ಸಿೆತಿಯಹಗಿದ. ಒಂದೇ ಷಭಮದಲ್ಲಿ ಅತಿ ಷಚುಾ ಭಧುಮೇಸ
ಔಶಧಿಮನುು

ತೆಗೆದುಕ ಳುಳಸದು,

ಇನುಸಲ್ಲನ್

ವಿಳಂಫಮಹಡುಸದು, ಸಹಮಹನಯಕ್ಕಂತ್ ಷಚುಾ ಳಹಯಯಹಭ ಮಹಡುಸದು,
ಆಱ ಕೇಹಹಲ್ ಶೇವಿಷುಸದು ಷೈಪಹಗಿಿಶಮಿಯಹಕಕ ಕಹಯಣಳಹಗಫಸುದು.
• ನಿೇಸ ಭನೆಯಿಂದ ಷ ಯಗೆ ಷ ೇಗುಳಹಗ ಯಹಳಹಗಲ

ಒಂದು ಷಕಕರಮ

ಪಹಯಕಟ್ ಅಥಳಹ ಕಲುಿಷಕಕರ ಅಥಳಹ ಗುಿಕ ಸ್ ಪಹಯಕಟ್ ಗಳನುು
ತೆಗೆದುಕ ಂಡು ಷ ೇಗಿ.
• ಯಹಳಹಗಱಹದಯ

ಷೈಪಹಗಿಿಶಮಿಯಹದ ಲಕ್ಷಣಗಳು ಅನುಬಕಕ ಫಂದಲ್ಲಿ,

ಷೆಳಿೇಮ ಳೈದಯಯಲ್ಲಿ ಅಥಳಹ ಸತಿತಯದ ಆಷಪತೆರಮಲ್ಲಿ ನಿಭೆ ಯಕತದ

ಕಣಿುನ ಆರೈಕ
ಷೆಳಿೇಮ ಳೈದಯಯಲ್ಲಿ ಅಥಳಹ ಸತಿತಯದ ಆಷಪತೆರಮಲ್ಲಿ,
ನಿಭೆ ಕಣುನುು ನಿಮಮಿತ್ಳಹಗಿ ರಿೇಕ್ಷಿಸಿ ಏಕಂದರ
ಉಂಞಹಗಫಸುದು.

ಅನುು

ಫದಱಹಯಿಷುಸದು, ಊಟ್ನುು ತ್ಪಿಪಷುಸದು, ಊಟ್ ಮಹಡುಸದನುು

ಷಕಕರಮ ಭಟ್ಟನುು ನಿಮಮಿತ್ಳಹಗಿ ರಿೇಕ್ಷಿಸಿ.

ಭಧುಮೇಸದಿಂದ

ಡ್ಡ ೇಸ್

ಕಣಿುನ

ತೆ ಂದರಗಳು

ಇನುಸಲ್ಲನ್ ಕುರಿತ್ ರ ೇಗಿಮ ಮಹಹಿತಿ ತ್ರ

ಇನುಸಲ್ಲನ್ ಚುಚುಾವಿಕ ಎಂದರೇನು?

• ಬೇರ ಷೆಳಗಳಿಗೆ ರಯಹಣಿಷು ಷಂದಬಜದಲ್ಲಿ ಇನುಸಲ್ಲನ್ ಮಲ್

ಇದು ನಿಭೆ ಯಕತದ ಷಕಕರಮ ಭಟ್ಟನುು ನಿಮಂತ್ರಣದಲ್ಲಿಡಲು

ಗಳನುು ತ್ಂಪಹದ ಷೆಳದಲ್ಲಿ ಅಥಳಹ ಭುಚಿಾದ qÀಫâದಲ್ಲಿ ಷಂಗರಹಿಸಿಡಿ.

ಫಳಷಱಹಗುತ್ತದ.

• ನಿಭೆ

ಮಡಿಕಲ್ ಶ ಟೇರ್ ನಲ್ಲಿ ಯಹ ವಿಧದ ಇನುಸಲ್ಲನ್ ಚುಚುಾಭದುುಗಳು

ಕಹಟ್ಟರಜಡ್ು)ವಿರಿೇತ್ ಉಶುತೆ ಅಥಳಹ ತ್ಂಪಿನಿಂದ ಯಕ್ಷಿಸಿಕ ಳಿಳ.

ಲಬಯವಿಳ?

ಒಂದು

ಇನುಸಲ್ಲನ್

ದಿನದಲ್ಲಿ

ಅನುು

ನಹನು

(ಬಹಟ್ಲಗಳು,

ಎಶುಟ

ಬಹರಿ

ಪನ್

ಇನುಸಲ್ಲನ್

ಭತ್ುತ

ಅನುು

ತೆಗೆದುಕ ಳಳಬೇಕು?
ನಿಭೆ ಯಕತಷಕಕರ ಭಟ್ಟಗಳನುು ಅಲಂಬಿಸಿ ನಿಭೆ ಳೈದಯಯು ಷಲಷ
ಮಹಡುತಹತರ.
ನಹನು ಯಹಳಹಗ ಇನುಸಲ್ಲನ್ ಅನುು ತೆಗೆದುಕ ಳಳಬೇಕು?
ಳೈದಯಯ ಷಲಷಮನಹುಧರಿಸಿ ಭತ್ುತ ಳೈದಯಯು ನಿಭಗೆ ನಿೇಡಿಯು ಇನುಸಲ್ಲನ್
ಸಿರಿಂಜ್ ನೆ ಂದಿಗೆ
ಇನುಸಲ್ಲನ್ ಮಲ್

ವಿಧನಹುಧರಿಸಿ, ಷಲಷ ಮಹಡಱಹದ ಷರಿಯಹದ ಷಭಮದಲ್ಲಿ ಇನುಸಲ್ಲನ್

ಇನುಸಲ್ಲನ್ ಂಪ್

ಇನುಸಲ್ಲನ್ ಪನ್

ತೆಗೆದುಕ ಳಳಬೇಕು.

ಇನುಸಲ್ಲನ್ ಅನುು ಯಹಯು ತೆಗೆದುಕ ಳಳಬೇಕು?
ಟ್ಟೈಪ್ 2 ಭಧುಮೇಸ ರ ೇಗಿಗಳಿಗೆ, ಬಹಯಿಮ ಭ ಲಕ ಶೇವಿಷು
ಔಶಧಿಗಳಿಗೆ ಷಪಂದಿಷದ ರ ೇಗಿಗಳಿಗೆ, ಗಭಿಜಣಿಮಯು, ಶ ೇಂಕ್ನ ಸಿೆತಿಗಳಲ್ಲಿ,
ಗಂಭಿೇಯ ಸೃದಮ, ಭ ತ್ರಪಿಂಡ ಭತ್ುತ ಮಕೃತಿತನ ಷಭಶಯಗಳಿಯು
ಭಧುಮೇಸ ರ ೇಗಿಗಳಿಗೆ ಇನುಸಲ್ಲನ್ ಅನುು ನಿೇಡಱಹಗುಸದು ಭತ್ುತ
ಟ್ಟೈಪ್ 1 ಭಧುಮೇಸ ರ ೇಗಿಗಳಿಗೆ ಇದು ಅಗತ್ಯಳಹಗಿ ಬೇಕೇಬೇಕು.

¸ÁªÀiÁ£Àå ಯಕತದಷಕಕರ ಭಟ್ಟಗಳ ರಿಮಹಣಳೇನು?
ನಿಭೆ ಳೈದಯಯ ಷಲಷ ಮೇರಗೆ, ನಿಭೆ ಫಿಡ್ ಗುಿಕ ೇಸ್ ಮಿೇಟ್ಯನುು
ಫಳಸಿ ನಿಭೆ ಯಕತ ಷಕಕರಮ ಭಟ್ಟಗಳನುು ರಿೇಕ್ಷಿಸಿಕ ಳಳಬೇಕು
ಯಕತ ಷಕಕರ ಭಟ್ಟದ ರಮಹಣಕ ಅಳತೆಗಲಂದರ:
• 70 ರಿಂದ 130 ಎಂಜಿ/ಡಿಎಲ್ ಖಹಲ್ಲ ಷ ಟ್ಟಟಮಲ್ಲಿ
• 180 ಎಂಜಿ/ಡಿಎಲ್ ಗಿಂತ್ ಕಡಿಮ, ಊಟ್ ಆಯಂಭಿಸಿದ 1 ರಿಂದ 2 ಗಂಟ್ಟಗಳ

ಇನುಸಲ್ಲನ್ ಚುಚುಾಭದುು ನಿೇಡು ಷೆಳಗಳು ಯಹಸಸ?

¤ªÀÄä ªÉÊzÀågÀÄ ¸À®ºÉ ªÀiÁrzÀ ¥ÀæPÁgÀ ಇನುಸಲ್ಲನ್ ಅನುು ZÀªÀÄðzÀ
M¼À¥ÀzÀgÀzÉÆ¼ÀUÉ PÉÆqÀ ಬೇಕು

ಫಳಿಕ.
ಇನುಸಲ್ಲನ್ ಫಳಷುಳಹಗ ತೆಗೆದುಕ ಳಳಬೇಕಹದ ಆವಯಕ ಎಚಾರಿಕಗಲೇನು?
• ಪನ್ ಫಳಷು ದಲು, ಷ ಚನೆಗಳನುು ಎಚಾರಿಕಯಿಂದ ಓದಿ ಅಥಳಹ
ನಿಭೆ ಆರ ೇಗಯ ಆರೈಕದಹಯಯು ಅಥಳಹ ಳೈದಯಯು ಅಸಗಳನುು ನಿಭಗೆ

ಚುಚುಾಭದುು ನಿೇಡು

ವಿರಿಷುಂತೆ ಕೇಳಿಕ ಳಿಳ.
• ಈ ಔಶಧಿಮನುು ನಿಭೆ ಳೈದಯಯು ಷೇಳಿಯುಂತೆ ಚಭಜದ ಅಡಿ

ಜಹಗ
ಮೇಱಹಾಗದ ತೆ ೇಳು,

ಚುಚಿಾಸಿಕ ಳಿಳ.

ಕ್ಬ ಿಟ್ಟಟ,

• ರತಿ ಡ್ಡ ೇಷನುು ಚುಚಿಾಸಿಕ ಳುಳ ದಲು, ಚುಚುಾಭದುು ನಿೇಡು

ತೆ ಡ್ಡಮ ಮೇಱಹಾಗ,

ಜಹಗನುು ಸಿಪರಿಟ್ ನಿಂದ ಉಜಿು ಷವಚಛಗೆ ಳಿಸಿ.

ೃಶಠ

• ಚಭಜದಡಿಮಲ್ಲಿ

ಹಹನಿಮನುು

ಕಡಿಮ

ಮಹಡಲು

ಭತ್ುತ

ಷಭಶಯಗಲಹಗದಂತೆ ತ್ಡ್ಡಮಲು ರತಿ ಬಹರಿ ಚುಚುಾಭದುು ನಿೇಡು
ನಹನು ಇನುಸಲ್ಲನ್ ಮಲ್ ಅನುು ಎಲ್ಲಿ ಷಂಗರಹಿಸಿಡಬೇಕು?
•

ಇನುಸಲ್ಲನ್

ಅನುು

ರಫ್ರರರ್ರೇಟ್ರ್

ನಲ್ಲಿ

ಜಹಗನುು ಫದಲ್ಲಸಿ.

(2°ಶ

to

8°ಶ)

• ಇನುಸಲ್ಲನ್ ಚುಚುಾಭದುು ಫಣುದಲ್ಲಿದುರ, ಅಥಳಹ ಅದಯಲ್ಲಿ ಘನ

ಷಂಗರಹಿಸಿಡಬೇಕು. ಇನುಸಲ್ಲನ್ ಸಿೇಶಮನುು ಫ್ರರೇಜ್ ಮಹಡಬೇಡಿ.

ಕಣಗಳಿದುಲ್ಲಿ ಅಥಳಹ ಗಟ್ಟಟಕಣಗಳಿದುಲ್ಲಿ ಅದನುು ಫಳಷಬೇಡಿ.

• ತೆರಮದಿಯು ಇನುಸಲ್ಲನ್ ಮಲ್ ಗಳನುು, ಕಹಟ್ಜ ರಿಡ್ು ಗಳನುು ಭತ್ುತ

• ನಿಭೆ ಳೈದಯಯು ಷಲಷ ಮಹಡಿದಂತೆ ರತಿದಿನ ಒಂದೇ ಷಭಮದಲ್ಲಿ

ಪಿರಱ ೇಡ್ಡಡ್ ಪನ್ ಗಳನುು ಎಸ ಪೈರಿ ದಿನಹಂಕದರಗೆ

ಅದನುು ಫಳಸಿ.

ರಫ್ರರರ್ರೇಟ್ರ್

ನಲ್ಲಿ ಷಂಗರಹಿಸಿಡಫಸುದು.

•ನಿೇಸ ಷ ಯಗೆ ಷ ೇಗುಳಹಗ ಯಹಳಹಗಲ

ಷಕಕರಮ ಪಹಯಕಟ್, ಷಕಕರ

• ನಿಭೆ ಇನುಸಲ್ಲನ್ ಮಲ್ ಅನುು ¸ÀÆ0iÀÄð£À ಬಳಕ್ನಿಂದ ದ ಯ ಇಡಿ.

ಕಹಯಂಡಿ ಅಥಳಹ ಗುಿಕ ೇಸ್ ಪಹಯಕಟ್ ಗಳನುು ಒಯಿಯರಿ.

• ನಡುಕ, ಬಯುವಿಕ, ಆತ್ಂಕ, ತ್ಱಷುತ್ುತವಿಕ, ತ್ಱನೆ ೇಸ , ನಿವಯಕ್ತಮಂಥ

ಇನುಸಲ್ಲನ್ ಚುಚುಾಭದಿುನ ಸಹಮಹನಯ ಅಡಡರಿಣಹಭಗಲೇನು?

ಕಡಿಮ ಯಕತಷಕಕರಮ ರ ೇಗಲಕ್ಷಣಗಳು ನಿಭಗೆ ಕಂಡು ಫಂದಹಗ ಸತಿತಯದ

• ಷೈಪಹಗಿಿಶಮಿಯಹ: ಅತಿಯಹಗಿ ಇನುಸಲ್ಲನ್ ತೆಗೆದುಕ ಳುಳಸದರಿಂದ

ಳೈದಯರಿಗೆ ತೆ ೇರಿಸಿ.

ಯಕತ ಷಕಕರಮ ಅಂವಗಳು ಕಡಿಮಯಹಗಫಸುದು.

ಇನುಸಲ್ಲನ್

ಚುಚುಾಭದುುಗಳನುು

ಉೇಗಿಷುಳಹಗ

ತೆಗೆದುಕ ಳಳಬೇಕಹದ ವಿೇಶ ಭುಂಜಹಗರತೆಗಲೇನು?
• ಕಂಪಹದ, ಬಹತ್ುಕ ಂಡಿಯು ಅಥಳಹ ತ್ುರಿಕಯಿಯು ಚಭಜದ ಮೇಱ
ಇನುಸಲ್ಲನ್ ಚುಚಾಬೇಡಿ, ರತಿ ಬಹರಿ ಚುಚುಾಭದುು ನಿೇಡು ಜಹಗನುು
ಫದಲ್ಲಸಿ.
• ಉೇಗಿಷು ದಲು ಎಸ ಪೈರಿ ದಿನಹಂಕನುು ರಿೇಕ್ಷಿಸಿ, ಭತ್ುತ
ಎಸ ಪೈರಿ ದಿನಹಂಕ ಭುಗಿದಿಯು ಇನುಸಲ್ಲನ್ ಅನುು ಫಳಷಬೇಡಿ.
• ನಿಭೆ ಳೈದಯಯ ಷಲಷ ಇಲಿದ ಇನುಸಲ್ಲನ್ ನ ಬಹರಂಡ್ ಅಥಳಹ
ರಕಹಯನುು ಫದಲ್ಲಷಬೇಡಿ.
• ನಿಭೆ ಳೈದಯಯು ನಿದೇಜಶಿಸಿದ ರಿೇತಿಮಲ್ಲಿಯೇ ನಿಭೆ ಭ vÀæ/ಯಕತ ಷಕಕರ
ಭಟ್ಟಗಳನುು ನಿಮಮಿತ್ಳಹಗಿ ರಿೇಕ್ಷಿಸಿಕ ಳಿಳ.
• ಷ ಜಿ ಸಲಮದಹುಗಿದುಲ್ಲಿ ಅಥಳಹ ಬಹಗಿಕ ಂಡಿದುಲ್ಲಿ ಅಥಳಹ ಷವಚಛ
ಚಭಜನುು ಷ ಯತ್ುಡಿಸಿ ಬೇರಹಸದೇ ಷುತವಿನ ಷಂಕಜಕಕ ಫಂದಿದುಲ್ಲಿ
ಆ ಇನುಸಲ್ಲನ್ ಸಿರಿಂರ್ನುು ಎಶಯಿರಿ.
• ನಿೇಸ ನಿಭೆ ಇನುಸಲ್ಲನ್ ಅನುು ತೆಗೆದುಕ ಳಳಲು ಭರತ್ಲ್ಲಿ, ನಿಭೆ ಯಕತ
ಷಕಕರ ಅಂವಸ ಅತ್ಯಧಿಕ ಭಟ್ಟಕಕ ಏಯಫಸುದು (ಷೈರ್ ಗಿಿಶಮಿಯಹ),
ಇದು ಗಂಭಿೇಯ ಷಭಶಯಗಳನುುು ಉಂಟ್ುಮಹಡಫಸುದು.
ನನಗೆ ಯಹ ರಕಹಯದ ಇನುಸಲ್ಲನ್ ನ ಅವಯಕತೆ ಇದ?
• ತ್ವರಿತ್ಗತಿಮ ಇನುಸಲ್ಲನ್ ಚುಚುಾಭದುು ನಿೇಡಿದ ಕಲಳೇ ಕ್ಷಣಗಳಲ್ಲಿ
ಕಹಯಹಜಚರಿಷುತ್ತದ, ಆದರ ಇದು ಕಲಳೇ ಗಂಟ್ಟಗಳ ತ್ನಕ ಮಹತ್ರ ತ್ನು
ರಭಹನುು ತೆ ೇರಿಷುತ್ತದ.
ರಭಹನುು

ಅಥಳಹ

ತೆ ೇರಿಷಲು

ಅಱಹಪಧಿಮ
ಷುಮಹಯು

ನಿೇಡಿದ

ಷೆಳದಲ್ಲಿ

ಕ ಬಿಿನ

ಅಂಗಹಂವಗಳ ಷಂಗರಸ. ಇದು ಚುಚುಾಭದುು ನಿೇಡಿದ
ಷೆಳದಲ್ಲಿ ಊತ್, ತ್ುರಿಕ, ಕಂಪಹಗುವಿಕಮನುುಂಟ್ು

• ಚುಚುಾಭದುು ನಿೇಡಿದ ಜಹಗನುು ಉರ್ುಬೇಡಿ.

• ರಗುಯಲರ್(ನಿಮಮಿತ್)-

• ಚುಚುಾಭದುು

30

ಇನುಸಲ್ಲನ್

ತ್ನು

ನಿಮಿಶಗಳನುು

ತೆಗೆದುಕ ಳುಳತ್ತದ ಭತ್ುತ ಇದಯ ರಭಹ 3 ರಿಂದ 6 ಗಂಟ್ಟಗಳ ತ್ನಕ
ಇಯುತ್ತದ.
• ಭಧಯಭ ಅಧಿಮ ಇನುಸಲ್ಲನ್ ತ್ನು ರಭಹನುು ತೆ ೇರಿಷಲು 2 ರಿಂದ
4 ಗಂಟ್ಟಗಳನುು ತೆಗೆದುಕ ಳುಳತ್ತದ, ಭತ್ುತ ಇದಯ ರಭಹ 18 ಗಂಟ್ಟಗಳ
ತ್ನಕ ಇಯುತ್ತದ.
• ದಿೇಘಹಜಧಿಮ ಇನುಸಲ್ಲನ್ ತ್ನು ರಭಹನುು ತೆ ೇರಿಷಲು 6 ರಿಂದ 10
ಗಂಟ್ಟಗಳನುು ತೆಗೆದುಕ ಳುಳತ್ತದ .
• ನಿಭೆ ಭಧುಮೇಸದ ವಿಧ ಭತ್ುತ ಯಕತಷಕಕರ ಭಟ್ಟಗಳ ಆಧಹಯದ ಮೇಱ
ನಿಭೆ ಳೈದಯಯು ಷಲಷ ಮಹಡು ಇನುಸಲ್ಲನ್ ರಕಹಯನುು ಉೇಗಿಸಿ.

ಮಹಡಫಸುದು.
• ತ್ ಕ ಷಙಹಾಗುಸದು

ಗಿಿಮಪಿರೈಡ್

ಮಟ್ ಫಹಮಿಜನ್

ಗಿಿಮಪಿರೈಡ್ ಎಂದರೇನು?
ಇದನುು

ನಿಭೆ

ಅಧಿಕ

ಮಟ್ ಫಹಮಿಜನ್ ಎಂದರೇನು?
ಯಕತ

ದಷಕಕರ

ಭಟ್ಟನುು

ನಿಮಂತಿರಷಲು

ಇದನುು ನಿಭೆ ಯಕತದಷಕಕರ ಭಟ್ಟನುು ನಿಮಂತಿರಷಲು ನಿೇಡಱಹಗುತ್ತದ.

ನಿೇಡಱಹಗುತ್ತದ.

ಯಹ ರಮಹಣಗಳಲ್ಲಿ ಲಬಯವಿದ?

ಯಹ ರಮಹಣಗಳಲ್ಲಿ ಲಬಯವಿದ?

500 ಎಂಜಿ , 850 ಎಂಜಿ, 1000 ಎಂಜಿ

1 ಎಂಜಿ, 2 ಎಂಜಿ, 4 ಎಂಜಿ

ನಹನು ಎಶುಟ ಡ್ಡ ೇಸ್ ತೆಗೆದುಕ ಳಳಬೇಕು?

ನಹನು ಎಶುಟ ಡ್ಡ ೇಸ್ ತೆಗೆದುಕ ಳಳಬೇಕು?

ಕಹಯಿಱಮ ರಷುತತ್ ರಗತಿಮ ಆಧಹಯದ ಮೇಱ ಔಶಧದ ಡ್ಡ ೇಸ್

ಈ ಔಶಧಿಮನುು ಬಹಯಿಮ ಭ ಲಕ ತೆಗೆದುಕ ಳಳಬೇಕು, ಭತ್ುತ ನಿಭೆ

ರ ೇಗಿಯಿಂದ ರ ೇಗಿಗೆ ಫದಱಹಗುತ್ತದ.

ಳೈದಯಯ ಷಲಷ ಮೇರಗೆ ರತಿದಿನ ಒಂದು ಬಹರಿ ತೆಗೆದುಕ ಳಳಬೇಕು.

ಔಶಧಿಮನುು ತೆಗೆದುಕ ಳುಳಸದು ಷೇಗೆ?

ಕಹಯಿಱಮ ರಷುತತ್ ರಗತಿಮ ಆಧಹಯದ ಮೇಱ ಔಶಧದ ಡ್ಡ ೇಸ್

ಒಂದು ಗಹಿಸ್ ನಿೇರಿನೆ ಂದಿಗೆ ಈ ಔಶಧಿಮನುು ತೆಗೆದುಕ ಳಿಳ

ರ ೇಗಿಯಿಂದ ರ ೇಗಿಗೆ ಫದಱಹಗುತ್ತದ.

ಮಹತೆರಮನುು

ಔಶಧಿಮನುು ತೆಗೆದುಕ ಳುಳಸದು ಷೇಗೆ?

ಸಡಿಮಹಡಬೇಡಿ ಅಥಳಹ ಚಿೇಬೇಡಿ.

ಒಂದು ಗಹಿಸ್ ನಿೇರಿನೆ ಂದಿಗೆ ಈ ಮಹತೆರಮನುು ತೆಗೆದುಕ ಳಿಳ
ಮಹತೆರಮನುು

ಒಮೆಗೆ

ಇಡಿಯಹಗಿ

ತೆಗೆದುಕ ಳಿಳ.

.

ಮಹತೆರಮನುು

ಒಮೆಗೆ

ಇಡಿಯಹಗಿ

ತೆಗೆದುಕ ಳಿಳ.

.

ಮಹತೆರಮನುು

ಔಶಧಿಮನುು ಯಹಳಹಗ ತೆಗೆದುಕ ಳಳಬೇಕು?
ಈ ಔಶಧಿಮನುು ನಿಭೆ ಳೈದಯಯ ಷಲಷ ಮೇರಗೆ ರತಿದಿನ ಊಟ್ದ ನಂತ್ಯ

ಸಡಿಮಹಡಬೇಡಿ ಅಥಳಹ ಚಿೇಬೇಡಿ.

ಒಂದು ಅಥಳಹ ಎಯಡು ಬಹರಿ ತೆಗೆದುಕ ಳಳಬೇಕು. ಒಂದುಳೇಲ ರತಿದಿನ ಒಂದು

ಮಹತೆರಮನುು ಯಹಳಹಗ ತೆಗೆದುಕ ಳಳಬೇಕು?

ಬಹರಿ ತೆಗೆದುಕ ಳುಳಂತೆ ಷ ಚಿಸಿದುಲ್ಲಿ, ಳೈದಯಯು ಷ ಚಿಸಿದ ನಿದಿಜಶಟ

ನಿಭೆ ಳೈದಯಯು ಷಲಷ ಮಹಡಿದ ರಕಹಯ ಮಹತೆರಮನುು ಉಹಹಯ ಅಥಳಹ

ಷಭಮದಲ್ಲಿ ತೆಗೆದುಕ ಳಿಳ.

ಆ ದಿನದ ದಲ ಊಟ್ದ ಫಳಿಕ ತೆಗೆದುಕ ಳಳಬೇಕು.

ಡ್ಡ ೇಸ್ ತ್ಪಿಪಸಿದಲ್ಲಿ ನಹನೆೇನು ಮಹಡಬೇಕು?

ಡ್ಡ ೇಸ್ ತ್ಪಿಪಸಿದಲ್ಲಿ ನಹನೆೇನು ಮಹಡಬೇಕು?

ಡ್ಡ ೇಸ್ ತೆಗೆದುಕ ಳಳಲು ನಿಭಗೆ ಭರತ್ುಷ ೇದಲ್ಲಿ, ನೆನಪಹದ ಕ ಡಱ

ಡ್ಡ ೇಸ್ ತೆಗೆದುಕ ಳಳಲು ನಿಭಗೆ ಭರತ್ುಷ ೇದಲ್ಲಿ, ನೆನಪಹದ ಕ ಡಱ

ತೆಗೆದುಕ ಳಿಳ. ಭಯುದಿನದ ತ್ನಕ ನಿಭಗೆ ನೆನಪಹಗದಿದುಲ್ಲಿ, ತ್ಪಿಪಷ ೇದ

ತೆಗೆದುಕ ಳಿಳ. ಭಯುದಿನದ ತ್ನಕ ನಿಭಗೆ ನೆನಪಹಗದಿದುಲ್ಲಿ, ತ್ಪಿಪಷ ೇದ

ಡ್ಡ ೇಷನುು ತೆಗೆದುಕ ಳಳಬೇಡಿ.

ಡ್ಡ ೇಷನುು ತೆಗೆದುಕ ಳಳಬೇಡಿ.

ಎಯಡು ಮಹತೆರಗಳನುು ಒಟ್ಟ ಟಟ್ಟಟಗೆ ತೆಗೆದುಕ ಳಳಬೇಡಿ.

ಎಯಡು ಮಹತೆರಗಳನುು ಒಟ್ಟ ಟಟ್ಟಟಗೆ ತೆಗೆದುಕ ಳಳಬೇಡಿ.

ಸಹಮಹನಯ ಅಡಡರಿಣಹಭಗಳು ಯಹಸಸ?

ಸಹಮಹನಯ ಅಡಡರಿಣಹಭಗಳು ಯಹಸಸ?

ಯುಚಿಮಲ್ಲಿ ಫದಱಹಣ್ಣ, ಳಹಕರಿಕ ಭತ್ುತ ಳಹಂತಿ

ಷೈಪಹಗಿಿಶಮಿಯಹ, ತ್ಱಷುತ್ುತವಿಕ, ತ್ಱನೆ ೇಸ ಭತ್ುತ ಳಹಕರಿಕ, ತೂಕ

ತೆಗೆದುಕ ಳಳಬೇಕಹದ ಅವಯಕ ಭುಂಜಹಗರತಹ ಕರಭಗಲೇನು?

ಹೆಚ್ಚಾಗುವುದು

ಷೈಪಹಗಿಿಶಮಿಯಹ ರ ೇಗಲಕ್ಷಣಗಳನುು ತ್ಪಿಪಷಲು ರತಿದಿನ

ತೆಗೆದುಕ ಳಳಬೇಕಹಗ ಅವಯಕ ಭಂಜಹಗರತಹ ಕರಭಗಲೇನು?

ಒಂದೇ ಷಭಮದಲ್ಲಿ ಔಶಧಿಮನುು ತೆಗೆದುಕ ಳಿಳ.

ಷೈಪಹಗಿಿಶಮಿಯಹ ರ ೇಗಲಕ್ಷಣಗಳನುು ತ್ಪಿಪಷಲು ರತಿದಿನ

• ಈ ಔಶಧಿಮನುು ತೆಗೆದುಕ ಳುಳಳಹಗ ಸಹಕಶುಟ ನಿೇರಿನಂವನುು ಕುಡಿಯಿರಿ.

ಒಂದೇ ಷಭಮದಲ್ಲಿ ಔಶಧಿಮನುು ತೆಗೆದುಕ ಳಿಳ.

• ಈ ಔಶಧಿಮನುು ತೆಗೆದುಕ ಳುಳ ದಲು ಸಹಕಶುಟ ಊಟ್ನುು ಮಹಡಿ.

• ಈ ಔಶಧಿಮನುು ತೆಗೆದುಕ ಳುಳ ದಲು ಸಹಕಶುಟ ಊಟ್ನುು

•ಈ

ಮಹಡಿ.

ಅನಹರ ೇಗಯದಿಂದ, ಶ ೇಂಕುಗಳಿಂದ, ಪಿತ್ತರ್ನಕಹಂಗದ ಕಹಯಿಱಯಿಂದ ಅಥಳಹ

• ಈ ಔಶಧಿಯಿಂದ ನಿಭಗೆ ತ್ಱಷುತ್ತಫಸುದು. ಳಹಸನ ಚಱಹಯಿಷಬೇಡಿ ಭತ್ುತ

ಭ ತ್ರಪಿಂಡದ ಕಹಯಿಱಯಿಂದ ಫಳಲುತಿತದುಲ್ಲಿ ಳೈದಯಯಲ್ಲಿ ಯದಿ ಮಹಡಿ.

ನಿೇಸ ಎಚಾಯದಿಂದಿಯಬೇಕಹದ ಯಹಸದೇ ಚಟ್ುಟ್ಟಕ ಮಹಡಬೇಡಿ.

• ಔಶಧಿಗಳನುು ಭಕಕಳ ಕೈಗೆ ಸಿಗದಂತೆ ಇಡಿ.

• ಔಶಧಿಗಳನುು ಭಕಕಳ ಕೈಗೆ ಸಿಗದಂತೆ ಇಡಿ. ನಿಭೆ ಔಶಧಿಮನುು

• ನಿಭೆ ಔಶಧಿಮನುು ಯಹರ ಂದಿಗ ಸಂಚಿಕ ಳಳಬೇಡಿ.
ಚಿಕ್ತೆಸಮ ಷಭಮದಲ್ಲಿ ಯಹಳಲಿ ಆಹಹಯಗಳನುು ನಿವೇಧಿಷಬೇಕು?

ಯಹರ ಂದಿಗ ಸಂಚಿಕ ಳಳಬೇಡಿ.
ಚಿಕ್ತೆಸಮ ಷಭಮದಲ್ಲಿ ಯಹಳಲಿ ಆಹಹಯಗಳನುು ನಿವೇಧಿಷಬೇಕು?
ಓರ್-ದ-ಕೌಂಟ್ರ್
ಉತ್ಪನುಗಳನುು

ಔಶಧಿಗಳು,

ನಿೇಸ

ತಿೇರ

ಓರ್-ದ-ಕೌಂಟ್ರ್ ಔಶಧಿಗಳು, ವಿಟ್ಮಿನ್ಸ ಭತ್ುತ ಸಫಜಲ್ ಉತ್ಪನುಗಳನುು
ಸಫಜಲ್

ಡಬಿಿಮಲ್ಲಿ, ಬಿಸಿ, ತೆೇ ಭತ್ುತ ಷ ಮಜನ ನೆೇಯ ಬಳಕು ಬಿೇಳದಿಯುಂತೆ
ಭುಚಿಾದ

ಔಶಧಿಗಳನುು

ಒಳಗೆ ಂಡಂತೆ, ಇತ್ಯ ಯಹಸದೇ ಔಶಧಿಗಳನುು ಉೇಗಿಷು ದಲು

ವಿಙಹರಿಸಿ.
ಮಹತೆರಮನುು ಎಲ್ಲಿ ಷಂಗರಹಿಸಿಡಬೇಕು?
ಉಶುತೆಮಲ್ಲಿ

ಯಹಸದೇ

ದಲು,

ಉೇಗಿಷು ದಲು ಳೈದಯಯಲ್ಲಿ ಅಥಳಹ ಫಹಮಹಜಸಿಸ್ಟ ನೆ ಂದಿಗೆ

ಕ ಠಡಿಮ

ಇತ್ಯ

ಭತ್ುತ

ತೆಗೆದುಕ ಳುಳ

ಳೈದಯಯಲ್ಲಿ ಅಥಳಹ ಫಹಮಹಜಸಿಸ್ಟ ನೆ ಂದಿಗೆ ವಿಙಹರಿಸಿ.
ಮಹತೆರಮನುು ಎಲ್ಲಿ ಷಂಗರಹಿಸಿಡಬೇಕು?

ಮಹತೆರಮನುು

ಒಳಗೆ ಂಡಂತೆ,

ವಿಟ್ಮಿನ್ಸ

ಔಶಧಿಮನುು

ಷಂಗರಸಣಹ

ಡಬಿಿಮಲ್ಲಿ, ಬಿಸಿ, ತೆೇ ಭತ್ುತ ಷ ಮಜನ ನೆೇಯ ಬಳಕು ಬಿೇಳದಿಯುಂತೆ
ಷಂಗರಹಿಸಿಡಿ.

ಮಹತೆರಮನುು
ಷಂಗರಹಿಸಿಡಿ.

ಕ ಠಡಿಮ

ಉಶುತೆಮಲ್ಲಿ

ಭುಚಿಾದ

ಷಂಗರಸಣಹ

ಗಿಿಬನ್ ಕಿಮೈಡ್

ಗಿಿಬನ್ ಕಿಮೈಡ್ ಎಂದರೇನು?
ಇದನುು

ನಿಭೆ

ಯಕತದಲ್ಲಿನ

ಅಧಿಕ

ಯಕತ

ಷಕಕರ

ಭಟ್ಟಗಳನುು

ನಿಮಂತ್ರಣದಲ್ಲಿಡಲು ನಿೇಡಱಹಗುತ್ತದ
ಯಹ ರಮಹಣದಲ್ಲಿ ಲಬಯವಿದ?
2.5 ಎಂಜಿ, 5 ಎಂಜಿ
ನಹನು ಎಶುಟ ಡ್ಡ ೇಸ್ ತೆಗೆದುಕ ಳಳಬೇಕು?
ಕಹಯಿಱಮ

ರಷಕತ

ಬಳಣಿಗೆಮನಹುಧರಿಸಿ

ಔಶಧಿಮ

ಡ್ಡ ೇಸ್

ರ ೇಗಿಯಿಂದ ರ ೇಗಿಗೆ ಫದಱಹಗುತ್ತದ. ಈ ಔಶಧಿಮನುು ನಿಭೆ ಳೈದಯಯ
ಷಲಷಮಂತೆ ದಿನಕ ಕಮೆ ತೆಗೆದುಕ ಳಳಬೇಕು.
ಔಶಧಿಮನುು ಷೇಗೆ ತೆಗೆದುಕ ಳುಳಸದು?
ಈ ಮಹತೆರಮನುು ಒಂದು ಗಹಿಸ್ ನಿೇರಿನೆ ಂದಿಗೆ ತೆಗೆದುಕ ಳಿಳ
ಒಂದು

ಬಹರಿಗೆ

ಒಂದು

ಮಹತೆರಮನುು

ಇಡಿಯಹಗಿ

.

ತೆಗೆದುಕ ಳಿಳ.

ಮಹತೆರಮನುು ಸಡಿಮಹಡಬೇಡಿ ಅಥಳಹ ಚಿೇಬೇಡಿ.
ಯಹಳಹಗ ಔಶಧಿಮನುು ತೆಗೆದುಕ ಳಳಬೇಕು?
ಈ ಔಶಧಿಮನುು ಬಳಗಿಗನ ಉಪಹಹಹಯದ ಜ ತೆಗೆ ಅಥಳಹ ದಿನದ ದಲ
ಭುಖಯ

ಊಟ್ದ ಡನೆ

ತೆಗೆದುಕ ಳಿಳ;

ನಿಭೆ

ಳೈದಯಯು

ಹಿೇಗೆ

ತೆಗೆದುಕ ಳಳಬೇಡಿ ಎಂದು ಷೇಳದ ಷ ಯತ್ು.
ನಹನು ಡ್ಡ ೇಷನುು ತ್ಪಿಪಸಿದಲ್ಲಿ ಏನು ಮಹಡಬೇಕು?
ನಿೇಸ ಡ್ಡ ೇಸ್ ತೆಗೆದುಕ ಳಳಲು ಭರತ್ರ, ನೆನಪಹದ ತ್ಕ್ಷಣ ತೆಗೆದುಕ ಳಿಳ.
ಮಹಯನೆ

ದಿನದ

ತೆಗೆದುಕ ಳಿಬೇಡಿ.

ತ್ನಕ

ನೆನಪಿಲಿದಿದುಲ್ಲಿ,
ಎಯಡು

ತ್ಪಿಪಸಿದ

ಮಹತೆರಗಳನುು

ಡ್ಡ ೇಷನುು
ಒಟ್ಟ ಟಟ್ಟಟಗೆ

ತೆಗೆದುಕ ಳಳಬೇಡಿ.
ಸಹಮಹನಯ ಅಡಡರಿಣಹಭಗಳು ಯಹಸಸ?
ಷೈಪಹಗೆಿೈಸಿೇಮಿಯಹ, ಎದಉರಿ, ತ್ ಕ ಷಚಾಳ
ತೆಗೆದುಕ ಳಳಬೇಕಹದ ಆವಯಕ ಭುನೆುಚಾರಿಕಗಲೇನು?
ಯಕತದಲ್ಲಿ ಷಕಕರ ಅಂವ ಕಡಿಮಯಹಗು ರ ೇಗಲಕ್ಷಣಗಳನುು
ತ್ಪಿಪಷಲು ರತಿದಿನ ಮಹತೆರಮನುು ಒಂದೇ ಷಭಮದಲ್ಲಿ ತೆಗೆದುಕ ಳಿಳ.
• ನಿಭಗೆ

ಭ ತ್ರಪಿಂಡ,

ಪಿತ್ತರ್ನಕಹಂಗ,

ಅಥಳಹ

ಸೃದಮದ

ತೆ ಂದರಗಳಿದುಲ್ಲಿ ನಿಭೆ ಳೈದಯರಿಗೆ ತಿಳಿಸಿ.
• ಈ ಔಶಧಿಮನುು ಉೇಗಿಷುತಿತಯುಳಹಗ ಭದಯಪಹನ ಮಹಡಬೇಡಿ.
• ಎಲಿ ಔಶಧಿಗಳನುು ಭಕಕಳ ಕೈಗೆ ಸಿಗದಂತೆ ಇಡಿ.
• ನಿಭೆ ಔಶಧಿಮನುು ಬೇರ ಫಿರ ಂದಿಗೆ ಸಂಚಿಕ ಳಳಬೇಡಿ.
ಮಹತೆರಮನುು ಎಲ್ಲಿ ಷಂಗರಹಿಸಿಟ್ುಟಕ ಳಳಬೇಕು?
ಮಹತೆರಮನುು ಕ ಠಡಿಮ ಉಶುತೆಮಲ್ಲಿ ಭುಚಿಾದ ಕಂಟ್ಟೈನರ್ ನಲ್ಲಿ,
ಬಿಸಿ, ತೆೇ ಭತ್ುತ ನೆೇಯ ಬಳಕ್ನಿಂದ ದ ಯ ಇಡಬೇಕು.

PARTICIPANT INFORMATION SHEET

Project title: Study the impact of Pharmaceutical care on the Diabetic patients in a tertiary care
hospital in South India.
IEC No.:
Sponsor Name: NA
Language: English
Principal Investigator: Divyashree
Designation: 2nd M.Pharm, Reg.No. 170608007, Department of Pharmacy Practice
Hospital: Kasturba medical college and hospital.
Mobile number: +91 7204673475
Please read this form carefully. If you don’t understand the language or any information in this
document, please discuss with study doctor. Your participation in this study is voluntary, and
you can enquire about all the details before giving your written consent to participate in this
study.
1. Introduction to the research study:
You are invited to participate in this study because you have Type 2 diabetes mellitus.
2. Purpose of the study: Study the impact of Pharmaceutical care on the Diabetic patient
3. Who can take part:
Type 2 Diabetic patients above 18 years of age, DM patients who are having glycosylated
hemoglobin more than 7%, excluding Type 1 Diabetic patients, Gestational diabetes, Bedridden
patients and patients who are not willing to participate in the study.
4. Information about the study:
Patients diagnosed with type 2 diabetes admitted/visited department of medicine unit 2 and 4
of the Department of Medicine at Kasturba Hospital Manipal between period August 2018 to
March 2019 will be identified and studied. There are two arms for the study, Intervention group
and the Usual medical care group. Total of 104 type 2 DM patients including for the study. Out
of 104 DM patients, 52 each allotted in the intervention group and the usual medical care
group. For intervention group DM patients provided with pharmaceutical care in addition to
standard medical care given by the physician and usual medical care group DM patients
provided only standard medical care given by the physician without pharmaceutical care.

5. What will happen to you during the study:
There are 2 groups in this study ,Based on the study criteria you will be allocated either in
Intervention group or Usual medical care group. Both the group will be getting common
medical care where as Intervention group will get special service like Prescription reviewing,
Patient counseling regarding taking medicine and life style change in the diabetes as a part of
study. Questionnaire will be administered for the both group to understand the effect of
services with respect to improvement and control of disease. The interview conducted
approximately 20 minutes for each questionnaire, interview conducted on Day of Admission,
Before Discharge, 1st Follow-up, 2nd Follow-up.
The Pharmaceutical care will be extended to usual medical care group once the study period
over. Patients will be provided with Medication Counseling and Patient information leaflet of
Diabetes. 1st Follow-up will be done in the first month and 2nd Follow-up will be done in the
fourth month after patient is getting discharged. You will be the part of this study around six
months.
6. Your role/responsibility in the study:
Provide accurate information whenever asked.
If you want to discontinue from the study, your doctor to be informed.
7. What are the risks?
It is an Interventional study, there is only minor increase over minimal risk. As the patient is
undergoing for interview so he may have little bit anxiety.

8. What are the potential benefits of participating in the study :
You may not get a direct benefit from participating in this study. If you take part in this study
you may help other patients with Diabetic Mellitus by contributing to the knowledge about
disease.
9. What are the alternative treatments available: The alternative is to receive Standard of care
from the treating Physician.

10. Cost of participating in the study:
No additional costs for drugs or investigations incurred for the patients participating in the
study. All the test will be performed as the part of routine medical care and there will no extra
financial burden for the patients. All the education material, counseling provided to Diabetic
patients as the part of study for free.

11. Compensation for injury:
There may not be any major injuries to the patient, If any study related injury compensated by
the Principal investigator.

12. Confidentiality of information:
Information from the study will be kept confidential. The data will not be made available to
another individual unless you specifically give permission in writing. Information and results
from this study may be presented at meetings or published in journals without including your
name and personal identifications. No reference will be made in oral or written reports which
could link you to the study.

13. New information about the study:
Any new information available during the study will be informed to you if it has relevance to
your decision regarding continuing in the study. Results of your participation will be disclosed to
you if you indicate your desire for it.
14. Voluntary participation:
Your participation in this study is voluntary; you may decline to participate at any time and you
need not give any reason for the same, and such withdrawal shall be without penalty and
without loss of benefits to which you are otherwise entitled. If you withdraw from the study
prior to its completion, you will receive the usual standard of care for your disease, and your
nonparticipation will not have any adverse effects on your subsequent medical treatment or
relationship with the treating physician.
If you withdraw from the study before data collection is completed, your data collected until
you indicated withdrawal will be used in the study report. The investigator may stop the
research or your participation in it at any time for some or other reason without your
permission.

15. Whom to contact in case of any questions:
If you experience any adverse effects as a result of participating in this study, you may contact
the Principal Investigator Divyashree, If you have any questions about the informed consent
process or your rights as a participant, you may contact the Member Secretary of the Kasturba
Medical College and Kasturba Hospital - Institutional Ethics Committee at Room 22, Ground

floor, KMC Faculty Rooms, adjacent to KMC Administrative Block, Kasturba Medical College,
Manipal - 576104. Phone: 0820 29 33522. Timings: 9: 00 AM to 5: 00 PM.
If you have any questions about this form or any study related issue, you may also contact the
following person.
Name : Dr. M. Surulivel Rajan ,Associate Professor
Address : Department of Pharmacy Practice ,MCOPS ,Manipal 576104
Mobile No. +919886921414

CzsÀåAiÀÄ£À¨sÁVAiÀÄ ªÀiÁ»w ¥ÀvÀæ
CzsÀåAiÀÄ£À ²Ã¶ðPÉ: zÀQët ¨sÁgÀvÀzÀ vÀÈwÃAiÀÄ DgÉÊPÉ D¸ÀàvÉæAiÀÄ°è£À ªÀÄzsÀÄªÉÄÃºÀ gÉÆÃVUÀ½UÉ ªÉÊzÀåQÃAiÀÄ OµÀ¢üPÁgÀgÀÄ MzÀV¸ÀÄªÀ DgÉÊPÉAiÀÄ ¥Àæ¨sÁªÀzÀ
CzsÀåAiÀÄ£À.
LE¹ ¸ÀASÉå:
¥ÁæAiÉÆÃdPÀgÀ ºÉ¸ÀgÀÄ: C£Àé¬Ä¸ÀÄªÀÅ¢®è.
¨sÁµÉÀ: EAVèµï/ PÀ£ÀßqÀ
¥ÀæzsÁ£À CzsÀåAiÀÄ£ÀUÁgÀgÀÄ: ¢ªÀå²æÃ
ºÀÄzÉÝ: ¢éwÃAiÀÄ ªÀµÀðzÀ JA ¥sÁªÀiÁð, ¥sÁªÀiÁð ¥ÁæQÖÃ¸ï «¨sÁUÀ
D¸ÀàvÉæ: PÀ¸ÀÆÛ¨Áð ªÉÊzÀåQÃAiÀÄ PÁ¯ÉÃdÄ ªÀÄvÀÄÛ D¸ÀàvÉæ
zÀÆgÀªÁtÂ ¸ÀASÉå: +91 7204673475

zÀAiÀÄ«lÄÖ F ªÀiÁ»w ¥ÀvÀæªÀ£ÀÄß ¸ÀjAiÀiÁV N¢PÉÆ½î. MAzÀÄªÉÃ¼É AiÀiÁªÀÅzÉÃ ªÀiÁ»w, ¨sÁµÉ CxÀðªÁUÀzÉ EzÀÝ°è, CzsÀåAiÀÄ£À £ÀqÉ¸ÀÄwÛgÀÄªÀ
ªÉÊzÀågÀ/¸ÀA±ÉÆÃzsÀPÀgÀ §½ ZÀað¹. F CzsÀåAiÀÄ£ÀzÀ°è ¤ªÀÄä ¥Á¯ÉÆÎ¼ÀÄî«PÉAiÀÄÄ ¸ÀéAiÀÄA¥ÉæÃjvÀªÁVzÀÄÝ, ¤ªÀÄä F CzsÀåAiÀÄ£ÀzÀ°è ¨sÁUÀªÀ»¸ÀÄªÀÅzÀPÉÌ °TvÀ
¸ÀªÄÀ äwAiÀÄ£ÀÄß ¤ÃqÀÄªÀÅzÀPÉÌ ªÀÄÄ£Àß J®è «ZÁgÀUÀ¼À£ÀÄß ¸ÀA¥ÀÇtðªÁV PÉÃ½ w½zÀÄPÉÆ¼Àî§ºÀÄzÀÄ.
1. CzsÀåAiÀÄ£À ¥ÀjZÀAiÀÄ:
¤ªÀÄUÉ JgÀqÀ£ÉÃ «zsÀzÀ ªÀÄzsÀÄªÉÄÃºÀ«gÀÄzÀjAzÀ F CzsÀåAiÀÄ£ÀzÀ°è ¨sÁUÀªÀ»¸ÀÄªÀAvÉ PÉÃ½PÉÆ¼Àî¯ÁVzÉ.
2. CzsÀåAiÀÄ£ÀzÀ GzÝÉÃ±À:
ªÀÄzsÀÄªÉÄÃºÀ gÉÆÃVUÀ¼À°è OµÀzsÀzÀ DgÉÊPÉAiÀÄ ¥Àæ¨sÁªÀzÀ CzsÀåAiÀÄ£À.
3. AiÀiÁgÀÄ ¨sÁUÀªÀ»¸À§ºÀÄzÀÄ:
JgÀqÀ£ÉÃ «zsÀzÀ ªÀÄzsÀÄªÉÄÃºÀªÀÅ¼Àî 18 ªÀµÀð ªÉÄÃ®àlÖªÀgÀÄ, UÉèöÊPÉÆÃ¹¯ÉÃmÉqï »ªÉÆÃUÉÆèÃ©£ï 7%QÌAvÀ ºÉZÀÄÑ EgÀÄªÀ gÉÆÃVUÀ¼ÀÄ F CzsÀåAiÀÄ£ÀzÀ°è
¨sÁUÀªÀ»¸À§ºÀÄªÀÅzÀÄ.
ªÀÄzsÀÄªÉÄÃºÀªÀÅ¼Àî UÀ©üðtÂ, ºÁ¹UÉ »rzÀ ªÀÄzsÀÄªÉÄÃºÀ gÉÆÃV ºÁUÀÆ AiÀiÁgÀÄ F CzsÀåAiÀÄ£ÀzÀ°è ¨sÁUÀªÀ»¸À®Ä EaÒ¸ÀÄªÀÅ¢®èªÉÇÃ CªÀgÀ£ÀÄß
CzsÀåAiÀÄ£À¢AzÀ ºÉÆgÀvÀÄ ¥Àr¸À¯ÁVzÉ.
4. CzsÀåAiÀÄ£ÀzÀ §UÉÎ ªÀiÁ»w:
2£ÉÃ «zsÀzÀ ªÀÄzsÀÄªÉÄÃºÀªÀÅ¼Àî gÉÆÃVAiÀÄ£ÀÄß PÀ¸ÀÆÛ¨Áð D¸ÀàvÉæAiÀÄ ªÉÄr¹£ï «¨sÁUÀzÀ 2 ºÁUÀÆ 4£ÉÃ AiÀÄÆ¤mï£À°è UÀÄgÀÄw¸À¯ÁUÀÄ ªÀÅzÀÄ. F
CzsÀåAiÀÄ£ÀªÀ£ÀÄß DUÀ¸ïÖ 2018jAzÀ ªÀiÁZïð 2019gÀ vÀ£ÀPÀ £ÀqÉ¸À¯ÁUÀÄªÀÅzÀÄ. F CzsÀåAiÀÄ£ÀzÀ°è 2 UÀÄA¥ÀÄUÀ½ªÉ EAlgïªÉ£Àë£ï UÀÆæ¥ï ºÁUÀÆ
AiÀÄÄdÄªÀ¯ï ªÉÄrPÀ¯ï PÉÃgï UÀÆæ¥ï. MnÖUÉ 104, 2£ÉÃ «zsÀzÀ ªÀÄzsÀÄªÉÄÃºÀªÀÅ¼Àî gÉÆÃVUÀ¼ÀÄ CzÀgÀ°è 52 EAlgïªÉ£Àë£ï UÀÆæ¥ï. F UÀÄA¦UÉ OµÀ¢üÃAiÀÄ
DgÉÊPÉAiÀÄ£ÀÄß ªÉÊzÀåQÃAiÀÄ DgÉÊPÉAiÀÄ eÉÆvÉUÉ ¤ÃqÀ¯ÁUÀÄªÀÅzÀÄ. G½zÀ 52 AiÀÄÄdÄªÀ¯ï ªÉÄrPÀ¯ï PÉÃgï UÀÆæ¥ï, F UÀÄA¦UÉ OµÀ¢üÃAiÀÄ DgÉÊPÉAiÀÄ£ÀÄß
¤ÃqÀ¯ÁUÀÄªÀÅ¢®è.
5. CzsÀåAiÀÄ£ÀzÀ CªÀ¢üAiÀÄ°è K£ÁUÀÄvÀÛzÉ?:
F CzsÀåAiÀÄ£ÀzÀ°è 2 UÀÄA¥ÀÄUÀ½zÀÄÝ ¤ªÀÄä CzsÀåAiÀÄ£ÀzÀ ¤uÁðAiÀÄPÀzÀ CA±ÀzÀ ¥ÀæPÁgÀ ¤ªÀÄä£ÀÄß EAlgïªÉ£Àë£ï UÀÆæ¥ï ºÁUÀÆ AiÀÄÄdÄªÀ¯ï ªÉÄrPÀ¯ï PÉÃgï
UÀÄA¦UÉ ¸ÉÃj¸À¯ÁUÀÄªÀÅzÀÄ. 2 UÀÄA¥ÀÄUÀ½UÉ ¸ÁªÀiÁ£Àå ªÉÊzÀåQÃAiÀÄ G¥ÀZÁgÀªÀÅ ¹UÀÄvÀÛzÉ, EAlgïªÉ£Àë£ï UÀÄA¦£ÀÀ gÉÆÃVUÀ½UÉ «±ÉÃµÀªÁV OµÀ¢ü
aÃnAiÀÄ «ªÀÄµÉðAiÉÆA¢UÉ gÉÆÃVUÉ ¨ÉÃPÁzÀ CUÀvÀå«gÀÄªÀ fÃªÀ£À ±ÉÊ° §zÀ¯ÁªÀuÉAiÀÄ §UÉÎ ªÀiÁ»w PÉÆqÀÄªÀÅzÀ®èzÉÃ , ªÀÄzsÀÄªÉÄÃºÀ gÉÆÃUÀzÀ §UÉÎ
gÉÆÃVAiÀÄ ªÀiÁ»w ºÁ¼É PÉÆqÀ¯ÁUÀÄvÀÛzÉ. ¥Àæ±ÁßªÀ½AiÀÄ£ÀÄß 2 UÀÄA¦UÉ ¤Ãr ªÀÄzsÀÄªÉÄÃºÀ gÉÆÃVAiÀÄ fÃªÀ£À UÀÄtªÀÄlÖ ºÁUÀÆ w¼ÀÄªÀ½PÉ, ¤®ÄªÀÅ,
C¨sÁå¸À ¥Àæ±ÁßªÀ½AiÀÄ£ÀÄß ¤ÃqÀ¯ÁUÀÄªÀÅzÀÄ. F ¥Àæ±ÁßªÀ½AiÀÄÄ gÉÆÃVAiÀÄ fÃªÀ£À ªÀÄlÖzÀ ¸ÀÄzsÁgÀuÉ ºÁUÀÆ gÉÆÃUÀzÀ ¤AiÀÄAvÀætzÀ ªÀiÁ»wAiÀÄ£ÀÄß
¥ÀqÉAiÀÄ®Ä G¥ÀAiÉÆÃV¸À¯ÁUÀÄvÀÛzÉ. F ¥Àæ±ÁßªÀ½UÀ¼À£ÀÄß gÉÆÃVAiÀÄ D¸ÀàvÉæAiÀÄ ©qÀÄUÀqÉAiÀÄ ªÉÆzÀ®Ä ºÁUÀÆ ªÉÆzÀ®, JgÀqÀ£ÉÃAiÀÄ C£ÀÄ¸ÀgÀuÉAiÀÄ ªÉÃ¼É
¥ÀqÉAiÀÄ¯ÁUÀÄªÀÅzÀÄ.(D¸ÀàvÉæAiÀÄ ©qÀÄUÀqÉ DzÀ §½PÀ ªÉÆzÀ®£É wAUÀ¼ÀÄ ºÁUÀÆ £Á®Ì£ÉÃ wAUÀ½À£À°è £ÀqÉ¸À¯ÁUÀÄªÀÅzÀÄ) F ¸ÀAzÀ±Àð£ÀªÀÅ 20 ¤«ÄµÀ ¥Àæw
¥Àæ±ÁßªÀ½UÉ vÉUÉzÀÄPÉÆ¼ÀÄîvÀÛzÉ. ¤ÃªÀÅ F CzsÀåAiÀÄ£ÀzÀ°è 6 wAUÀ¼ÀÄUÀ¼À PÁ® ¨sÁVAiÀiÁVgÀÄwÛj. MªÉÄä CzsÀåAiÀÄ£À ªÀÄÄVzÀ ªÉÄÃ¯É F «±ÉÃµÀ vÀgÀºÀzÀ
¸Ë®¨sÀåAiÀÄ£ÀÄß E£ÉÆßAzÀÄ UÀÄA¦UÉ (AiÀÄÄdÄªÀ¯ï ªÉÄrPÀ¯ï PÉÃgï UÀÆæ¥ï) ¤ÃqÀ¯ÁUÀÄªÀÅzÀÄ.

6. CzsÀåAiÀÄ£ÀzÀ°è ¤ªÀÄä ¥ÁvÀæ/ ºÉÆuÉUÁjPÉÀ:


PÉÃ½zÁUÀ¯É®è ¤RgÀªÁzÀ ªÀiÁ»wAiÀÄ£ÀÄß MzÀV¸À¨ÉÃPÀÄ.



¤ÃªÀÅ CzsÀåAiÀÄ£À¢AzÀ ºÉÆgÀºÉÆÃUÀÄ«gÁzÀgÉ CzsÀåAiÀÄ£ÀUÁgÀ ªÉÊzÀåjUÉ ªÀiÁ»w ¤ÃqÀ¨ÉÃPÀÄ.

7. C¥ÁAiÀÄUÀ¼ÉÃ£ÀÄ?
EzÀÄ MAzÀÄ EAlgïªÉ£Àë£ï CzsÀåAiÀÄ£ÀªÁVzÀÄÝ, EzÀgÀ°è ¸Àé®à jÃwAiÀÄ C¥ÁAiÀÄ EgÀ§ºÀÄªÀÅzÀÄ ¤ÃªÀÅ CzÀåAiÀÄ£ÀPÁgÀjAzÀ ¸ÀAzÀ±Àð£À ªÉÃ¼ÉAiÀÄ°è ¸Àé®à
ªÀiÁ£À¹PÀ GzÉéÃPÀvÉ GAmÁUÀ§ºÀÄªÀÅzÀÄ.
8. CzsÀåAiÀÄ£ÀzÀ°è ¨sÁUÀªÀ»¸ÀÄªÀÅzÀjAzÀ ¸ÀA¨sÁªÀå ¥ÀæAiÉÆÃd£ÀUÀ¼ÉÃ£ÀÄ:
CzsÀåAiÀÄ£ÀzÀ°è ¨sÁUÀªÀ»¸ÀÄªÀÅzÀjAzÀ ¤ªÀÄUÉ £ÉÃgÀ ¥ÀæAiÉÆÃd£À DUÀzÉ EgÀ§ºÀÄzÀÄ. ¤ÃªÀÅ F CzsÀåAiÀÄ£ÀzÀ°è ¨sÁUÀªÀ»¸ÀÄªÀÅzÀjAzÀ ªÀÄzsÀÄªÉÄÃºÀ PÁ¬Ä¯ÉAiÀÄ
§UÉV£À eÁÕ£ÀPÉÌ PÉÆqÀÄUÉ ¤ÃqÀÄªÀ ªÀÄÆ®PÀ ªÀÄzsÀÄªÉÄÃºÀ ¦ÃrvÀgÁzÀ EvÀgÀ gÉÆÃVUÀ½UÉ £ÉgÀªÁUÀ§ºÀÄzÀÄ.
9. ®¨sÀå«gÀÄªÀ ¥ÀAiÀiÁðAiÀÄ aQvÉìUÀ¼ÉÃ£ÀÄ: ¥ÀAiÀiÁðAiÀÄªÁV ªÉÊzÀågÀ ªÀÄÆ®PÀ UÀÄtªÀÄlÖ aQvÉìAiÀÄ£ÀÄß ¥ÀqÉAiÀÄÄªÀÅzÀÄ.
10. CzsÀåAiÀÄ£ÀzÀ°è ¨sÁUÀªÀ»¸À®Ä ªÉZÀÑ:
F CzsÀåAiÀÄ£ÀzÀ°è ¨sÁUÀªÀ»¸À®Ä gÉÆÃVUÀ½AzÀ ºÉZÀÄÑªÀj AiÀiÁªÀÅzÉÃ OµÀzsÀ CxÀªÁ vÀ¥Á¸ÀuÉ RZÀÄð ¥ÀqÉAiÀÄÄ¢®è. gÉÆÃVAiÀÄ ªÀiÁ»w ºÁ¼É ªÀÄvÀÄÛ
OµÀ¢üAiÀÄ PÀÄjvÀ ¸ÀAzÀ±Àð£ÀªÀ£ÀÄß GavÀªÁV PÉÆqÀ¯ÁUÀÄªÀÅzÀÄ.
11. UÁAiÀÄPÉÌ ¥ÀjºÁgÀ:
F CzsÀåAiÀÄ£ÀzÀ°è AiÀiÁªÀÅzÉÃ ºÉZÀÄÑªÀj C¥ÁAiÀÄUÀ¼ÀÄ EgÀÄªÀÅ¢®è, AiÀiÁªÀÅzÀzÁgÀÆ CzsÀåAiÀÄ£À ¸ÀA§A¢üvÀ C¥ÁAiÀÄzÀ ¥ÀjºÁgÀ zsÀ£ÀªÀ£ÀÄß ¥ÀæzsÁ£À
vÀ¤SÉzÁgÀgÀÄ ¤ÃqÀÄvÁÛgÉ.
12. ªÀiÁ»wAiÀÄ UË¥ÀåvÉ:
CzsÀåAiÀÄ£À zÁR¯ÉAiÀÄ°è EgÀÄªÀ ¤ªÀÄä ºÉ¸ÀgÀÄ «¼Á¸À, ªÉÊzÀåQÃAiÀÄ zÁR¯É, ¥ÀjÃPÁë ¥sÀ°vÁA±À CzsÀåAiÀÄ£À ¥sÀ°vÁA±À ªÀÄÄAvÁzÀ ªÀiÁ»wAiÀÄ£ÀÄß UË¥ÀåªÁV
EqÀ¯ÁUÀÄvÀÛzÉ. ªÀÄvÀÄÛ CzÀ£ÀÄß CzsÀåAiÀÄ£ÀPÉÌ ¸ÀA§¢ü¹zÀ C¢üPÀÈvÀ ªÀåQÛUÀ¼ÁzÀ ¥ÁæAiÉÆÃdPÀgÀÄ CxÀªÁ CªÀgÀ ¥Àæw¤¢ü, £ÉÊwPÀ ¸À« Äw CxÀªÁ ¤AiÀÄAvÀæt
¸ÀA¸ÉÜ¬ÄAzÀ ªÀiÁvÀæ ¥Àj²Ã°¸À¯ÁUÀÄªÀÅzÀÄ, ¤ªÀÄä °TvÀ C£ÀÄªÀÄw E®èzÉ ªÀiÁ»wAiÀÄ£ÀÄß C£ÀåªÀåQÛUÀ½UÉ ®¨sÀåªÁUÀ®Ä ©qÀÄªÀÅ¢®è. F CzsÀåAiÀÄ£ÀzÀ
ªÀiÁ»w ªÀÄvÀÄÛ ¥sÀ°vÁA±ÀªÀ£ÀÄß ªÉÊeÁÕ¤PÀ PÀÆl /¸À¨sÉ CxÀªÁ ¥Àæ§AzsÀUÀ¼À°è ¤ªÀÄä ºÉ¸ÀgÀÄ ªÀÄvÀÄÛ ªÉÊAiÀÄQÛPÀ UÀÄgÀÄvÀÄ E®èzÉ ¥ÀæPÀn¸À¯ÁUÀÄªÀÅzÀÄ. ªÀiËTPÀ
CxÀªÁ °TvÀªÀgÀ¢AiÀÄ°è F CzsÀåAiÀÄ£ÀPÉÌ ¸ÀA§¢ü¹zÀAvÉ ¤ªÀÄä G¯ÉèÃR EgÀÄªÀÅ¢®è.
13. CzsÀåAiÀÄ£ÀzÀ §UÉÎ ºÉÆ¸À ªÀiÁ»w:
CzsÀåAiÀÄ£ÀzÀ ¸ÀªÀÄAiÀÄzÀ°è AiÀiÁªÀÅzÉÃ ºÉÆ¸À ªÀiÁ»wUÀ¼ÀÄ ®¨sÀåªÁzÀ°è CzÀÄ ¤ªÀÄUÉ F CzsÀåAiÀÄ£ÀzÀ°è ªÀÄÄAzÀÄªÀjAiÀÄ®Ä
¤ªÀÄUÉ w½¸À¯ÁUÀÄªÀÅzÀÄ ¤ªÀÄä ¨sÁUÀªÀ¸ÀÄ«PÉ¬ÄAzÁzÀ ¥sÀ°vÁA±ÀªÀ£ÀÄß ¤ÃªÀÅ EaÒ¹zÀ°è ¤ªÀÄUÉ w½¸À¯ÁUÀÄªÀÅzÀÄ.

¸ÀºÀPÁjAiÀiÁzÀ°è CzÀ£ÀÄß

14. ¸ÀéAiÀÄA¥ÉæÃjvÀ ¥Á¯ÉÆÎ¼ÀÄî«PÉ:
F CzsÀåAiÀÄ£ÀzÀ°è ¤ªÀÄä ¨sÁUÀªÀ»¸ÀÄ«PÉAiÀÄÄ LaÒPÀªÁVzÀÄÝ ¤ÃªÀÅ F CzsÀåAiÀÄ£ÀzÀ°è ¨sÁUÀªÀ»¸À®Ä ¸ÀªÀÄäw¹zÀgÀÆ AiÀiÁªÀÅzÉÃ ¸ÀªÀÄAiÀÄzÀ°è ¤ªÀÄä
C£ÀÄªÀÄwAiÀÄ£ÀÄß »AvÉUÉÀzÀÄPÉÆ¼Àî§ºÀÄzÀÄ. ºÁUÀÆ EzÀPÉÌ AiÀiÁªÀÅzÉÃ PÁgÀt ¤ÃqÀ ¨ÉÃPÁV®è. EzÀPÁÌV ¤ªÀÄUÉ AiÀiÁªÀÅzÉÃ zÀAqÀ«gÀÄªÀÅ¢®è ªÀÄvÀÄÛ ¤ªÀÄUÉ
¹UÀ¨ÉÃPÁUÀÄªÀ G¥ÀAiÉÆÃUÀ/¯Á¨sÀPÉÌ AiÀiÁªÀÅzÉÃ £ÀµÀÖ«®è. ¤ÃªÀÅ CzsÀåAiÀÄ£À ¥ÀÇtðUÉÆ¼ÀÄîªÀ ªÉÆzÀ®Ä CzsÀåAiÀÄ£À¢AzÀ ºÉÆgÀ§AzÀgÉ ¤ÃªÀÅ ¤ªÀÄä PÁ¬Ä¯ÉUÉ
¨ÉÃPÁUÀÄªÀ ¸ÁªÀÄ£ÁåªÁzÀ aQvÉìAiÀÄ£ÀÄß ¥ÀqÉAiÀÄÄwÛÃj ªÀÄvÀÄÛ ¤ªÀÄä ¨sÁUÀªÀ»¸ÀÄ«PÉAiÀÄÄ ¤ªÀÄä ªÀÄÄA¢£À aQvÉìAiÀÄ ªÉÄÃ¯É AiÀiÁªÀ CqÀØ ¥ÀjuÁªÀÄªÀ£ÀÄß
©ÃgÀÄªÀÅ¢®è CxÀªÁ ¤ªÀÄUÉ aQvÉì ¤ÃqÀÄªÀ ªÉÊzÀågÉÆA¢V£À ¸ÀA§AzsÀPÉÌ AiÀiÁªÀÅzÉ vÉÆAzÀgÉ AiÀiÁUÀÄªÀÅ¢®è. CzsÀåAiÀÄ£À ¥ÀÇtðUÉÆ¼ÀÄîªÀ ªÉÆzÀ®Ä ¤ÃªÀÅ
CzsÀåAiÀÄ£À¢AzÀ »AzÉ ¸ÀjzÀgÉ ¤ÃªÀÅ CzsÀåAiÀÄ£À¢AzÀ »AzÉ ¸ÀjAiÀÄÄªÀ ªÉÆzÀ®Ä ¸ÀAUÀæ»¹zÀ CzsÀåAiÀÄ£ÀzÀ ªÀiÁ»wAiÀÄ£ÀÄß CzsÀåAiÀÄ£À ªÀgÀ¢AiÀÄ°è
G¥ÀAiÉÆÃV¸À¯ÁUÀÄªÀÅzÀÄ. ¥ÁæAiÉÆÃdPÀgÀÄ CxÀªÁ CzsÀåAiÀÄ£ÀPÁgÀgÀÄ AiÀiÁªÀÅzÉÃ ¸ÀªÀÄAiÀÄzÀ°è CªÀgÀ CzsÀåAiÀÄ£ÀªÀ£ÀÄß CxÀªÁ ¤ªÀÄä ¨sÁUÀªÀ»¸ÀÄ«PÉAiÀÄ£ÀÄß
MAzÀ®è MAzÀÄ PÁgÀtPÁÌV ¤ªÀÄä C£ÀÄªÀÄw E®èzÉAiÉÄÃ ¤°è¸À§ºÀÄzÀÄ.

15. AiÀiÁªÀÅzÉÃ ¥Àæ±ÉßUÀ½zÀÝ°è AiÀiÁgÀ£ÀÄß ¸ÀA¥ÀQð¸À¨ÉÃPÀÄ:
F CzsÀåAiÀÄ£ÀzÀ°è ¤ÃªÀÅ ¨sÁUÀªÀ»¸ÀÄwÛgÀÄªÁUÀ CzÀgÀ ¥ÀjuÁªÀÄªÁV AiÀiÁªÀÅzÉÃ CqÀØ ¥ÀjuÁªÀÄUÀ¼À£ÀÄß C£ÀÄ¨sÀ«¸ÀzÀ°è ¤ÃªÀÅ ªÀÄÄRå CzsÀåAiÀÄ£ÀPÁgÀgÁzÀ
¢ªÀå²æÃ CªÀgÀ£ÀÄß ªÉÄÃÃ¯É PÁtÂ¹zÀ «ªÀgÀUÀ¼ÀAvÉ ¸ÀA¥ÀQð¸ÀºÀÄzÀÄ.
CzsÀåAiÀÄ£ÀzÀ ¨sÁVzÁgÀgÁV ªÀiÁ»w ¸ÀªÀÄäw ¥ÀvÀæzÀ ¥ÀæQæAiÉÄ §UÉÎ CxÀªÁ ¨sÁVzÁgÀgÁV ¤ªÀÄä ºÀPÀÄÌUÀ¼À §UÉÎ ¤ªÀÄUÉ AiÀiÁªÀÅzÉÃ ¥Àæ±ÉßUÀ½zÀÝ°è EªÀgÀ£ÀÄß
¸ÀA¥ÀQð¸À§ºÀÄzÀÄ: ¸ÀzÀ¸Àå PÁAiÀÄðzÀ²ð, PÀ¸ÀÆÛ¨Áð ªÉÄÃrPÀ¯ï PÁ¯ÉÃdÄ ªÀÄvÀÄÛ PÀ¸ÀÆÛ¨Áð D¸ÀàvÉæ £ÉÊwPÀ ¸À«Äw ¸ÀA¸É Ü, PÉÆoÀr £ÀA. 22, £É®ªÀÄºÀr,
PÉJªÀiï¹ ¥ÁæzsÁå¥ÀPÀgÀ PÉÆoÀrUÀ¼ÀÄ, PÉJªÀiï¹ DqÀ½vÀ PÀbÉÃj ¥ÀPÀÌ, PÀ¸ÀÆÛ¨Áð ªÉÄrPÀ¯ï PÁ¯ÉÃdÄ, ªÀÄtÂ¥Á® - 576 104, EªÀgÀ£ÀÄß ¸ÀAzÀ²ð¸À§ºÀÄzÀÄ.
¥sÉÇÃ£ï : 0820 2933522.
¸ÀªÀÄAiÀÄ: ¨É½UÉÎ 9:00jAzÀ ¸ÁAiÀÄAPÁ® 5:00
F ªÀiÁ»w ¥ÀvÀæzÀ §UÉÎ CxÀªÁ CzsÀåAiÀÄ£ÀPÉÌ ¸ÀA§¢ü¹zÀAvÉ AiÀiÁªÀÅzÉÃ «ªÁzÁA±ÀUÀ½zÀÝgÉ F PÉ¼ÀV£ÀªÀgÀ£ÀÄß PÀÆqÁ ¸ÀA¥ÀQð¸À§ºÀÄzÀÄ.
ºÉ¸ÀgÀÄ: qÁ. JªÀiï. ¸ÀÄgÀÄ°ªÉ¯ï gÁd£ï, C¸ÉÆÃ¹AiÉÄmï ¥ÉÆæ¥É¸Àgï
«¼Á¸À: ¥sÁªÀÄð¹ ¥ÁæQÖÃ¸ï «¨sÁUÀ, JA¹M¦J¸ï, ªÀÄtÂ¥Á®-576104
zÀÆgÀªÁtÂ: +91 9886921414

INFORMED CONSENT FORM

Project title: Study the impact of Pharmaceutical care on the Diabetic patients in a tertiary care
hospital in South India.

I confirm I have read the Participant Information Sheet for the above study and its
contents were explained and I have had the opportunity to ask questions and received
satisfactory answers.
I understand that my participation in the study is voluntary and that I have the right to
withdraw at any time without giving any reason, without my medical care or legal rights
being affected.
I agree to take part in the above study. I confirm that I have received a copy of the
Participant Information Sheet along with this signed and dated informed consent form.

Name of the Research Participant :
Age of the Research Participant :
Address of the Research Participant :
Occupation:
Annual Income of the Participant:
Name & address of the nominee(s) and his relation to the Participant :
_________________________________________________________________________

__________________________
Signature of the research subject

_________
Date

__________________________
Name & Signature of the witness

_________
Date

______________________________________________
Name & Signature of the person explaining the consent

_________
Date
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ªÀiÁ»wAiÀÄÄPÀÛ ¸ÀªÀÄäw ¥ÀvÀæ
CzsåÀ AiÀÄ£À ²Ã¶ðPÉ: zÀQët ¨sÁgÀvÀzÀ vÀÈwÃAiÀÄ DgÉÊPÉ D¸ÀàvÉæAiÀÄ°è£À ªÀÄzsÀÄªÉÄÃºÀ gÉÆÃVUÀ½UÉ ªÉÊzÀåQÃAiÀÄ
OµÀ¢üPÁgÀgÀÄ MzÀV¸ÀÄªÀ DgÉÊPÉAiÀÄ ¥Àæ¨sÁªÀzÀ CzsåÀ AiÀÄ£À.
ªÉÄÃ®ÌAqÀ CzsåÀ AiÀÄ£ÀzÀ §UÉV£À «µÀAiÀÄ ªÀiÁ»w¥Àvª
Àæ À£ÀÄß £Á£ÀÄ N¢PÉÆArzÝÉÃ£É ªÀÄvÀÄÛ CzÀgÀ ªÀiÁ»wUÀ¼£
À ÀÄß
£À£ÀUÉ ¸ÀªÄÀ ¥ÀðPÀªÁV «ªÀj¸À¯ÁVzÉ. £À£ÀUÉ ¥Àæ±ßÉ UÀ¼£
À ÀÄß PÉÃ¼À®Ä CªÀPÁ±À ¤ÃqÀ¯ÁVvÀÄÛ ªÀÄvÀÄÛ CªÀÅUÀ½UÉ
¸ÀªiÀ ÁzsÁ£ÀPÀgª
À ÁzÀ GvÀÛgÀU¼
À ÀÄ £À£ÀUÉ ®©ü¹ªÉ.
F CzsåÀ AiÀÄ£Àz°
À è £À£Àß ¨sÁUÀªÀ»¸ÀÄ«PÉAiÀÄÄ ¸ÀA¥ÀÇtðªÁV LaÒPÀªÁVzÀÄÝ, AiÀiÁªÀÅzÉÃ ¸ÀªÄÀ AiÀÄzÀ°è, AiÀiÁªÀÅzÉÃ
PÁgÀtUÀ¼£
À ÀÄß ¤ÃqÀzÉ CzsåÀ AiÀÄ£À¢AzÀ »AzÉ ¸ÀjAiÀÄÄªÀ ¸ÁévÀAvÀæöå £À£ÀVzÉ ªÀÄvÀÄÛ CzÀjAzÀ £À£Àß ªÉÊzÀåQÃAiÀÄ
DgÉÊPÉ ªÀÄvÀÄÛ PÁ£ÀÆ£ÀÄ§zÀÞ ºÀPÄÀ ÌU½
À UÉ AiÀiÁªÀÅzÉÃ vÉÆAzÀgA
É iÀiÁUÀÄªÀÅ¢®è JA§ÄzÀ£ÀÄß w½¢zÝÉÃ£É.
£Á£ÀÄ F CzsåÀ AiÀÄ£Àz°
À è ¨sÁUÀª»
À ¸À®Ä ¸ÀªÄÀ äw¹zÝÉÃ£É. «µÀAiÀÄ ªÀiÁ»w ¥ÀvÀæ ºÁUÀÆ ¸À» ªÀÄvÀÄÛ ¢£ÁAPÀ ¸À»vÀ
F ªÀiÁ»wAiÀÄÄPÀÛ ¸ÀªÄÀ äw ¥ÀvÀæzÀ ¥Àæw £À£ÀUÉ ®©ü¹zÉ JA§ÄzÀ£ÀÄß zÀÈrüÃPÀj¸ÀÄwÛzÝÉÃ£É.

CzsåÀ AiÀÄ£À¨Ás VAiÀÄ ºÉ¸g
À ÀÄ:
CzsåÀ AiÀÄ£À¨Ás VAiÀÄ ªÀAiÀÄ¸ÀÄì:
CzsåÀ AiÀÄ£À¨Ás VAiÀÄ «¼Á¸À:
ªÀÈwÛ:
CzsåÀ AiÀÄ£À¨Ás VAiÀÄ ªÁ¶ðPÀ DzÁAiÀÄ:
£Á«Ä¤ (UÀ¼)À ºÉ¸g
À ÀÄ ªÀÄvÀÄÛ CzsåÀ AiÀÄ£À¨Ás VAiÀÄ dvÉUÉ CªÀgÀ ¸ÀA§AzsÀ:
___________________________________________________________________

__________________________
CzsåÀ AiÀÄ£À¨Ás VAiÀÄ ¸À»

_________
¢£ÁAPÀ

__________________________
¸ÁQëAiÀÄ ºÉ¸g
À ÀÄ ªÀÄvÀÄÛ ¸À»

_________
¢£ÁAPÀ

__________________________
¸ÀªÄÀ äwAiÀÄ£ÀÄß «ªÀj¹zÀ ªÀåQÛAiÀÄ ºÉ¸g
À ÀÄ ªÀÄvÀÄÛ ¸À»

_________
¢£ÁAPÀ
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